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Several atypical antipsychotics have entered the market since the last decade.  
Evaluating the utilization patterns and overall cost savings generated by these expensive 
agents is becoming more important as their use continues to expand.  Phase 1 of this 
study describes the patterns of antipsychotic utilization and its impact on total and mental 
health-related costs for schizophrenia and bipolar disorder patients in a state Medicaid 
program.  Phase 2 of this study compares typical antipsychotics, risperidone, olanzapine, 
and quetiapine in terms of direct costs and utilization of healthcare services such as 
hospitalizations, emergency room visits, outpatient visits, psychiatric prescription use and 
antipsychotic therapy modifications among schizophrenia and bipolar disorder patients.  
A retrospective, longitudinal study design was employed and a state Medicaid claims 
data from January 1, 1998 to December 31, 2002 was used.  Multivariate analysis was 
used to statistically control for various confounding factors including patient 
demographics, prescribing physician type, mental health diagnosis, other comorbidities, 
pre-index alcohol and substance abuse, pre-index concomitant medication use, and pre-
index healthcare utilization.  Phase 1 results revealed that a large proportion of 
schizophrenia and bipolar disorder patients are non-adherent to antipsychotic therapy.  
Schizophrenia and bipolar disorder patients who are non-adherent to antipsychotic 
therapy or receive antipsychotic polytherapy incurred significantly higher total and 
mental healthcare costs.  Phase 2 results revealed that there were no significant 
differences in total and mental healthcare costs among schizophrenia patients initiated on 
any of the study antipsychotics.  Bipolar disorder patients initiated on typical 
antipsychotics incurred higher total and mental healthcare costs as compared to patients 
initiated on atypicals.  There were no significant differences in total and mental 
healthcare costs among patients initiated on any of the study atypical antipsychotics. 
Patients initiated on olanzapine incurred highest pharmacy costs whereas patients 
initiated on typical antipsychotics incurred lowest pharmacy costs.  Schizophrenia and 
bipolar disorder patients initiated on typical antipsychotics showed significantly lower 
adherence and higher likelihood of modifying antipsychotic therapy as compared to 
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 Schizophrenia is a complex psychiatric disorder affecting about 1.1% of the 
population. Despite the low prevalence of the disease, schizophrenia is the most 
expensive psychiatry disorder to treat (Knapp, 1997). Schizophrenia costs constitute 
2.5% of total healthcare expenditures.   In 1991, direct and indirect costs associated with 
schizophrenia were estimated to be $18.6 billion and $46.5 billion, respectively. 
Hospitalizations are responsible for almost 70% of costs, drug costs for  almost 10%, and 
outpatient costs usually make up the rest of the 20% (Revicki, 1997).  Annual total 
healthcare costs per schizophrenia patient were estimated to range between $16,000 and 
$57,000 in 1999 (Mauskopf, David, Grainger, & Gibson, 1999).  
Bipolar Disorder 
The lifetime prevalence of bipolar disorder in the US population is about 1.2% to 
1.6% (Kessler et al., 1994).  The estimated economic burden of the disorder is about $45 
billion. The direct costs are estimated at $7.6 billion and indirect costs at $38 billion. 
About 60-70% of direct costs were attributable to inpatient costs (Wyatt & Henter, 1995). 
Medication costs constitute about 2% of direct costs.  The annual medication cost per 
treated patient was about $548 (Wyatt et al., 1995).  About 75% of bipolar patients 
undergo at least one hospitalization during the course of their illness (Lish, Dime-
Meenan, Whybrow, Price, & Hirschfeld, 1994).  About 10% of inpatient healthcare in US 
is utilized by bipolar patients (Narrow, Regier, Rae, Manderscheid, & Locke, 1993).  
2 
Costs for patients with bipolar disorder is higher than costs for patients treated for 
depression or diabetes (Simon & Unutzer, 1999).   
Antipsychotic Treatment Patterns  
Pharmacotherapy of schizophrenia involves use of conventional antipsychotics 
and relatively newer atypical antipsychotics.  With the advent of newer atypical 
antipsychotics over the last decade, the treatment pattern of antipsychotic therapy is 
changing.  Various studies conducted in different healthcare settings and time periods 
have reported this trend.  A study by Williams et al using the Regenstrief Medical Record 
System reported only 12% atypical antipsychotic use among schizophrenia patients in 
1995.  About 25% of patients switched medications and 90% augmented medications 
during a 12-month period (Williams, Johnstone, Kesterson, Javor, & Schmetzer, 1999).  
A chart review of 83 outpatients showed that patients who switched antipsychotics made 
greater use of psychiatric services (Tempier & Pawliuk, 2003).  McCombs et al used the 
claims data from the California Medicaid program (Medi-Cal) from 1987 to 1996 to 
study antipsychotics utilization patterns in terms of no drug therapy for over 1 year; 
delayed onset of antipsychotic drug therapy; and, switches in antipsychotic drugs within 
1 year.  During the time period of the study, they found that about 98% of patients were 
on conventional antipyschotics.  About 47% of patients switched or augmented their 
therapy within one year.  Only 11.6% of patients received continuous antipsychotic 
therapy for one year (McCombs, Nichol, Stimmel, Shi, & Smith, 1999b).  These studies 
used data earlier than 1998 during which atypical antipsychotics were not widely used. 
Drug use pattern of antipsychotics has probably changed since this study as newer 
atypical antipsychotics have entered market and are being more widely used.  
3 
 Until recently, atypical antipsychotics were not approved for use for bipolar 
patients though their use was prevalent in clinical practice (Licht et al., 1994; Shattell & 
Keltner, 2004).  Pattern of antipsychotic use among bipolar patients has been less studied. 
A meta-analysis by Tohen et al revealed that about 84.7% of bipolar patients received 
typical antipsychotics.  About 53.8% of typical antipsychotic use was as monotherapy. 
About 47.4% of typical antipsychotic use was as an adjunct with a mood stabilizer 
(Tohen et al., 2001).  A study by Russo et al reported that typical antipsychotics were 
used by 16.4% of patients and atypical antipsychotics by 12.4% of bipolar patients 
between 1994 and 1998.  The study also found that patients initiated on antipsychotics 
continued on the therapy for more than 12 months, while patients initiated on 
anticonvulsants or antidepressants were more likely to discontinue or switch to another 
medication class (Russo, Smith, Dirani, Namjoshi, & Tohen, 2002).    
Antipsychotic polypharmacy  
Literature reveals widespread practice of antipsychotic polypharmacy.  Various 
studies have reported prevalence of antipsychotic polypharmacy in clinical practice 
despite the lack of clinical evidence supporting such practice.  Analyzing prescription 
records of patients hospitalized between 1995 and 2000, McCue et al reported about 16% 
of schizophrenia patients on multiple antipsychotics.  However, the study claims that 
polypharmacy was linked with shorter length of hospitalization and fewer adverse effects 
(McCue, Waheed, & Urcuyo, 2003).  Procyshyn et al found that 27.5% of schizophrenic 
patients discharged from a tertiary psychiatric clinic were prescribed multiple 
antipsychotics. As compared to monotherapy, antipsychotic polytherapy was linked with 
greater use of anticholinergics (Procyshyn, Kennedy, Tse, & Thompson, 2001).  Clark et 
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al reported that antipsychotic polytherapy has increased from 5.7% in 1995 to 35.6% in 
1999 among schizophrenia patients (Clark, Bartels, Mellman, & Peacock, 2002).  A 
retrospective case-control study of multiple versus single antipsychotic treatment in 
psychiatric inpatients revealed that multiple antipsychotic therapy is associated with more 
adverse effects and hospitalizations but no clinical benefit (Centorrino et al., 2004).  A 
retrospective survey of discharge medications at a tertiary care psychiatric hospital found 
that antipsychotic polytherapy  was very common in schizoaffective disorder (49.3%), 
followed by schizophrenia (44.7%), bipolar disorder (29.9%), and psychosis not 
otherwise specified (22.5%) (Procyshyn & Thompson, 2004).  More data on polytherapy 
practices in bipolar disorder is lacking.  More studies are needed to develop guidelines to 
aid clinicians and health policy decision makers regarding antipsychotic polytherapy.  
Antipsychotic Use for Other Indications  
Though atypicals were introduced for the management of schizophrenia, they are 
increasingly being used for other indications.  A cross-sectional analysis of nursing home 
residents  from Jan. 1, 1999, to Jan. 31, 2000 revealed that atypical antipsychotic were 
generally used in Parkinson's disease, depression, Alzheimer's disease, and non-
Alzheimer dementia (Liperoti et al., 2003).   Antipsychotic use has also substantially 
increased for attention-deficit/hyperactivity disorder, conduct disorder, and affective 
disorders among patients aged 2 to 18 years (Cooper, Hickson, Fuchs, Arbogast, & Ray, 
2004).  Though already prevalent to some extent in clinical practice, use of certain 
atypical antipsychotics for bipolar disorder was recently approved by FDA.  However, 
antipyschotics use for conditions other than schizophrenia and bipolar disorders is not 
clearly supported by clinical studies and are not approved by FDA.   
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Antipsychotic Therapy and Economic Outcomes 
As schizophrenia and bipolar disorders are associated with the extensive use of 
inpatient services, treatments that can reduce inpatient utilization may decrease the 
overall costs and improve the quality of life for patients, their families, and society. 
Though more costly than typical antipsychotics, atypical antipsychotics offer better 
outcomes and may be cost-effective in the long run.  Despite the increase in pharmacy 
costs, atypicals have been shown to offset inpatient and outpatient costs as compared to 
typical antipsychotics (Csernansky & Schuchart, 2002; Gianfrancesco, Durkin, 
Mahmoud, & Wang, 2002; Gibson, Damler, Jackson, Wilder, & Ramsey, 2004; 
Nightengale, Garrett, Waugh, Lawrence, & Andrus, 1998).   
Each atypical antipsychotic has its unique pharmacologic profile and is priced 
differently.  However, there are very few pharmacoeconomic comparisons among the 
atypical antipsychotics.  To date, most of the published studies have compared only 
risperidone and olanzapine.  Relative advantage offered by one drug as compared to the 
other has differed depending upon study population, outcome measures, research and 
statistical design.  A prospective observational study comparing olanzapine and 
risperidone showed that olanzapine had a lower risk of psychiatric hospitalization than 
risperidone-treated schizophrenia patients within the first year (Ascher-Svanum, Zhu, 
Faries, & Ernst, 2004).  A retrospective analysis comparing total health care costs for 
patients initiated on risperidone or olanzapine between March 1997 and March 1999 
reported decline in costs for risperidone-treated patients and increase in costs for 
olanzapine-treated patients (Fuller, Shermock, Secic, Laich, & Durkin, 2002).  An 
analysis of Michigan Medicaid claims from January 1995 through September 1998 
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revealed that total costs were not significantly different between olanzapine, risperidone 
and haloperidol treated schizophrenia patients.  However, olanzapine was associated with 
lower inpatient costs and risperidone was associated with greater persistence with therapy 
(Gibson et al., 2004).  The results from the health economic data from the Risperidone 
Olanzapine Drug Outcomes studies in Schizophrenia (RODOS) program show that 
olanzapine was associated with higher total costs as compared to risperidone without any 
clinical benefit (Kasper, Jones, & Duchesne, 2001).  A study examining inpatient data of 
789 patients with schizophrenia or schizoaffective disorder initiated on risperidone or 
olanzapine reported higher discharge rate and lower drug costs among risperidone treated 
patients (Kelly, Nelson, Love, Yu, & Conley, 2001).  Another study showed that patients 
initiated on olanzapine were prescribed anti-parkinson drugs less frequently (Zhao, 
2002).  Costs and utilization among patients initiated on olanzapine or risperidone 
between January 1, 1997 and August 31, 1998 were compared using Texas Medicaid 
data.  Results showed no significant differences among schizophrenia-related costs but 
the total medical costs were lower among patients initiated in olanzapine (Rascati, 
Johnsrud, Crismon, Lage, & Barber, 2003).    
There is only one published economic analysis that compares risperidone, 
olanzapine and quetiapine in real world settings. This study evaluated only the pharmacy 
costs in an acute care inpatient setting.  The study reports lower pharmacy cost for 
risperidone and quetiapine as compared to olanzapine (Mladsi et al., 2004).  There are no 
other published studies comparing quetiapine, a relatively newer atypical antipsychotic, 
with other atypical antipsychotics in real world settings.  A clinical decision modeling 
study comparing atypical antipsychotics in terms of non-compliance, relapse and cost 
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among schizophrenia patients showed higher non- compliance, relapses, and incremental 
cost among risperidone and olanzapine treated patients as compared to quetiapine 
(Mortimer, Williams, & Meddis, 2003).  The Partial Responders International 
schizophrenia Evaluation (PRIZE) clinical trial comparing quetiapine and haloperidol 
using a Markov model showed that though quetiapine has the higher acquisition cost, it 
can lower costs for other medications, hospitalization, and other medical services (Tilden, 
Aristides, Meddis, & Burns, 2002).  
Literature on health care cost and utilization outcomes of antipsychotic therapy in 
bipolar disorder is lacking.  Economic outcomes from a randomized clinical trial of 
olanzapine treatment in patients diagnosed with bipolar I disorder with mania showed 
cost saving of almost $900 per month during the 49 weeks of olanzapine therapy. These 
cost savings were mainly attributed to reductions in in-patient costs.  Thus, it is possible 
that olanzapine and other atypicals may prove to be cost-effective in bipolar disorders if 
similar results can be shown in non-clinical trial populations (Namjoshi et al., 2002). 
There is only one published study comparing economic outcomes of different 
antipsychotics in bipolar disorder.  This study reports that mental-health related costs 
were higher for olanzapine as compared to risperidone and quetiapine.  There was no 
significant difference in costs between risperidone and quetiapine (Gianfrancesco, Pesa, 
& Wang, 2005).   
STATEMENT OF PROBLEM 
Several atypical antipsychotics have entered the market since the last decade.  
Evaluating utilization pattern and the value added to the therapy by these expensive 
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agents is becoming more important as their use continues to expand.  There is lack of 
data on the population demographics, treatment patterns, utilization and costs of these 
newer drugs in general population.  There is a need to document that antipsychotic use is 
not restricted to schizophrenia in clinical practice.  The purpose of the present study is to 
link the antipsychotic therapy patterns with healthcare utilization and costs in the West 
Virginia Medicaid population.  As previous studies have used data until 1998, there is a 
need for observational studies evaluating changes in utilization patterns with introduction 
of newer drugs.  
Antipsychotic polypharmacy is prevalent in clinical practice despite the lack of 
scientific evidence.  The practice probably results due to past experience or intuitive 
judgment of practicing physicians.  Studying the healthcare outcomes and economic 
consequences of this practice can be helpful in developing guidelines for antipsychotic 
polypharmacy.  They can also support the need for clinical trials evaluating the decision 
to use antipsychotic polypharmacy in some patients.    
State Medicaid is the single largest payer for mental health care.  In 1996, 
Medicaid spent about $12.6 billion on mental health care (Hogan, 1999).  The burden of 
mental disorders such as schizophrenia and bipolar disorder is very high due to the 
chronic nature, hospitalizations, comorbidities and disabilities associated with these 
diseases.  Due to very high unemployment among patients with such mental disorders, 
the state Medicaid bears the greatest impact of this disease (Hogan, 1998; Hogan, 1999).  
Atypical antipsychotics are among the ten most expensive medications for Medicaid 
(Clark et al., 2002).   If the pharmacotherapy is effective in controlling the disease 
symptoms and severity, it can reduce the need for medical services and offset costs.  
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Though newer antipsychotics have high acquisition costs, they offer advantages in 
treatment such as better adherence and reduced hospitalizations.  From a payer’s 
perspective, it is important to determine which atypical antipsychotic would be most 
effective in reducing utilization and generating savings in total healthcare expenditures in 
their patient population.  
Though the total medical cost is the most relevant economic outcome for 
formulary decision-making purposes, the differences in total cost depend upon 
differences in the use of inpatient services, physician services, concomitant medications, 
changes in treatment or treatment discontinuation rates, and relapse rates.  These 
components of healthcare costs need to be studied to gain better understanding of costs 
associated with antipsychotic use.  Very few studies in the literature have looked at the 
use of antipsychotics in bipolar disorder.  This study aims to provide more information in 
terms of describing utilization pattern and economic comparisons of antipsychotics in 
bipolar disorder.    
Randomized clinical trials have strict inclusion and exclusion criteria for patient 
enrollment. Their findings cannot be generalized to the real world settings where the 
patient population and treatment pattern is more diverse and complex.  Use of WV 
Medicaid data will allow us to study our objectives in a naturalistic setting and with 
larger sample sizes. 
CONCEPTUAL FRAMEWORK 
 
 In phase I, the study will describe different patterns of antipsychotic use in 
schizophrenia and bipolar disorder patients.  Predictors of different pattern of use will be 
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determined.   The effect of different patterns of use on utilization of healthcare services 
and costs will be evaluated.  The goal of phase II is to compare risperidone, olanzapine, 
quetiapine and typical antipsychotics on multiple healthcare outcomes such as healthcare 
costs, hospitalizations, emergency room visits, outpatient visits, concomitant drug use, 
and adherence and persistence with the index drug,  
 The rationale for the use of Medicaid data, sample selection criteria, identification 
of study cohorts, outcomes evaluation and sample selection bias adjustment is provided 
below.  
Selection of Database 
 Administrative claims database are usually large longitudinal databases developed 
for billing and payment purposes by the health plans.  They contain medical and 
pharmacy claims records of the health plan subscribers that can be used for research 
purposes.  Studies using retrospective databases use more relaxed exclusion criteria as 
compared to randomized clinical trials and have greater generalizability.  Claims database 
studies are a good alternative if the relevant clinical trial has not been conducted or 
cannot be conducted for ethical reasons.  Claims database studies are less costly and more 
reflective of real world setting.  These databases offer large population size and can 
provide sufficient sample size to give adequate power to the study.  They are less 
susceptible to Hawthorne effect (improvement of performance under observation) as the 
providers and patients are not contacted (Motheral & Fairman, 1997; Strom, 2005).   
 Medicaid offers comprehensive prescription and health benefits and likelihood of 
out-of system healthcare use among Medicaid population is rare.  Due to very high 
unemployment rate among schizophrenia and bipolar patients, prevalence and burden of 
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these diseases in Medicaid is high (Hogan, 1998; Hogan, 1999).  In addition, as the actual 
amount paid for each claim is present in the Medicaid data, it is a valuable resource to 
study direct costs and utilization of various healthcare components such as 
hospitalizations, emergency room visits, physician visits and prescriptions among 
schizophrenia and bipolar patients.   
Sample Selection 
 West Virginia Medicaid maintains data on patient-level demographic information, 
medical and prescription drug claims for its recipients.  West Virginia Medicaid data for 
the period January 1, 1998 to December 31, 2002 will be used for the purpose of the 
study.  Schizophrenia and bipolar disorder patients can be identified from this data on 
basis of ICD-9-CM codes.  All paid claims information on patients receiving at least two 
prescriptions of antipsychotics from January 1, 1999 to December 31, 2001 will be 
extracted.  This period will be defined as the index period.  Index date will be the first 
date of paid claim during the index period for the antipsychotic.  Patients should have at 
least 12 months of continuous enrollment with the West Virginia Medicaid before and 
after the index date.  The patients should not have any claims of an antipsychotic 
medication during a 90 days period before the index date to allow for a ‘wash-out’ period 
before considering the index prescription as initiation of antipsychotic therapy. 
Patients who were 65 years or older will be excluded as they have Medicare as their 
primary payer for health services.  Managed care recipients will be excluded as they do 
not have all their utilization information in the Medicaid claims.  As clozapine is 
indicated for treatment refractory schizophrenia, patients initiated on clozapine will be 
excluded.   Figure 1 provides the timeframe and study design.   
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Phase I 
Patterns of antipsychotic Use 
 The phase I of the study aims to evaluate the pattern of use of antipsychotic in 
schizophrenia and bipolar disorder patients.   All prescription claims after initiation of 
antipsychotic will be reviewed to determine the pattern of use of antipsychotic. 
 The pattern of antipsychotic use in schizophrenia will be categorized into 
following mutually exclusive categories: 
1) Antipsychotic Polytherapy (patients who are receiving two or more antipsychotics)  
2) Antipsychotic Monotherapy 
a) Switching (patients who change the index antipsychotic to another antipsychotic) 
b) Interrupted Therapy (patients receiving less than 80% days supply of index 
antipsychotic in the post-index period) 
c) Continuous Therapy (patients receiving at least 80% days supply of index 
antipsychotic in the post index period)  
 In addition, the pattern of antipsychotic use will also be studied in terms of: 
1) Stabilization on initiating antipsychotic therapy  
2) Gaps in antipsychotic therapies that indicate the missing days of antipsychotic therapy 
in the post-index period. 
1) Stabilization on initiating antipsychotic therapy  
 Proportion of patients who continued on index antipsychotic beyond the trial 
duration (based on recommendations by the Texas Medication Algorithm Project 
(TMAP) guidelines) will be determined (Miller et al., 1999). This indicates that the 
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patients responded to the index antipsychotic therapy during the trial duration and were 
continued on the index antipsychotic.  
 TMAP guidelines recommend trial duration of 3 -10 weeks (including a week of 
titration to therapeutic dose) after initiation of an antipsychotic before switching 
antipsychotics.  In this study, trial duration of 90 days after initiation of antipsychotic was 
selected as cut-off to classify the patients who continued on index antipsychotics for 3 
months or more and the patients who changed or discontinued the index antipsychotic 
within 3 months.  The 70 days trial duration recommended by TMAP was extended to 90 
days in our study based on expert opinion estimating usual physician practices and to 
allow for some gaps in refills by the patient.   
 In addition, the pattern of antipsychotic use in bipolar disorder will be categorized 
into following mutually exclusive categories: 
1) Antipsychotic Polytherapy (patients who are receiving two or more antipsychotics)  
2) Antipsychotic Monotherapy 
a) Switching (patients who change the index antipsychotic to another antipsychotic) 
b) Interrupted Therapy (patients receiving less than 80% days supply of index 
antipsychotic in the post-index period) 
c) Continuous Therapy (patients receiving at least 80% days supply of index 
antipsychotic in the post index period)  





Evaluating effect of patterns of use on healthcare cost and utilization 
 Treatment pattern of antipsychotic therapy is changing with the introduction of 
newer antipsychotics.  Switching between different antipsychotics is common (McCombs 
et al., 1999b; Tempier et al., 2003; Williams et al., 1999). Literature also reveals that 
there is considerable prevalence of antipsychotic polypharmacy in clinical practice 
settings (Clark et al., 2002; McCue et al., 2003).   Various factors such as disease 
severity, multiple comorbidities, antipsychotic type and patient characteristics can be 
responsible for existence of different pattern of use for antipsychotics.  Also, pattern of 
antipsychotic use can affect healthcare utilization and costs. It has been shown in some 
studies that antipsychotic polypharmacy or switching is associated with greater adverse 
affects, hospitalizations and psychiatric service utilization (Centorrino et al., 2004; Clark 
et al., 2002; McCue et al., 2003; Tempier et al., 2003).  It is likely that patients with 
polytherapy are more severe than patients on monotherapy. Our approach is to adjust for 
the sample selection bias that may exist between the different patterns of use groups prior 
to determining the relationship between patterns of use and healthcare outcomes.   Figure 
2 presents the conceptual framework regarding relationship between various factors that 
can influence pattern of antipsychotic therapy in the post-index period.  It also gives 
relationship between patterns of antipsychotic use, costs, and utilization.  
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Antipsychotic therapy and healthcare utilization and outcomes 
 
 Patients will be classified into the study cohorts based on the index prescription 
during the index period (January 1, 1999 – December 31, 2001). The first prescription of 
a study medication (Risperidone, Olanzapine, Quetiapine or typical antipsychotics) 
during the index period will be defined as the index prescription.  Intent to treat approach 
will be employed wherein the outcomes will be attributed to the index prescription 
irrespective of the medication pattern subsequent to index prescription.  The affect of 
index antipsychotic on healthcare costs and various components of healthcare utilization 
such as physician visits, hospitalizations and length of stay, emergency room visits, and 
concomitant psychiatric prescription use will be evaluated.  In addition, persistence with 
the index prescription and adherence to the index prescription will also be compared 
across the cohorts.  Adherence will be measured in terms of medication possession ratio 
(MPR).  
 Multivariate regression analysis will be conducted with each of the outcome 
variable as dependent variable and antipsychotic type as independent variable. Various 
other factors that affect  the outcome variables such as age, gender, prescribing physician 
specialty,  schizophrenia/bipolar subtype, disease severity,  schizophrenia/bipolar 
subtype, other mental illnesses,  substance abuse, alcohol abuse,   pre-index typical 
antipsychotic and other psychiatric  medication use, pre-index health care costs and 
utilization will be controlled for in the multivariate analysis.  As the assignment of 
patients into the index cohorts is not randomized, sample selection techniques will be 
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used to control for sample selection bias.  Figure 3 presents the conceptual framework 
describing the relationship between the index antipsychotic therapy and healthcare 
utilization and outcomes. 
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Sample Selection Bias Adjustment  
 As there is no randomization in studies based on claims database, they are prone 
to selection bias.  Selection bias is a systematic error associated with how the study 
sample is derived from study population and/or how study subjects are assigned to 
treatment group (Strom, 2005).  If we had all variables that are associated with the 
likelihood of receiving certain antipsychotic, we can control for them in a multivariate 
regression.  However, information on many relevant variables usually is not available in 
retrospective data.  This can bias the regression coefficients in a multivariate regression 
model estimating affect of treatment on costs and utilization.  Unobserved variables could 
be clinical variables needed to determine patient’s severity, prescribing physician’s 
preferences and prior experience, patient preference, and market structure forces 
 Heckman two-stage technique is a specialized econometric technique to control 
for the sample selection bias (Greene, 2000; Heckman, 1979).  The main concept behind 
the technique is that though we cannot correct the sample, we can correct the estimation.  
It tries to adjust the final estimation from the regression analysis for the unobserved or 
omitted variables. 
 Heckman two-stage technique involves the following two steps:   
Step 1:  
 The first step of the Heckman two-stage technique involves developing a 
selection model.  The selection bias is present due to differences in certain characteristics 
between the study cohorts that are related to the outcome variables (cost and utilization).  
The selection model compares the study cohorts to determine these differences.  
Heckman first-stage sample selection model uses a probit model as the selection model 
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when there are two choices.  Lee’s modification of Heckman sample selection model 
involves use of a multinomial logit (MNL) model as the selection model when there are 
more than two choices (Greene, 2000).  
 In the selection model, the dependent variable is the choice of drug therapy (or 
any treatment group).  The independent variables are relevant observed variables such as 
age, gender, race, comorbidities, physician specialty and prior medication history that can 
affect the choice of drug therapy.    The affect of these observed variables on the choice 
of drug therapy is estimated using the selection model.  When the affect of these observed 
variables on the dependent variable is removed, the remaining variation in the dependent 
variable is due to the unobserved variables.  Therefore, the residuals of the selection 
model provide information on the unobserved variables and are used to calculate a 
covariate or a control factor that can correct for selection bias in the second-stage model.  
Step 2: 
 The second-stage model is a multivariate regression model where the dependent 
variable is the study outcome such as cost and utilization.  The independent variables are 
relevant variables that can influence cost and utilization such as patient demographics, 
comorbidities, prior healthcare utilization, and choice of drug therapy.  The independent 
variables in the second-stage regression equation may overlap with those in the first-stage 
regression equation.  In addition, the control factor calculated in the first-stage selection 
model to control for unobserved variables is also included as an independent variable in 
the second-stage regression model. 
 If the coefficient of the control factor in the second-stage regression model is 
significant, it indicates that selection bias was present and some variation in the 
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dependent variable is due to unobserved variables.  However, the coefficient of the 
control factor captures the effects of unobserved variables on the outcome variables in the 
second-stage regression model.  This results in unbiased coefficients for other 
independent variables in the model.   
 Heckman’s two-stage model has been used successfully in many outcomes 
research studies (Crown et al., 1998; Crown, Treglia, Meneades, & White, 2001; 
McCollam, Lage, & Bala, 2001).  Other methods such as propensity scores technique and 
instrumental variable can also be used to control for selection bias.   However, propensity 
scores technique is more laborious and can reduce the sample size to matched 
observations.  Also, it controls for only observed variables whereas Heckman two-stage 
technique controls for both observed and unobserved variables.  The hindrance in using 
instrumental variable technique is to find an instrumental variable in claims database that 
is related to treatment choice but not to treatment outcomes (Crown et al., 1998) 
STUDY OBJECTIVES 
The overall goal of phase I is to study the pattern of antipsychotics use and its 
effects on utilization of healthcare services and expenditures.  The goal of phase II is to 
compare risperidone, olanzapine, quetiapine and typical antipsychotics on multiple 




Research Question 1  
To determine the annual prevalence rate of schizophrenia and bipolar disorder in West 
Virginia Medicaid from 1998 to 2002 
Rationale:  This is an exploratory question to assess prevalence rate of schizophrenia and 
bipolar disorder in West Virginia Medicaid from 1998 to 2002 
Research Question 2   
To determine the medical conditions for which antipsychotics are being prescribed in the 
West Virginia Medicaid population as well as describe patterns of distribution of certain 
demographic factors such as age, gender, and ethnicity in patients using antipsychotics.  
Rationale:  This is an exploratory question to assess prevalence of antipsychotic use for 
different medical conditions and differences in antipsychotic utilization by age, gender 
and ethnicity.  
Research Question 3 
For schizophrenia and bipolar disorder patients, determine different types of utilization 
pattern of antipsychotics.  
Rationale: For schizophrenia and bipolar disorder patients, there is no difference in the 
patterns of antipsychotic utilization in terms of: 
1) Polytherapy 
2) Monotherapy 
a) switching   
b) interrupted therapy  
c) continuous therapy   
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3) Stabilization of index antipsychotic (for schizophrenia patients) 
Research Question 4 
For schizophrenia and bipolar disorder patients, determine the gaps between the refills of 
antipyschotics.  
Rationale: There are no gaps in the antipsychotic therapy.  
Research Question 5 
For schizophrenia and bipolar disorder patients, determine predictors of different 
utilization patterns of antipsychotics    
Null Hypothesis: There is no association between utilization patterns of antipsychotics 
and patient demographics, prescribing physician type, mental health diagnosis, other 
medical diagnosis, type of antipsychotic, year of index antipsychotic, pre-index 
concomitant medication use, pre-index alcohol and substance abuse and pre-index 
healthcare utilization.  
Research Question 6 
For schizophrenia and bipolar disorder patients, determine the relationship between 
utilization pattern of antipsychotics and total health-related healthcare costs.  
Null Hypothesis: There is no association between utilization patterns of antipsychotics 
and total health-related healthcare utilization and costs.  
Research Question 7  
For schizophrenia and bipolar disorder patients, determine the relationship between 
utilization pattern of antipsychotics and mental health care utilization and costs.  
Null Hypothesis: There is no association between utilization patterns of antipsychotics 
and mental health healthcare utilization and costs.  
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Phase II 
Research Question 8 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine with 
risperidone, olanzapine, and typical antipsychotics on total and mental healthcare costs  
Null Hypothesis: There is no association between the choice of index antipsychotic drug 
and total and mental healthcare costs.  
Research Question 9 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine with 
risperidone, olanzapine, and typical antipsychotics on components of mental healthcare 
costs (costs associated with mental health-related inpatient, emergency room, outpatient 
and pharmacy services)  
Null Hypothesis: There is no association between the choice of index antipsychotic drug 
and costs associated with mental health-related inpatient, emergency room, outpatient and 
pharmacy services 
Research Question 10 
For schizophrenia and bipolar patients, to compare the impact of quetiapine with 
risperidone, olanzapine, and typical antipsychotics on mental health-related healthcare 
hospitalizations  
Null Hypothesis: There is no association between the choice of index antipsychotic drug 
and costs associated with mental health-related healthcare hospitalizations. 
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Research Question 11 
For schizophrenia patients and bipolar disorder patients, to compare the impact of 
quetiapine with risperidone, olanzapine, and typical antipsychotics on mental healthcare-
related emergency room visits 
Null Hypothesis: There is no association between the choice of index antipsychotic drug 
and costs associated with mental healthcare-related emergency room visits. 
Research Question 12 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine with 
risperidone, olanzapine, and typical antipsychotics on mental healthcare-related 
outpatient visits  
Null Hypothesis: There is no association between the choice of index antipsychotic drug 
and costs associated with mental healthcare-related physician visits. 
Research Question 13 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine with 
risperidone, olanzapine, and typical antipsychotics on psychiatric medication utilization  
Null Hypothesis: There is no association between the choice of index antipsychotic drug 
and costs associated with psychiatric medication utilization. 
Research Question 14 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine with 
risperidone, olanzapine, and typical antipsychotics on patient’s adherence to the index 
medications in the post-index period 
Null Hypothesis: There is no association between the choice of index antipsychotic drug 
and patient’s adherence to the index medications in the post-index period. 
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Research Question 15 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine with 
risperidone, olanzapine, and typical antipsychotics on subsequent index antipsychotic 
therapy modification  
Null Hypothesis: There is no association between the choice of index antipsychotic drug 




The results of this study will describe the prevalent pattern of antipsychotic drug 
use in the WV Medicaid and report the costs and health services utilization associated 
with these patterns. This can give us a picture of complex pharmacotherapy regimens that 
are used to manage patients in clinical practice. It will help us understand both patient 
behavior such as medication adherence as well as prescriber behavior in the West 
Virginia Medicaid program.  Economic endpoints will also be relevant from a formulary 
decision making perspective.  It can identify the consequences of inappropriate 
prescribing such as polytherapy that can add to the already strained Medicaid budget 
covering expensive antipsychotics.  This study can provide the basis for need for 
interventions such as academic detailing and other educational programs to improve 
prescribing patterns.  
As newer atypicals are similar in efficacy, costs associated with their use can play 
an important role in treatment decisions.  Considering the high acquisition costs of 
atypical antipsychotics, it important to monitor their utilization and costs within the 
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system.  In the proposed study, comparisons of antipsychotics will be differentiated in 
terms of multiple endpoints such as hospitalizations, emergency room visits, concomitant 
medication use, adherence and treatment discontinuation rates to give a better 
understanding of their impact on costs.   The study will also control for selection bias to 
provide a better estimation of affect of choice of antipsychotics on costs and utilization.  
The results of this study will also be useful in understanding relatively less studied 
economics of antipsychotic use in bipolar disorder.  These results can be useful to WV 
Medicaid to develop policies to provide better medication management for schizophrenia 
and bipolar patients.  
LIMITATIONS 
Use of administrative data can have certain disadvantages (Motheral et al., 1997). 
Inaccurate identification of diseases can occur due to errors in coding.  Identification of 
cases in a research study solely on the basis of an outpatient visit can seriously affect the 
validity of study.  However, hospital-based diagnoses have been shown to be very 
accurate (Bright, Avorn, & Everitt, 1989).  A study by Schwartz et al reported that about 
90-94% of cases with psychiatric diagnoses in Medicaid matched with the diagnoses in 
the chart demonstrating a very high reliability (Schwartz, Perlman, Paris, Schmidt, & 
Thornton, 1980).  A study by Lurie et al validated using an inpatient claim or two 
outpatient claims with ICD codes for schizophrenia within past 2 years as inclusion 
criteria to accurately identify schizophrenics in Medicaid.  They validated the diagnosis 
with the help of psychiatrics using DSM-III-R criteria for schizophrenia.  Therefore, the 
inclusion criteria of an inpatient claim or two outpatient claims within past 2 years could 
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be used with considerable confidence in our study to identify cases of schizophrenia in 
the WV Medicaid population (Lurie P, Popkin M, Dysken M, & Finch M., 1992).  
A claim for a prescription in the database indicates that the claim has been paid to 
the provider and not that medication has been taken correctly by the patient.  Claims for a 
drug do not necessarily indicate adherence with the therapy.  However, databases contain 
information such as date of service, amount dispensed and days of supply that can be 
used to calculate proxy measures for compliance.  Several studies have found significant 
correlations between adherence measured from refill information and other methods such 
as self-report, pill count, and medication diary (Choo et al., 1999). 
Threats to external validity are relatively lower in database studies as compared to 
randomized clinical trial.  However, one should be careful in claiming generalizability as 
characteristic of study population in different databases may differ according to age, sex, 
race, socioeconomic status, geography, etc.  Also, various factors such as co-pays, 
formularies, and provider access may be unique to West Virginia Medicaid. Practice 
patterns and costs also vary across time and geographically.  Thus, findings from a study 
population of a certain plan may not apply to populations from other plans.  Descriptive 
information about our study population characteristics will be given so that the readers 
can weigh the similarities and differences between the study population and the 
population in question. 
Due to lack of random assignment, there may be differences between patients 
initiated on different therapies.  Therefore, adjustments for sample selection bias are 
necessary.  Risk adjustments are also important to control for differences between the 
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groups.  A study by Sernyak et al validated use of sociodemographic variables, prior 
utilization and cost variables obtained from administrative data as risk adjusters to predict 
future utilization and costs.   The study compared models that used administrative data 
alone with models that used administrative data as well as clinical data from a 
prospective, double-blind clinical trial.  The models using combination data yielded an 
adjusted r-square of 0.31-0.27 that was not significantly different from adjusted r-square 
of 0.24-0.28 that was obtained from models that used only administrative data (Sernyak 
& Rosenheck, 2003).  Our study will control for confounding using sociodemographics, 







Epidemiology and Cost 
 Schizophrenia is a complex psychiatric disorder affecting about 0.2% to 2% of the 
population.  Despite the low prevalence of the disease, schizophrenia is the most 
expensive psychiatry disorder to treat (Knapp, 1997).  The burden of disease is high due 
to early onset, chronic nature, hospitalizations, comorbidities and disabilities.  
Schizophrenia costs constitute 2.5% of total healthcare expenditures.  Schizophrenic 
patients consume about 10% of social security benefits.  About 70-80% schizophrenic 
patients are unemployed (Foster & Goa, 1998).   In 1991, direct and indirect costs 
associated with schizophrenia were estimated to be $18.6 billion and $46.5 billion, 
respectively.  Hospitalizations are responsible for almost 70% of costs, drug costs for            
almost 10%, and outpatient costs usually make up the rest of the 20% (Revicki, 1997). 
Prolonged / frequent episodes, long term hospitalization, and care in intensive community 
programs incur most of the direct costs.  Cost of social welfare, criminal justice services 
and family productivity are included in the indirect costs (Revicki, 1997).  Annual total 
healthcare costs per schizophrenia patient was estimated to range between $16,000 and 
$57,000 in 1999 (Mauskopf et al., 1999).  
 Schizophrenia symptoms usually appear in the late teens or early twenties in men 
and in the twenties to early thirties in women (APA, 1997; Crismon ML & Dorson PG., 
1997).  Prevalence is similar between the genders (APA, 1997; Crismon ML et al., 1997).   
The disease is chronic in nature and relapses requiring hospitalization could be frequent. 
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Most patients are readmitted within 3 to 5 years (APA, 1997).  Risk of other medical 
illnesses and mortality from suicide is also high among patients with Schizophrenia 
(Carpenter, Jr. & Buchanan, 1994).  Schizophrenic patients are at risk for substance 
abuse, suicide, and disability (APA, 1997).  Almost 25-50% attempt suicides and almost 
10% commit suicide.  About 10% of disabled US population is schizophrenic (Foster et 
al., 1998). 
Disease Description 
 Symptoms of schizophrenia include thought disorders, emotional changes, 
delusion and perception disorders (hallucinations, sensory effects), aggressive behavior, 
impaired judgment, ideas of reference, withdrawal from external reality, eccentric or 
ritualistic behavior (Crismon ML et al., 1997).  A schizophrenic patient may not be able 
to function in society and take care of himself (Crismon ML et al., 1997).  According to 
the American Psychiatry Association (APA) guidelines, (APA, 1997) phases of 
schizophrenia can be classified into: 1) Acute phase: The patient exhibits some of the 
most severe symptoms in this phase.  The patient may experience hallucinations, 
delusions, and severely disorganized behavior and/or thinking.  Prior to this phase, the 
individual may become more withdrawn or behave in an unusual manner.  Symptoms 
may gradually become more severe and lead to an acute episode.  An acute episode 
usually requires hospitalization.  The duration of this phase depends on several factors 
including patient characteristics and environment. 2) Stabilization phase:  This phase 
begins as the psychotic symptoms decrease in severity and may last for 6 months or 
more. 3) Stable phase: Most of the psychotic symptoms become stable in this phase. 
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Some idiosyncratic behaviors and nonpsychotic symptoms, such as depression, anxiety, 
tension, or insomnia, may still persist.  
Pharmacotherapy in Schizophrenia  
Schizophrenia treatment comprises of pharmacotherapy and psychosocial 
treatment or rehabilitation (Lehman et al., 2004b).   Pharmacotherapy of schizophrenia 
involves use of conventional antipsychotics and relatively newer atypical antipsychotics.  
The typical or conventional antipsychotics include the phenothiazines (chlorpromazine, 
fluphenazine, mesoridazine, perphenazine, prochlorperazine, trifluoperazine, and 
thioridazine), butyrophenones (haloperidol), thioxanthenes (thiothixene), and 
dihydrolones (molindone and loxapine).  Efficacy of the typical agents is due to blockade 
of the dopamine D2 receptors.   The blockade also is responsible for their side-effect 
profiles.  Most of the conventional antipsychotics are comparable in efficacy. Typically, 
these agents decrease only the positive symptoms of schizophrenia.  Depending on the 
extent of blockade, these agents may actually worsen negative symptoms.  The common 
side-affects of typical antipsychotics (Crismon ML et al., 1997) are: 
a. Acute extrapyramidal effects:  These can lead to acute dystonia (spasm of face, neck, 
back muscles), Akathesia, Parkinsonism (bradykinesia, rigidity, tremor, mask face).  
b. Neuroleptic malignant syndrome:  These are rare but can be fatal. These are 
characterized by course tremor, catatonia, fluctuating vital signs, metabolic 
abnormalities.  
c. Chronic extrapyramidal effect or tardive dyskinesia can develop during long-term 
treatment.  
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d. Autonomic effects such as antimuscarinic effects (dry mouth, constipation, difficulty 
urinating) or effects due to blockade of α1 receptors (orthostatic hypotension, sexual 
dysfunction).  
e. Endocrine effects are responsible for hyperprolactinemia (due to dopamine receptor 
blockade) that can lead to galactorrhoea, amenorrhoea and gynaecomastia. Weight gain is 
possible due to hyperprolactinemia and 5HT blockade.  
f. Psychological effects such as sedation and cognitive impairment can occur depending 
upon the drug. 
Atypical Antipsychotics  
 Several atypical antipsychotics, especially effective in addressing both the 
negative symptoms and positive symptoms of schizophrenia, have entered the market in 
the last decade.  For example, Clozapine (Novartis 1990), Risperidone (Janssen 1993),  
Olanzapine (EliLilly 1996), Quetiapine (Zeneca 1997), Ziprasidone (Pfizer 2001) and 
Aripiprazole (Bristol Myers Squibb 2002).  These agents antagonize serotonin 5HT2a and 
dopamine D2 receptors.  Therefore, there is a lower incidence of extrapyramidal side 
effects (Carpenter, Jr. et al., 1994).  These atypical antipsychotics have high acquisition 
costs but are more affective in controlling positive symptoms and have more tolerable 
extra pyramidal symptoms profile. 
  Efficacy of atypical antipsychotics is comparable to typical antipsychotics for 
most aspects of schizophrenia (Carpenter, Jr. et al., 1994; Carpenter, Jr. et al., 1994).  
Atypicals have similar or slightly better global clinical efficacy for positive symptoms as 
compared to typical antipsychotics.  They have shown better relapse prevention than 
typical antipsychotics in controlled trials.   Clozapine, risperidone, olanzapine and 
35 
ziprasidone have been shown to be much better efficacy for negative symptoms as 
compared to typical antipsychotics.  Quetiapine is similar to typical antipsychotic for 
negative symptoms.  Atypical antisychotics show better efficacy than typical 
antipsychotics in controlling affective symptoms, depression and suicidality.  Clozapine 
is much superior to typical antipsychotics and other atypical antipsychotics for treatment 
refractory patients (Carpenter, Jr. et al., 1994). 
Side effect profile of atypical antipsychotics is much better than typical 
antipsychotics (APA, 1997; Carpenter, Jr. et al., 1994).  Acute extrapyramidal effects 
(EPS) are less likely with atypical antipsychotics.  Neuroleptic malignant syndrome is 
rare but can occur.  Chronic extrapyramidal effect / tardive dyskinesia is much less likely 
with atypical antipsychotics.  Autonomic effects depend upon the drug but are similar to 
typical antipsychotics.  Endocrine effects such as hyperprolactinemia are less likely with 
typical antipsychotics.  However, recent studies have shown that risk of hyperglycemia, 
diabetes, and hyperlipedemia may be higher in patients using antipsychotics (Koro et al., 
2002; Lindenmayer et al., 2003).  These effects may vary from drug to drug (Koro et al., 
2002; Lindenmayer et al., 2003).   Also, weight gain can be greater due to 5HT and 
histamine receptor blockade.  Psychological effects such as sedation depend on drug but 
are similar to typicals.  Impaired cognition may be less than with typical antipsychotics.  
Clozapine can cause blood dyscrasias (agranulocytosis) and requires white count check 
frequently (Amadio, Cross, & Amadio, Jr., 1997).  
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Antipsychotic Treatment Guidelines for Schizophrenia 
 The Texas Medication Algorithm Project (TMAP) has developed stepwise 
algorithms for schizophrenia pharmacotherapy.  First published in 1999, they were 
updated in 2003 to include recommendations for ziprasidone and ariprazole (Miller et al., 
1999; Miller, 2004). TMAP guidelines recommend using atypical antipsychotics 
(olanzapine/ quetiapine/ risperidone) as first-line of treatment (Miller et al., 1999). In 
2003, ziprasidone and ariprazole were also included among the list of atypical 
antipsychotic to be used as first-line therapy (Miller, 2004).  According to TMAP 
guidelines, duration of trial with the antipsychotic should be at least 3 weeks and at the 
most 10 weeks.  The guidelines suggest trying the 3 atypicals in sequential order and then 
a typical antipsychotic before using clozapine. Monotherapy is recommended until 
clozapine fails.  Weekly (or at least every two weeks) visits until the patient is stable is 
advised for outpatients who are switching antipsychotic medications.  Other guidelines 
such as American Psychiatric Association (APA) guidelines suggest typical or atypical 
antipsychotics as first-line treatment whereas TMAP guidelines emphasize use of 
atypicals (American Psychiatric Association, 1997).   However, APA guidelines do not 
recommend any form of polytherapy.  TMAP guideline recommends polytherapy but 
only after a trial with clozapine fails.  
Antipsychotics Utilization Patterns in Schizophrenia  
 Antipsychotic utilization patterns among schizophrenia patients in clinical 
practice can be classified into predominant categories such as polypharmacy, switching, 






 Despite the lack of controlled clinical trials evaluating efficacy of antipsychotic 
polypharmacy, it has considerable prevalence in clinical practice.  Prevalence of 
antipsychotic polypharmacy has been reported to range from 6.8% to 41% in various 
populations.  An analysis of outpatient prescriptions in Veteran Administration (VA) 
schizophrenia population revealed only 6.8% received polytherapy (Leslie & Rosenheck, 
2001).  Studies evaluating antipsychotic use among hospitalized patients have found 
higher rates (16% - 45%) of polytherapy (Schumacher, Makela, & Griffin, 2003; 
Procyshyn et al., 2001; Procyshyn et al., 2004; McCue et al., 2003). Antipsychotic 
polypharmacy increased from 5.7% in 1995 to 24.5% in 1999 among the New Hampshire 
Medicaid beneficiaries with schizophrenia (Clark et al., 2002). Prevalence of 
antipsychotic polypharmacy between 1998 and 2000 was about 40% in a sample of 
Georgia Medicaid and California Medicaid Schizophrenia patients (Ganguly, Kotzan, 
Miller, Kennedy, & Martin, 2004).  Prevalence of antipsychotic polytherapy among 
Rhode Island Medicaid’s elderly and disabled population was about 10% in 2003 (Kogut, 
Yam, & Dufresne, 2005).  A retrospective review of medication information for all 
patients discharged from a tertiary care psychiatric facility between January 1, 2000 and 
December 31, 2000  revealed highest rate of antipsychotic polypharmacy among patients 
with schizoaffective disorder (49.3%), followed by schizophrenia (44.7%) (Procyshyn et 
al., 2004). 
 As each atypical antipsychotic has a unique receptor profile, there may be 
theoretical rationale in combining these medications to manage symptoms for some 
patients.  Physician surveys have revealed that the most common reason cited for 
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prescribing polytherapy was to reduce the positive symptoms.  In many cases, physicians 
have stated that addition of another antipsychotic was intended to be transitional but 
continued because of patient’s preference or improvement in symptoms (Sernyak & 
Rosenheck, 2004; Tapp et al., 2003).  A physician survey by Schumacher and colleagues 
reported therapy augmentation as the most common rationale for polytherapy. However, 
majority of the patients treated by these physicians had not received a trial of atypical or 
typical monotherapy or clozapine before receiving polytherapy (Schumacher et al., 
2003).   Case reports and retrospective charts reviews evaluating antipsychotic 
polypharmacy do not provide any conclusive information regarding efficacy and adverse 
effects of this practice (Freudenreich & Goff, 2002).   One open prospective trial reported 
increased risk of mortality during 10-year follow-up period among schizophrenia patients 
on antipsychotic polytherapy (Waddington, Youssef, & Kinsella, 1998).  The difference 
in mortality rates may be due to selective prescription of antipsychotic polypharmacy to 
more severe patients.   
 There are very few studies evaluating economic consequences of antipsychotic 
polytherapy.  Majority of these studies are restricted to inpatient settings.  McCue and 
colleagues used hospital records of an inpatient psychiatry facility to compare 
schizophrenia patients who were discharged in the year 1995 to schizophrenia patients 
who were discharged in 2000.   They reported that no patients discharged in 1995 
received polytherapy whereas 15.9% of patients discharged in 2000 received polytherapy.  
They also report lesser adverse drug reactions and shorter length of hospital stay among 
patients discharged in 2000.   As they examined cross-sectional data in 1995 and 2000, 
we cannot make inference regarding association of polypharmacy with decreased adverse 
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drug reactions and length of stay.  Prescribing practices for schizophrenia has changed 
considerably between 1995 and 2000 due to greater use of atypical antipsychotics.  Fewer 
adverse effects may be attributed to fewer EPS side-effects with the atypicals.   A 
retrospective review of medications prescribed during discharge from a tertiary 
psychiatry facility to non-elderly patients between November 1, 1996 and October 31, 
1998 revealed that 27.5% were discharged on antipsychotic polypharmacy.  Despite a 
small sample size of the study (N = 229), antipsychotic polytherapy was significantly 
associated   with greater use of anticholinergics compared to monotherapy (Procyshyn et 
al., 2001).   Centorrino and colleagues used a case-control study design to compare 
polypharmacy with monotherapy using inpatient records of psychiatric patients.  Seventy 
patients receiving 2 or more antipsychotics for at least 3 consecutive days were identified 
as cases and matched with 70 patients who received only one antipsychotic.  Cases and 
controls were matched on gender, age, psychiatric disorder (schizophrenia/ bipolar 
disorder/ or other disorders) and illness severity.  The analysis revealed that although 
there were similar clinical improvements in both groups, patients on polytherapy had 
55% longer length of stay and 56% higher risk of adverse effects than patients on 
monotherapy (Centorrino et al., 2004).   
Antipsychotic Switching and Discontinuation 
 
Pharmacotherapy of schizophrenia often requires switching between the 
medications (Bogan, Shellhorn, Brown, McDanald, & Suppes, 2000; Burns, Chabannes, 
& Demyttenaere, 2002; Menzin, Boulanger, Friedman, Mackell, & Lloyd, 2003). 
Switching can occur if there is inadequate control of positive symptoms, residual 
negative symptoms such as apathy and mood symptoms.  Atypical antipychotics are 
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better at controlling mood symptoms like depression.  Atypicals also have fewer 
pyramidal side-effects compared to conventional antipsychotics.  Therefore, many 
patients can be switched to atypicals.  Introduction of new atypical drugs in market can 
lead to switches from previously used drugs.  Prescriber may switch drug if the patient 
relapses despite compliance.  However, weight gain and high cost of atypical drugs can 
also lead to non-compliance(1999).   
Non-compliance is a critical problem with antipsychotic therapy.  Non-
compliance is mainly a result of disabling adverse effects such as extrapyramidal 
symptoms (EPS) that can offset the benefits of the therapy (Van Putten, 1974).  EPS 
symptoms include muscular rigidity and cramping, tremors, gait disturbances, drooling, 
agitation, and involuntary abnormal movements of the lips, tongue, and facial muscles.  
Other adverse effects such as gynecomastia, galactorrhea, amenorrhea and impotence that 
are related to elevated prolactin concentrations also reduce compliance (Hamner, 
Arvanitis, Miller, Link, & Hong, 1996).  About 50% of schizophrenic patients who 
discontinue their antipsychotic therapy relapse within a year (Pigott et al., 2003).  Non-
compliance is also responsible for repeated hospitalizations also known as “revolving 
door syndrome” among schizophrenics (Haywood et al., 1995).  About 37% of direct 
costs within 2 years of discharge after first hospitalization results due to non-compliance 
(Weiden & Olfson, 1995).  Because of better side-effect profile, atypical antipyschotics 
have shown better compliance and are recommended as the first-line treatment for 
schizophrenia.  About 30% of patients relapse with typical antipychotics whereas about 
20% of patients relapse with atypical antipsychotics (Weiden, Aquila, & Standard, 1996).   
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Patient non-compliance due to disease nature and side-effects of medications can 
result in high discontinuation rates. Increasing patient persistence with the given 
antipsychotic therapy is a challenge for health care providers.  In addition, about 5%-25% 
of schizophrenia patients are treatment refractory (Brenner et al., 1990).  The physician’s 
attempts to control symptoms in these patients can lead to varying patterns of 
antipsychotic use.   
In 1995, Williams and colleagues studied use of antipsychotic in an outpatient 
patient population with schizophrenia using Regenstrief Medical Record System. Out of 
316 study sample, about 88% received typical and 12% received atypical antipsychotic.  
About 71.5% of patients received only antipsychotic whereas about 25% of patients 
switched to another antipsychotic during the 1-year follow-up period.  About 30% of 
patients received continuous antipsychotic treatment for one year.  About 67.1% of 
patients had a gap of 1-11 months in their antipsychotic therapy.  Factors associated with 
continuous use of antipsychotics in this patient population were not investigated 
(Williams et al., 1999).  A study by Al-Zakwani and colleagues followed 469 managed 
care plan enrollees who were initiated on antipsychotics irrespective of mental health 
diagnosis for one year. Patients were initiated on antipsychotic between 1999 and 2000. 
About 81.8% received atypical and 18.2% received typical antipsychotic.  The proportion 
of patients who switched from atypical antipsychotics (18.2%) was not significantly 
different from proportion of patients who switched from typical antipsychotics (12.9%) 
(Al Zakwani et al., 2003).   
There are two studies investigating various types of antipsychotic utilization 
patterns in schizophrenia patient population predominantly on typical antipsychotics.  
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McCombs and colleagues used administrative claims data from the California Medicaid 
program (Medi-Cal) to study utilization pattern of antipsychotics from 1987 to 1996.  A 
total of 2,655 schizophrenia patients were identified between 1987 and 1996. During the 
time period of the study, they found that about 98% of patients were on conventional 
antipyschotics. About 47% of patients switched or augmented their therapy within one 
year. Only 11.6% of patients received continuous antipsychotic therapy for one year.  The 
average duration of antipsychotic therapy was 142 days.  They also reported that factors 
such as increasing age, manic disorder, major depression, bipolar disorder and non-
organic psychosis are associated with switching (McCombs et al., 1999b).  A cost 
analysis of association between these patterns of use and healthcare costs revealed that 
antipsychotic switching can increase the annual total cost by $9,719 (McCombs et al., 
2000).  However, as 98% of their patient population was on typical antipsychotics, these 
factors do not provide information on switching from atypical therapy.   
Loosbrook and colleagues used an employer claims database to study utilization 
pattern of antipsychotics and associated costs with utilization patterns during the year 
1997 (Loosbrock, Zhao, Johnstone, & Morris, 2003).   The study reports about 26% of 
schizophrenia patients received no antipsychotic therapy, 52% received only one 
antipsychotic, 13% switched, 7% augmented with additional antipsychotic, and 2% 
received more than one antipsychotics at the beginning of the year.  Regression analysis, 
adjusting for various covariates such as age, gender, schizophrenia subtype, 
comorbidities, and prior costs, revealed that antipsychotic switching and augmentation 
can increase the total cost by $4,706 and $4,244, respectively.   
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None of the above studies adjusted for selection bias that may exist among 
patients who follow different patterns of utilization.  Majority of antipsychotic use was of 
typicals as the most recent data used was upto 1997.  
Bipolar Disorder 
Epidemiology and Cost 
Bipolar disorder, also referred to as manic depressive illness, is characterized by 
periodic episodes ranging from mania (e.g. euphoria, grandiosity, impulsivity, excessive 
libido) to the depression (e.g. depression, anxiety, violence, suicidal thoughts and 
activity).  Psychotic symptoms such as delusions and hallucinations are also common in 
case of acute mania (Perry, Tarrier, Morriss, McCarthy, & Limb, 1999; APA, 1994). The 
lifetime prevalence of bipolar disorder in the US population is about 1.2% to 1.6% 
(Kessler et al., 1994).  The estimated economic burden of the disorder is about $45 
billion.  The direct costs are estimated at $7.6 billion and indirect costs at $38 billion. 
About 60-70% of direct costs were attributable to inpatient costs (Wyatt et al., 1995). 
Medication costs constitute about 2% of direct costs.  The annual medication cost per 
treated patient was about $548 (Wyatt et al., 1995).  About 75% of bipolar patients 
undergo at least one hospitalization during the course of their illness (Lish et al., 1994). 
About 10% of inpatient healthcare in US is utilized by bipolar patients (Narrow et al., 
1993).  Costs for patients with bipolar disorder is higher than costs for patients treated for 
depression or diabetes (Simon et al., 1999).  Also, the disorder is the sixth leading cause 
of disability in the world (Jenkins, 1997).  The chronic relapsing nature of the bipolar 
disorder impairs psychosocial functioning and ability to work in patients (Goldberg, 
Harrow, & Grossman, 1995).  About 50% of patients are unable to live independently or 
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retain employment (Levine, Chengappa, Brar, Gershon, & Kupfer, 2001).  Among 
employed bipolar patients, the employment does not match the educational level attained 
by these patients before the onset of the disease (Tse & Walsh, 2001).  
About 20% of severely mentally ill patients have diagnosis of bipolar (Clark et 
al., 1998).  The prevalence of bipolar disorder is similar among adolescents and adults 
and between genders (Lewinsohn, Klein, & Seeley, 1995; Weissman et al., 1996).  Mean 
age of onset is 18 years for bipolar I and 22 years for bipolar II (Weissman et al., 1988). 
The rate of mortality among untreated bipolar disorder patients is about 19% and is 
comparable  to heart disease and cancer patients (Hopkins & Gelenberg, 1994). Suicide 
rates are about 11-15% (Hilty, Brady, & Hales, 1999; Shepherd & Hill, 1996). 
Commonly prevalent comorbidities among bipolar patients are alcohol and drug abuse, 
anxiety and personality disorders (Shepherd et al., 1996; Strakowski et al., 1998; 
Strakowski & DelBello, 2000).  
Disease Description 
The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-
IV) classifies bipolar disorder into: bipolar I, bipolar II and cyclothymia (APA, 1994).    
Bipolar I disorder is characterized by manic-depressive episodes of duration greater than 
1 week.   Manic episode is characterized by feelings of self-importance, elation, 
talkativeness, increased sociability, irritability, impatience, hyperactivity, and a decreased 
need for sleep.  Mixed states consisting of manic or hypomanic (milder form of mania) 
episodes and depressive episodes can also occur in bipolar I patients.  Bipolar II disorder 
is characterized by major depressive episodes along with episodes of hypomania.  
Patients with bipolar depression show retarded mental and physical processes, extreme 
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fatigue, and hypersomnia.  Bipolar depression may be difficult to distinguish from a 
unipolar major depressive episode.   Cyclothymia refers to less severe but multiple 
episodes of hypomania and depression.   DSM also defines a phenomenon of rapid 
cycling in bipolar episodes where manic and depressive episodes alternate at least 4 times 
in 12 months.   Studies have reported about 34-61% relapse rates among patients 
receiving treatment (Bowden, 2000; Harrow, Goldberg, Grossman, & Meltzer, 1990; 
O'Connell, Mayo, Flatow, Cuthbertson, & O'Brien, 1991).  
Pharmacotherapy in Bipolar Disorder 
Treatment for bipolar disorder aims to stabilize mood and alleviate mania or 
depression.  Although mood stabilizer such as lithium has been recommended as the first-
line treatment for bipolar disorder, about 42-62% of patients are resistant to lithium 
(Solomon, Keitner, Miller, Shea, & Keller, 1995).  About 80% of patients with mixed and 
rapid cycling bipolar disorder are resistant to lithium (Tohen & Zarate, Jr., 1998).   There 
are problems with lithium treatment like its toxic doses are close to its therapeutic range. 
Common side-effects of lithium are tremor, gastrointestinal irritation, cognitive dulling, 
and renal, thyroid and cardiovascular side-effects on prolonged use.  Early 
discontinuation of lithium therapy is common (Moller & Nasrallah, 2003).  Other 
medications recommended for bipolar treatment include anticonvulsants, antipsychotics, 
and antidepressants.  Anticonvulsants such as divalproex and carbamazepine are used for 
acute treatment and long term maintenance therapy (Moller et al., 2003).   
Antidepressants are recommended as an adjunct with mood stabilizer in severely 
depressed and suicidal patients (Bottlender, Rudolf, Strauss, & Moller, 2001).  Use of 
antidepressants is risky as they may induce mania or rapid cycling (Moller et al., 2003).  
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Antipsychotics have been recommended as an adjunct to a mood stabilizer in US 
for bipolar disorder with resistant mania, psychoses, agitation and insomnia (Sachs, 
Printz, Kahn, Carpenter, & Docherty, 2000).  However, monotherapy with antipsychotics 
has been used as first-line treatment for severe and hospitalized bipolar patients in Europe 
(Moller et al., 2003).   Typical antipsychotics show similar efficacy to lithium for treating 
mania but may fail to prevent or may induce depression (McElroy, Keck, Jr., & 
Strakowski, 1996).  Also, the risk of tardive dyskinesia with typical antipsychotics can 
lead to non-compliance and relapse (Moller et al., 2003).  Recent studies have shown 
efficacy of atypical antipsychotics in treating both manic and depressive symptoms in 
bipolar patients with and without psychoses (Frye et al., 1998; Sanger et al., 2003; 
Shattell et al., 2004; Strakowski, Del Bello, Adler, & Keck, Jr., 2003).  Use of olanzapine 
was recommended as an alternative to lithium or divalproex for acute mania by Texas 
Medication Algorithm (Suppes et al., 2003).   Though Olanzapine, quetiapine, 
risperidone, ziprasidone and ariprazole were recently approved by FDA for use in bipolar 
disorder (Shattell et al., 2004; Perlis, 2005), the use of antipsychotics to treat mania has 
been widely prevalent in clinical practice (Licht et al., 1994).  
Treatment Guidelines for Bipolar Disorder 
 Treatment guidelines for bipolar disorder differ between different committees 
such as TMAP, APA or expert consensus guidelines and according to bipolar subtype.  In 
general, monotherapy with lithium, divalproex sodium or atypical antipsychotic is 
recommended as first-line treatment for mania or hypomania.  In case of partial response 
or non-response, combination of mood stabilizer or anticonvulsant or atypical 
antipsychotic is usually advised (Fountoulakis et al., 2005).  TMAP guidelines 
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recommend monotherapy with lithium or divalproex or atypical antipsychotic as first-line 
treatment.  APA guidelines recommend use of lithium or a combination of mood 
stabilizer with an atypical antipsychotic as the first-line therapy.   For bipolar depression 
with psychosis, atypical antipsychotic is required as an alternative to electroconvulsive 
therapy (ECT) (Perlis, 2005). 
Antipsychotic Utilization Pattern in Bipolar Disorder 
 There are very few studies investigating pattern of use of antipsychotics among 
bipolar patients.  However, majority of studies looking at pharmacotherapy patterns in 
bipolar disorder have reported considerable prevalence of antipsychotic use as 
monotherapy and in combination with mood stabilizers among bipolar patients.  
A meta-analysis of 16 studies published between 1980 and 1999 showed that use 
of typical antipsychotic was common in bipolar patients.  About 84.7% of bipolar 
patients received typical antipsychotics.  About 53.8% of typical antipsychotic use was as 
monotherapy whereas about 47.4% of typical antipsychotic use was in combination with 
a mood stabilizer (Tohen et al., 2001).   A study by Russo and colleagues studied pattern 
of pharmacotherapy in bipolar disorder between 1994 and 1998 using a privately insured 
managed care patients.   The study reports that out of 3,057 bipolar patients, 78% were 
using lithium or valproate, 16.4% were using typical antipsychotics, 12.4% were using 
atypical antipsychotics and 74% were using antidepressants.  As the drug categories were 
not mutually exclusive, patients could be on all or any of these medications.  Patients 
who initiated on lithium or valproate, antipsychotics, antidepressants or anticonvulsants 
were followed for one year to study patterns of continuous or discontinuous use, and 
switch.  However, results of logistic regression analysis showed that patients initiated on 
48 
antipsychotics were more likely to use them for 12 months or more compared to patients 
initiated on lithium/ valproate.   As compared to lithium/valproate, patients initiated on 
antidepressants were more likely to switch and patients initiated on anticonvulsants were 
more likely to discontinue medications.  Proportion of patients initiated on each drug 
category was not reported (Russo et al., 2002).   
Craig and colleagues examined patterns of medication use among first-admission 
bipolar disorder patients between 1989 and 1995.  A sample of 155 patients was followed 
for 24 months.  Medication use and clinical assessments were observed at baseline, 6-
month and 24-month time period.   Early and regular use of lithium/ valproate or 
carbamazepine was associated with better Global Assessment of Functioning (GAF) 
scores and lesser time in remission.  The study reported that antipsychotic use was 
associated with poor clinical outcomes in these patients (Craig et al., 2004).   It is 
possible that more severe bipolar patients may be receiving antipsychotics.  Also, most 
patients in the study received typical antipsychotics 
 Procyshyn and colleagues conducted a retrospective review of medication 
information for all patients discharged from a tertiary care psychiatric facility between 
January 1, 2000 and December 31, 2000.   They found a 29.9% prevalence of 
antipsychotic polypharmacy among bipolar disorder (Procyshyn et al., 2004). 
Antipsychotic Use for Other Indications  
Few studies have reported us of antipsychotics for other indications. Liperotti and 
colleagues used a cross-sectional data between January 1, 1999 and January 31, 2000 
from 1,732 nursing homes from 5 US states.  They reported  that atypical antipsychotic 
use was associated with Parkinson's disease, depression, Alzheimer's disease, and non-
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Alzheimer dementia (Liperoti et al., 2003).   Cooper and colleagues used Tennessee's 
Medicaid managed care data to study the use of antipsychotics among patients aged 2 to 
18 years (Cooper et al., 2004).  They report that antipsychotic use among children has 
increased almost 2-5 folds in attention-deficit/hyperactivity disorder, and affective 
disorders between 1996 and 2001.   Other than schizophrenia, antipsychotics were also 
used in acute psychotic reaction and autism.   A retrospective chart review of 2000 charts 
to determine atypical antipsychotic use as augmentation agent to antidepressants in 
treatment-resistant major depression patients captured 49 cases (Barbee, Conrad, & 
Jamhour, 2004).    
Antipsychotics use for conditions other than schizophrenia and bipolar disorders 
is still under investigation in clinical trials and is not approved by FDA (Shelton, 2003; 
Ostroff & Nelson, 1999; Kaplan, 2000).   However, prevalence of antipsychotic use in 
other conditions is present in clinical practice and needs to be documented.  
Antipsychotic Therapy and Economic Outcomes in Schizophrenia  
Pharmacoeconomic studies in schizophrenia focus on testing the hypothesis that 
atypical antipsychotics will decrease utilization of healthcare services leading to 
reduction in overall treatment costs and improve patient outcomes.  Most 
pharmacoeconomic evaluations focus on comparing total healthcare costs, which are 
definitely an important endpoint from formulary decision-making perspective.   
Atypical antipsychotics have been shown to offset inpatient and outpatient costs 
as compared to typical antipsychotics.  However, they are also responsible for 
considerable proportion of pharmacy or formulary costs (Csernansky et al., 2002; 
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Gianfrancesco et al., 2002; Gibson et al., 2004; Nightengale et al., 1998).   The challenge 
for healthcare policymakers is to determine the degree to which benefits of antipsychotic 
overweigh their high acquisition costs.  Pharmacoeconomic comparisons between 
atypical antipsychotics have reported varying results depending upon study population, 
outcome measures, research and statistical design.   Most of the comparisons are between 
risperidone and olanzapine and have total treatment costs or inpatient drug costs as 
outcome measure.   
A retrospective database study using an employer claims database from 1994 to 
1999 compared one-year treatment outcomes between olanzapine and risperidone (Zhao, 
2004).  The outcomes measures were duration of therapy and direct healthcare costs.  
Results of multiple regression analysis show that the patients initiated on olanzapine (n = 
142) had significantly lower costs compared to patients initiated on risperidone (n=431). 
The average duration of therapy was also longer with olanzapine compared to 
risperidone.   Another study by Rascati and colleagues also reported that average duration 
of therapy was longer with olanzapine compared to risperidone based on analysis of 
Texas Medicaid data from 1996 to 1999.  However, risperidone has lower total medical 
costs compared to olanzapine (Rascati et al., 2003).   Better medication adherence for 
olanzapine was also reported by Gibson and colleagues in their analysis of Michigan 
Medicaid data from 1995 to 1998.   Olanzapine cohort had about 60% adherence 
compared to risperidone cohort with 54% adherence.   Though there were no significant 
differences in total healthcare costs across the cohorts, exclusion of index medication 
costs resulted in significantly lower total costs for olanzapine cohort  compared to 
risperidone (Gibson et al., 2004).  The differences in pharmacy costs may be attributed to 
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higher acquisition costs of olanzapine (Procyshyn & Zerjav, 1998; Byerly et al., 2003; 
Voris & Glazer, 1999) or better adherence resulting greater utilization of index drug.  A 
prospective observational study comparing olanzapine and risperidone showed that 
olanzapine had lesser psychiatric hospitalization than risperidone-treated schizophrenia 
patients within one year period (Ascher-Svanum et al., 2004).  
There are other studies that report cost savings with risperidone, especially for 
inpatient drug costs. The Risperidone Olanzapine Drug Outcomes studies in 
Schizophrenia (RODOS) used retrospective chart reviews of hospitalized patients (N = 
1,901) from nine countries.  The outcomes measures were utilization and costs of 
inpatient drugs among patients using olanzapine (n = 977) or risperidone (n = 924).  The 
average total inpatient drug costs were greater for olanzapine compared to risperidone 
($297 vs. $159).  This difference was attributed to longer duration of use for olanzapine 
compared to risperidone.  However, after adjusting for baseline difference and comparing 
the costs on daily basis, olanzapine group still showed significantly higher inpatient costs 
compared to risperidone (Kasper et al., 2001).  Similar results regarding inpatient drug 
costs were also reported by Kelly and colleagues in their study examining inpatient data 
of 789 patients with schizophrenia or schizoaffective disorder initiated on risperidone or 
olanzapine between July 1997 and June 1998.   Daily drug costs was lower among 
risperidone treated patients ($6.42) compared to olanzapine patients ($12.29).  In 
addition, they reported higher discharge rate after 30 days of treatment among risperidone 
patients (45%) compared to olanzapine patients (32%) (Kelly et al., 2001).   
Another study evaluating antipsychotic costs, psychiatric inpatient and outpatient 
costs among schizophrenia patients initiated on risperidone and olanzapine concluded 
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that though there are no significant differences in inpatient and outpatient costs among 
patients initiated on risperidone or olanzapine, it is more economic to prescribe 
risperidone due to its lower drug acquisition costs (Byerly et al., 2003).  The study was 
conducted using VA data among hospitalized patients who were initiated on risperidone 
(n = 23) or olanzapine (n = 47) after November 4, 1996 and had continuous therapy with 
the index drug for 9 months after initiation.  The cost of index antipsychotic, psychiatric 
hospitalizations and outpatient care after 9 months of initiation were the outcome 
measures.   Major limitation of this study is its limited sample size and lack of adjustment 
in cost comparisons for patient demographics or disease severity. 
There is only one published study that includes quetiapine among head-to-head 
comparisons of atypical antipsychotics.  This study has examined total pharmacy costs in 
acute care inpatient medical facilities using retrospective chart reviews.   The study 
sample consisted of patients hospitalized between May 1, 1998 and June 30, 2000 and 
discharged within 30 days after admission (N = 327).  Patients initiated on risperidone (n 
= 120), olanzapine (n = 153) and quetiapine (n = 54) within 7 days of hospital admissions 
were categorized in study drug groups.  After adjusting for selection bias using 
propensity scoring methodology, the study reported that average daily pharmacy cost 
during the inpatient stay was $4.35  less for  risperidone and $1.41 less for quetiapine 
compared to olanzapine (Mladsi et al., 2004).  As the study includes patients who were 
discharged within 30 days of hospitalizations, the results apply only to those patients who 
respond to the treatment.   Due to this inclusion criteria, discharge rate and length of 
hospital stay cannot be compared.  Other outcome measures such as total inpatient costs 
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were not reported.  Also, there was no information or control for extent of use of other 
concomitant medications.  
Most studies in literature have reported total costs or inpatient drug costs as 
outcome measures.  Except for the study by Mladsi and colleagues, none of the studies 
have controlled for selection bias or included quetiapine in their cost comparisons.  
Though Mladsi and colleagues included quetiapine in their analysis, their evaluation was 
restricted to only pharmacy costs in an inpatient setting (Mladsi et al., 2004).  
Other than curtailing costs, effectiveness of antipsychotic in improving adherence 
and persistence with therapy, preventing hospitalization and emergency room visits and 
decreasing concomitant usage of other medications is also important.   Non-adherence to 
therapy has been shown to be major predictor of hospitalizations.  Patients who are 
partially compliant or interrupt their antipsychotic therapy have 2-4 times greater risk of 
hospitalization (Weiden et al., 1995; Eaddy, Grogg, & Locklear, 2005).  Hospitalization 
costs represent about one-third to two-third of total healthcare costs for schizophrenia 
patients.   Persistence with initial therapy can also play an important role in cost savings.  
If patients are less likely to respond upon initiation on certain antipsychotic, it is possible 
there is greater likelihood of future hospitalizations and emergency care in these patients.  
Switching to other antipsychotics will be associated with additional expenses due to non-
response to earlier treatment.   Therefore, implications of antipsychotic treatment on 
utilization such as adherence, persistence, emergency room visits, hospitalizations, and 
outpatient visits also need to be considered while evaluating antipsychotic therapy.   
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Antipsychotic Therapy and Economic Outcomes in Bipolar Disorder 
Addition of atypicals antipsychotics is a significant advance in bipolar disorder 
pharmacotherapy. However, economic evaluation studies of antipsychotic use in bipolar 
disorder are limited.  There were only two randomized controlled trials and one 
retrospective database study comparing economic outcomes of atypical antipsychotic 
therapy in bipolar disorder.    
A randomized controlled trial conducted by Namjoshi and collegues (Namjoshi et 
al., 2002) evaluated the cost-effectiveness of olanzapine among patients diagnosed with 
bipolar I disorder exhibiting manic or mixed episodes.  The duration of follow-up 
consisted of a 3-week acute phase followed by a 49-week open label extension.  During 
the 49-week open label extension, inpatient costs reduced by $900 per month among 
patients treated with olanzapine.  Another randomized control trial by Revicki and 
colleagues (Revicki, Paramore, Sommerville, Swann, & Zajecka, 2003) compared 
divalproex and olanzapine among 120 patients with bipolar disorder Type I who were 
hospitalized for an acute manic episode.  Patients were recruited from 21 U.S. clinical 
centers and randomly assigned to the divalproex or olanzapine group (N = 63 divalproex, 
N = 57 olanzapine).  These patients were then followed in hospitals for 21 days.  Patients 
showing clinical improvement after 21 days of therapy were further followed for 12 
weeks.  The study only compared 12-week outpatient cost for these patients.  The 
divalproex group showed significantly lower outpatient costs ($541) as compared to 
olanzapine patients ($1080). 
Namjoshi and colleagues (Namjoshi et al., 2002) reported savings due to 
reduction in hospitalization whereas Revicki and colleagues (Revicki et al., 2003) 
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reported savings in outpatient medical costs.  Also, it should be noted that in the study by 
Revicki and colleagues, outpatient costs were compared for divalproex and olanzapine 
for hospitalized bipolar patients who had shown clinical improvement on their respective 
therapy after 21 days.  Thus, it is possible that the impact of increased cost and utilization 
by patients not showing clinical improvement or showing deterioration due to 
pharmacotherapy has not been captured in this evaluation.    
Gianfrancesco and colleagues used a commercial health plan’s administrative data 
to compare mental health costs associated with risperidone, olanzapine and quetiapine 
treatment in bipolar disorder patients (Gianfrancesco et al., 2005).  They identified 
treatment episodes with any of the study antipsychotics during a time period of January 
1999 and April 2002.  A total of 7,518 treatment episodes (29% associated with 
risperidone, 30.3% associated with olanzapine and 25.7% associated with quetiapine) 
were identified.  The unit of analysis was an antipsychotic treatment episode. Total 
mental healthcare costs for each treatment episode were the billed charges for mental 
healthcare services incurred during the treatment episode.  Controlling for factors such as 
patient demographics, bipolar subtype, prior healthcare charges, treatment length and 
substance abuse, the study reports that risperidone and quetiapine incurred about $84 and 
$76 lesser mental-health related charges per patient per month compared to olanzapine. 
There was no significant difference in costs between risperidone and quetiapine 
(Gianfrancesco et al., 2005).   
This study has certain limitations.  The study has compared only mental-health 
costs incurred between the initiation of therapy and discontinuation with the therapy.   
Patients may discontinue treatment due to treatment failure or adverse affects of the 
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therapy. Costs associated with this treatment failure would be incurred in the post-
discontinuation phase.  In addition, it is not possible to identify discontinuation of a 
treatment if it occurs during the hospitalization. Therefore, costs associated with this 
hospitalization may not be included in the total costs associated with the antipsychotic 
used in the episode.   Also, if the same patient has multiple episodes, it is possible that 
this patient is more severe or treatment refractory. As this person has not stabilized on 
earlier antipsychotic therapy, he or she may incur higher costs when initiated on another 
antipsychotic in the next episode.  It is also likely that such patients would be initiated on 
newer drugs in later episodes.  Therefore, treatment episodes with newer may have higher 
costs due to inclusion of more severe patients. The study does not control for selection 




 An overview of antipsychotic therapy for schizophrenia and bipolar population 
has been provided in the previous chapters.  Rationale for using Medicaid data, sample 
selection criteria, identification of cohorts, outcomes evaluation and sample selection bias 
adjustment has been explained under the conceptual framework section in chapter one.  
This chapter focuses on describing the data source, selection criteria, variable definitions, 
study design and statistical methodology.       
Data source  
West Virginia Medicaid Claims Data 
The West Virginia Medicaid Program (WVMP) is managed by the Bureau for 
Medical Services of the West Virginia Department of Health and Human Resources.    It 
is responsible for providing health care coverage to poor and disabled individuals.  The 
West Virginia Medicaid Bureau currently contracts with ACS, Inc (based in Atlanta,, 
GA) to serve as its claims processor.   ACS maintains and operates the Medicaid 
Management Information Systems (MMIS), which processes provider claims and 
payments.   MMIS data comprises of 3 files - provider files, recipient files, and claims 
(medical and pharmacy) files.   The following is a description of these files and the 
specific fields (variables) contained in each file. 
 The provider file contains specific information regarding all health care providers 
who are eligible to deliver services to Medicaid recipients.   This information includes a 
provider number, specialty and Medicaid eligibility related information.   The recipient 
file includes information such as Medicaid number, eligibility begin date, eligibility end 
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date, gender, and race.   The claims file stores detailed information specific to processed 
claims.   The medical claim file contains information, such as invoice type, provider 
number, recipient number, International Classification of Disease 9th edition (ICD-9) 
code of diagnosis for which the service was provided, Common Procedural Terminology 
(CPT) code for procedures and services provided, Diagnostic Related Group (DRG) 
codes, date claim was submitted, date of adjudication, through-date of service, 
coordination of benefit code, primary carrier code, and total amount paid.   The pharmacy 
claim file contains information such as number of days supply, metric quantity, National 
Drug Classification (NDC) code, generic code, therapeutic class code, refill number, 
provider ID number, and amount paid. 
 Permission to use the WV Medicaid data was obtained from the West Virginia 
Medicaid Bureau.  The approval to conduct the study was obtained from the Institutional 
Review Board (IRB).  The data was stored and analyzed according to the Health 
Insurance Portability and Accountability Act (HIPAA) standards.    
Data extraction and cleaning 
 The West Virginia University’s Rational Drug Therapy Program (RDTP) stores 
the West Virginia Medicaid data obtained from ACS, Inc on its server.  The data needed 
for this study was downloaded from the server using Access and converted to SAS 
datasets.  The extracted data was then put through cleaning and classification processes to 
obtain the final dataset.   
 The WV Medicaid organizes all its medical claims into two separate files: the 
outpatient claims file and the ER/ hospitalization claims file.   The ER/ hospitalization 
claims file contains ER and hospitalization claims as well as some outpatient claims.  All 
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claims from the ER/ hospitalization file having DRG greater than 0 were classified as 
hospitalization claims.  Revenue codes and hospitalization extract indicator variable 
indicating ER visit were used to identify ER visit. All claims occurring on the same day 
as ER visit were classified into ER file.  ER visits leading to hospitalization were 
considered as hospitalization events. Therefore, ER claims that had same date as 
hospitalization claims were transferred to hospitalization file.  Remaining claims in the 
ER/ hospitalization were identified as outpatient claims and transferred to the outpatient 
file.  The WV Medicaid’s outpatient file also contained few ER claims. These claims 
were identified on the basis on CPT codes (99281-99285) and transferred to the ER file.   
In addition, duplicate claims in the medical and pharmacy files (identified by presence of 
subsequent negative claims) were deleted.  
Study population 
 West Virginia Medicaid claims data for the period January 1st 1998 to December 
31st 2002 was extracted for the purpose of the study.   All patient-level demographic data 
as well as paid claims information on type of service, date of service, amount billed, 
length of service, and prescription drug claims were reviewed.   Patients who were 65 
years or older were excluded as they have Medicare as their primary payer for health 
services.   Only patients less than or of 64 years of age are included to avoid including 
those patients who would become eligible for Medicare during the period of follow-up 
after being initially present.   Managed care recipients also do not have all their utilization 
information in the Medicaid claims and were excluded.   
The index period for the study ranged from January 1st 1999 – December 31st 
2001, to allow for 12 pre-index and 12 post-index months.  From the prescription claims 
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data, all paid claims information on patients receiving at least two prescriptions of 
antipsychotics between January 1st, 1999 and December 31st 2001 was extracted.  The 
first date of paid claim for an antipsychotic during the index period was considered as the 
index prescription.  The selection criteria used to derive the final study sample for the 
study are listed below: 
Selection Criteria  
• At least two prescriptions of antipsychotics between January 1st, 1999 and 
December 31st, 2001  
• Patients who were 65 years or older were excluded as they have Medicare as their 
primary payer for health services  
• At least 12 months of continuous enrollment with the West Virginia Medicaid 
before and after the index date  
• Managed care recipients were excluded as they do not have all their utilization 
information in the Medicaid claims.    
• No claims of an antipsychotic medication during a 90 days period before the 
index date to indicate the index prescription is an initiation of antipsychotic 
therapy.    
• Patients initiated on clozapine were excluded. As clozapine is indicated for 
treatment refractory schizophrenia, patients initiated on clozapine are more likely 
to be more severe or inappropriately initiated on clozapine.  In addition, patients 
initiated on ziprasidone will excluded as it was introduced towards the end of our 
index period in 2001 and will probably have very small sample size.   
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Identification of schizophrenia and bipolar disorder patients 
 Schizophrenia patients will be identified by at least 1 inpatient or 2-outpatient 
diagnosis of schizophrenia.  Schizophrenia or Schizoaffective disorder diagnosis will be 
defined on the basis of International Classification of Diseases (9th Edition) (ICD-9-CM) 
code of 295.00 – 295.99.   This algorithm to identify schizophrenia patients in Medicaid 
has been validated in a study by Lurie and colleagues (Lurie P et al., 1992).  Based on a 
study by Unutzer and colleagues validating identification of bipolar disorder patients in a 
large HMO population, bipolar disorder patients will be identified by at least 2 or more 
paid claims with ICD-9-CM diagnosis for 296.00-296.19, 296.40-296.89 (Simon et al., 
1999).    
Measurement of cost 
Total health care costs will include costs associated with both medical and mental 
conditions.  Mental health-related costs will be identified by claims associated with 
diagnosis of a mental health disorder (ICD-9-CM codes 290.xx – 316.xx) or CPT codes 
for psychiatric services (90801-90899) and psychiatric medications.  Health care costs 
will be categorized into inpatient, ER, outpatient, and pharmacy cost.   As one-year pre-
index and post-index costs will be compared for patients initiated on antipsychotics 
anytime during the index period, all costs will be adjusted to 2002 US dollars using the 
medical care and prescription price index.   
Measurement of mental health-related variables 
 Psychotherapy utilization will be identified using CPT codes (90804-90829) or 
CPT codes (90846-90853).  Many psychiatric patients also receive medication 
management (identified by CPT code 90862) that includes prescribing, recommendations 
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for use, and review of medication with no more than minimal medical psychotherapy. 
Electroconvulsive therapy will be identified using CPT codes (90870-90871).  All 
hospitalization, ER visits, and physician office visits associated with a diagnosis of a 
mental health disorder (ICD-9-CM codes 290.xx – 316.xx) will be categorized as mental-
health-related utilization.  Psychiatric medications utilization will be categorized into 
different classes such as mood stabilizers, antidepressants, antipsychotics, 
anxiolytics/hypnotics/sedatives, antiparkinsons, anticholinergics, benzodiazepines and 
other psychiatric drugs.  Drugs from each of the above class will be identified from the 
pharmacy claims data using the NDC codes.  The provider identifier associated with the 
index prescription claim will be used to determine if the prescribing physician was a 
psychiatrist or a non-psychiatrist.  Various pre-index utilization variables such as pre-
index ER visits, pre-index hospitalizations, pre-index physician visits, number of 
psychotherapy visits, number of medication management visits, and pre-index period 
psychiatric medication use of mood stabilizers, antipsychotics, antidepressants and 
benzodiazepines will be used to control for confoundings in the multivariate analysis.  
Patient demographics  
The Medicaid recipient data file contained information on the patient’s date of 
birth, gender, race and county of residence.  The patient’s age was obtained by 
calculating the difference between the recipient’s date of birth and the date of index 
prescription.  As the proportion of non-Caucasian population in WV is very less, the 
patients were classified as Caucasians and non-Caucasians.  Patient’s county of residence 
was classified as metropolitan and non-metropolitan by using the Rural-urban Continuum 
Codes.  The Rural-urban Continuum Codes were developed by the standard Office of 
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Management and Budget (OMB) to differentiate metropolitan and non-metropolitan 
counties based on size, degree or urbanization and proximity to metro areas (Rural Urban 
Continuum codes, 2003).   
Co-morbidities 
 It is important to control for baseline co morbid conditions that may be present 
among patients initiated on antipsychotics.  Presence of specific mental health conditions 
such as major depression, mild to moderate depression, attention deficit disorder, non-
schizophrenia psychosis, other affective disorders, anxiety, personality disorder, 
dementia, and autism in the pre-index period will be determined on the basis of ICD-9-
CM codes.  Conditions such as arrhythmia, diabetes, hypertension, and arrhythmia that 
have been associated with the use of antipsychotic will also be determined from the pre-
index claims.  Alcohol and substance abuse is also a common co-morbid condition 
among schizophrenia patients and can be identified on basis of ICD-9-codes (291, 292, 
303, 304, 305.0-305.03, 305.2-305.9) from claims data.  Suicide attempts recorded in the 
claims data in form of ICD-9-CM code (E950-E959) will also be identified.  In addition, 
Charlson co-morbidity index will also be used to measure co morbidity.  Charlson co-
morbidity index is sum of the severity weights ranging from 1 to 6 that were calculated 
on the basis of relative risks of mortality and assigned to 19 co-morbid conditions.  This 
index was adapted by Deyo and colleagues for use with ICD-9-CM codes from 
administrative claims data to predict resource utilization (Deyo, Cherkin, & Ciol, 1992).  
Deyo’s adaptation of Charlson co-morbidity index will be used to control for severity of 
other medical conditions while predicting cost and utilization.   
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Phase 1 
Research Question 1 
To determine the annual prevalence rate of schizophrenia and bipolar disorder in West 
Virginia Medicaid from 1998 to 2002 
 The number of patients identified with the diagnosis of schizophrenia or bipolar 
disorder based on ICD-9 claims from the Medical claims file will be used as the 
numerator in the prevalence rate calculations.  The denominator will be the number of 
people eligible under the WV Medicaid for that year.  The number of people eligible 
under the WV Medicaid was derived from the Health Care Financing Administration 
(HCFA) 2082 Reports.  The eligible population consists of people who have paid claims 
in the Medicaid claims data as well as people who have never used/claimed any Medicaid 
services but were eligible for them.     
Research Question 2 
To determine the medical conditions among the patients initiated on antipsychotics 
during the study period in the West Virginia Medicaid population as well as describe 
patterns of distribution of certain demographic factors such as age, gender, and ethnicity 
in these patients  
Identifying Mental Health Comorbidities 
A patient will coded to be under mental health conditions listed below on the 
basis of ICD-9-CM diagnosis for that condition in the medical claims data during the pre-
index period or the index date.   
• Major Depression: At least 2 or more paid claims with ICD-9-CM diagnosis for 
296.20-296.39.   
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• Mild to Moderate Depression: At least 2 or more paid claims with ICD-9-CM 
diagnosis for 300.40-300.49, 311, 309.0 and 309.1. 
• Attention-Deficit Disorder:  At least 2 or more paid claims with ICD-9-CM 
diagnosis for  314.00, 314.01 and  314.0 
• Non-schizophrenia Psychosis: At least 2 or more paid claims with ICD-9-CM 
diagnosis for 291.00-294.99 
• Other Affective Disorders: At least 2 or more paid claims with ICD-9-CM 
diagnosis for 296, 296.0, 296.9, 296.90 and 296.99 
• Anxiety: At least 2 or more paid claims with ICD-9-CM diagnosis for 297.00-
297.00-297.99, 300.00-300.39, 300.5-300.99 
• Personality Disorder: At least 2 or more paid claims with ICD-9-CM diagnosis for 
301.00-301.99 
• Dementia: At least 2 or more paid claims with ICD-9-CM diagnosis for 290.00-
290.99 
• Autism: At least 2 or more paid claims with ICD-9-CM diagnosis for 299.0, 
299.00 and  299.01 
• Other Mental Health diagnosis:  At least 2 or more paid claims with ICD-9-CM 
diagnosis for  302.00-302.99, 306.00-308.99, 309.2-310.99, 311.1-313.99,  
 314.2-314.99, 316.00-316.99 
• Multiple Categories:  2 or more of above categories 
 Frequencies will be calculated to estimate proportion of patients initiated on 
antipsychotics under each mental health diagnostic category.  Patient population will be 
categorized on basis of age into two groups: less than 18 years and 18 years. 
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Demographic characteristics of patients under each diagnostic category will be presented 
in terms of age (mean, median), gender (frequency N, %), and race (frequency N, %).  In 
this exploratory analysis, the patients may suffer from multiple mental health conditions.  
Therefore, initiation of antipsychotic cannot be assumed to be indicated for the given 
mental health condition.  However, proportion of patients within each mental health 
condition who did not have any other psychiatric co-morbidity will be reported.    
Research Question 3 
For schizophrenia and bipolar disorder patients, determine different types of utilization 
pattern of antipsychotics.  
 Patients would be classified into schizophrenia and bipolar disorder disease 
category based on ICD-9-CM diagnosis code.  For schizophrenia, only patients 18 years 
or above will be used.  For bipolar disorder, patient population will be categorized on 
basis of age into two groups: less than 18 years and 18 years or above.  All prescription 
claims after initiation of antipsychotic will be reviewed to determine the pattern of use of 
antipsychotic.   
A) Pattern of antipsychotic use among schizophrenia and bipolar patients will be 
described in terms of: 
1) Antipsychotic Polytherapy:  Polytherapy refers to a situation when a second 
antipsychotic is started within 15 days of the index antipsychotics and both medications 
were refilled at least once.  Patients can be initiated on polytherapy or can switch to 
polytherapy in course of treatment.   
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2) Antipsychotic Monotherapy:  Use of only one antipsychotic at a time in the course of 
treatment is defined as antipsychotic monotherapy.  Antipsychotic monotherapy will be 
classified into the following types:  
a) Switching:  Switching refers to a situation when the index antipsychotic is changed to 
another antipsychotic. Antipsychotic switching will be defined as starting a different 
antipsychotic after the date of the index fill while not obtaining a refill for the index 
antipsychotic. 
 Patient using the same index antipsychotic throughout the 12-month post-index 
period will be classified as:  
b) Interrupted Therapy: Patients receiving less than 80% of total days of supply of 
medications during the 12-month post-index period.  
c) Continuous Therapy: Patients receiving greater or equal to 80% of the total days of 
supply of medications during the 12-month post-index period 
B) Schizophrenia patients initiated on index antipsychotic therapy will be categorized 
into:  
1. Patients who continued on index antipsychotic prescription for 3 or more months 
2. Patients who changed or discontinued index antipsychotic prescription within 3 
months 
Research Question 4 
For schizophrenia and bipolar disorder patients, determine the gaps between the refills of 
antipsychotics.  
 Gaps between the refills will be defined as number of days between the depletion 
date of one prescription and fill date of the subsequent prescription of the antipsychotic.  
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The depletion date of a prescription will be calculated as claims fill date plus days of 
supply.  The longest continuous gap between refills for each patient will be reported in 
terms of mean (+SD) and median gap.  Also, treatment gap categories will be created 
depending upon the length of the gaps.  Percentage distribution of patients across the 
treatment gap categories will be reported.  
Research Question 5 
For schizophrenia and bipolar disorder patients, determine predictors of patterns of use. 
Multinomial logistic regressions will be used to determine predictors of pattern of 
antipsychotic use among schizophrenia and bipolar patients.  The dependent variable will 
have four mutually exclusive categories: polytherapy, switching, interrupted therapy and 
continuous therapy.   Various predictors considered in the model would be: patient 
demographics (age, gender, and race), prescribing physician type, schizophrenia or 
bipolar subtype, other medical/mental diagnosis during the pre-index period, type of 
index antipsychotic, year of index antipsychotic, pre-index alcohol and substance abuse 
and pre-index healthcare utilization.  Separate analysis will be conducted for 
schizophrenia and bipolar patients.  Disease severity will be controlled using pre-index 
concomitant psychiatric medication use, mental-health related ER or physician visits, and 
schizophrenia or bipolar disorder-related hospitalization as covariates in regression 
models.  
Pattern of antipsychotic use (polytherapy, switching, interrupted therapy, continuous 
therapy) = constant +  β1 demographics + β2 physician type + β3 co morbidities + β4 
disease subtype + β5 pre-index utilization + β6 index antipsychotic type + error term 
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Research Question 6 
For schizophrenia and bipolar disorder patients, determine the relationship between 
utilization pattern of antipsychotics and total health care costs.  
 Heckman-2 stage technique will be used to control for observed and unobserved 
differences between patients having different pattern of use.  The first-stage selection 
model will be similar to multinomial regression model in research question 5.  
First-stage selection model: 
Pattern of antipsychotic use (polytherapy, switching, interrupted therapy, continuous 
therapy) = constant +  β1 demographics + β2 physician type + β3 co morbidities 
associated with treatment + β4 disease subtype + β5 pre-index utilization + β6 index 
antipsychotic type + error term 
Continuous therapy will be used as reference category for all comparisons in the 
multinomial logistic models.  The selection factor obtained from these models will be 
used as a covariate in the second stage regression models.   
 The dependent variable in the second-stage regression will be cost. As cost is 
usually skewed, it will be log transformed.  Control variables in the second stage 
regression include: age, gender, Charlson Comorbidity Index, schizophrenia/ bipolar 
subtype, alcohol and substance abuse, psychiatrist prescriber, pre-index mental-health 
care cost, type of index prescription, use of concomitant psychiatric medications, year of 
index prescription, pattern of antipsychotic use and selection factor.    
Second-stage selection model: 
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Log(Cost) = constant +  β1 demographics + β2 physician type + β3 Charlson 
comorbidity index + β4 disease subtype + β5 pre-index utilization + β6 index 
antipsychotic type  + β7 pattern of antipsychotic use + β8 selection factor  + error term 
 Separate models will be created for schizophrenia and bipolar disorder patients.  
Research Question 7 
For schizophrenia and bipolar disorder patients, determine the relationship between 
utilization pattern of antipsychotics and mental health care utilization and costs.  
 Mental health-related costs will be identified by claims associated with diagnosis 
of a mental health disorder (ICD-9-CM codes 290.xx – 316.xx) or CPT codes for 
psychiatric services (90801-90899) and psychiatric medications.   The first stage 
multinomial logistic regression model will be same as that used in research question 6.  
The second stage OLS regression models will have log transformed mental health-related 
costs as dependent variable.   Separate models will be created for schizophrenia and 
bipolar disorder patients.  
Phase 2 
Cohort Selection  
Patients were classified into the study cohorts based on the index prescription 
during the index period (January 1st 1999 –December 31st 2001).   The first prescription 
of a study medication (Risperidone, Olanzapine, Quetiapine, or typical antipsychotics) 
during the index period was defined as the index prescription.   Patients initiated on any 
other antipsychotics or multiple antipsychotics will be excluded from the analysis.   
Study Cohorts 
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The study participants were divided into following 4 study cohorts based on 
atypical antipsychotic therapy: 
• Cohort 1.  Patients initiated on  Risperidone 
• Cohort 2.  Patients initiated on  Olanzapine 
• Cohort 3.  Patients initiated on  Quetiapine 
• Cohort 4.  Patients initiated any typical antipsychotic (chlorpromazine, haloperidol, 
thioridazine, fluphenazine and others).   
Intent to treat approach will be employed wherein the outcomes will be attributed to the 
index prescription irrespective of the medication pattern subsequent to index prescription. 
Reference Cohort 
 Quetiapine was selected as the reference antipsychotic cohort for statistical 
analysis for following reasons: 
• Quetiapine cohort was the most recent atypical antipsychotic cohort in our study 
with adequate sample size.  As the index period for this study was between 
January 1st 1999 and December 31st 2001, there were not sufficient numbers of 
patients initiated on ziprasidone during this period to provide adequate sample 
size for statistical analyis. 
• Economic evaluations comparing quetiapine to other antipsychotics were lacking 
in the published literature.    
Research Question 8  
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine with 
risperidone, olanzapine, and typical antipsychotics on total and mental healthcare costs  
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Cost data will be collected for each of the study participants in the pre- and post 
index phase.  Mental health-related utilization will be identified by claims associated with 
diagnosis of a mental health disorder (ICD-9-CM codes 290.xx – 316.xx) or CPT codes 
for psychiatric services (90801-90899) and psychiatric medications.  Total health care 
costs will include all costs for medical and mental conditions.   
Univariate analysis will describe resource costs of care: 1) in the pre-index period, 
and 2) in the post-index period.  The Wilcoxon rank sum tests (equivalent to Mann-
Whitney U test) were used to measure between-cohort differences.  The Wilcoxon rank 
sum test is a non parametric alternative to two sample t test that can be used to compare 
differences between cohorts for non-normal data. 
 Next, multivariate regression techniques, controlling for specific covariates, will 
be used to evaluate the association between type of atypical antipsychotic therapy used 
and post-index cost.  Age, gender, prescribing physician specialty, index year, 
schizophrenia/bipolar subtype, substance and alcohol abuse, Charlson Comorbidity 
Score, pre-index cost and utilization, and concomitant medication use would be 
considered as covariates.  Sample selection models will be used to adjust for sample 
selection bias due to treatment selection.  The first stage sample selection model will be a 
multinomial logistic regression model predicting choice of index antipsychotic therapy.  
Index antipsychotic selection (quetiapine, risperidone, olanzapine, typical 
antipsychotic).   = constant +  β1 demographics + β2 physician type + β3 co-morbidities 
+ β4 disease subtype + β5 pre-index utilization + error term 
 The selection factor obtained from these models will be used as a covariate in the 
second stage regression models.   
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Log(Cost) = constant +  β1 demographics + β2 physician type + β3 co-morbidities/ 
Charlson comorbidity index + β4 disease subtype + β5 pre-index utilization + β6 index 
antipsychotic type  + β8 selection factor  + error term 
 Quetiapine will be used as reference category for all comparisons in the 
multinomial logistic models and regression models.  Separate analysis will be conducted 
for schizophrenia and bipolar disorder patients.  For each disease group, separate models 
will developed for mental health-related and total healthcare cost.  
Research Question 9 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine with 
risperidone, olanzapine, and typical antipsychotics on components of mental healthcare 
costs (costs associated with mental health-related inpatient, emergency room, outpatient 
and pharmacy services)  
 Univariate analysis will describe resource costs of care: 1) in the pre-index period, 
and 2) in the post-index period.  Univariate comparisons for the differences in mental 
health-related inpatient, emergency room, outpatient and pharmacy costs between the 
index drug cohorts will be conducted using the Wilcoxon rank sum tests. 
 A 2-part model will be used to establish relationship between drug therapy 
patterns and mental health related cost categories like ED and inpatient that are likely to 
have zero values for some patients.  The first part will consist of a logistic regression for 
each dependent variable (ED and inpatient) to distinguish between patients having no 
cost and any cost.  The second part will be a multiple regression analysis conducted 




Any Cost (0/ greater than 0) = constant +  β1 demographics + β2 physician type + β3 
Charlson comorbidity index + β4 disease subtype + β5 pre-index utilization + β6 index 
antipsychotic type  + β7 pattern of antipsychotic use + β8 selection factor  + error term 
Part 2: 
Log(Cost) = constant +  β1 demographics + β2 physician type + β3 Charlson 
comorbidity index + β4 disease subtype + β5 pre-index utilization + β6 index 
antipsychotic type  + β7 pattern of antipsychotic use + β8 selection factor  + error term 
 For dependent variables like total mental health-related costs, outpatient and 
pharmacy cost category that are not likely to have zero costs, multiple regression analysis 
will be used.   
 Treatment severity will be controlled using pre-index concomitant psychiatric 
medication use and other mental-health related healthcare utilization as covariates in 
regression models.  Control variables in the study will include: age, gender, Charlson 
Comorbidity Index, schizophrenia/ bipolar subtype, alcohol and substance abuse, 
psychiatrist prescriber, pre-index mental- health care cost and utilization, use of 
concomitant psychiatric medications, and year of index prescription.  As the cost data is 
skewed, log transformations will be used to normalize the data.  
Research Question 10 
For schizophrenia and bipolar patients, to compare the impact of quetiapine with 
risperidone, olanzapine, and typical antipsychotics on mental health-related healthcare 
hospitalizations  
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Univariate analysis will describe number of inpatient visits and length of inpatient 
visits: 1) in the pre-index period, and 2) in the post-index period.  The Wilcoxon rank 
sum tests were used to measure between-cohort differences.  
Hospitalization rates calculated as the percent of patients who were hospitalized 
with a psychiatric diagnosis during the pre and post index period will be analyzed using 
Mantel-Haenszel test.  Mantel-Haenszel test is used to compare proportion of people 
between two groups.  
Time to hospitalization will be defined as the number of days from the index date 
to the first hospitalization.  As this is time-to-event data, survival analysis procedures will 
be used for analysis.  Kaplan Meier survival curves will be used for univariate analysis. 
The relative hazard of hospitalization over a follow-up period will be analyzed using Cox 
proportional model that will control for confounding variables. 
Time to first hospitalization = constant +  β1 demographics + β2 physician type + β3 
Charlson comorbidity index + β4 disease subtype + β5 pre-index utilization + β6 index 
antipsychotic type  + β7 pattern of antipsychotic use + β8 selection factor  + error term 
Poisson regression analysis will be used for multivariate comparison of the 
number of inpatient visits among different cohorts.   
Separate analysis will be conducted for schizophrenia and bipolar disorder 
patients.  
Research Question 11 
For schizophrenia patients and bipolar disorder patients, to compare the impact of 
quetiapine with risperidone, olanzapine, and typical antipsychotics on mental healthcare-
related emergency room visits 
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Univariate analysis will describe ER visits: 1) in the pre-index period, and 2) in the post-
index period. The Wilcoxon tests will be used to measure between-cohort differences.  
ER visit rate is calculated as the percent of patients who were admitted with a 
psychiatric diagnosis during the pre and post index period and will be analyzed using 
Mantel-Haenszel test.   
Time to ER visit will be defined as the number of days from the index date to the 
first ER visit. The relative hazard (or incidence rate) of ER visit over a follow-up period 
will be analyzed using Cox proportional model. 
 Poisson regression analysis will be conducted to compare the number of ER visits 
among different cohorts.   
 Control variables in the study will include: age, gender, prescribing physician 
specialty, index year, adherence to index medication, schizophrenia/bipolar subtype, 
Charlson Comorbidity Score, pre-index psychiatric ER visits, substance abuse, alcohol 
abuse, and concomitant medication use.  
 Separate analysis will be conducted for schizophrenia and bipolar disorder 
patients.  
Research Question 12 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine with 
risperidone, olanzapine, and typical antipsychotics on mental healthcare-related 
outpatient visits  
 Univariate analysis will describe total and mental health-related physician visits, 
psychotherapy sessions and specific medication management psychotherapy in terms of: 
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1) in the pre-index period, and 2) in the post-index period.  The Wilcoxon rank sum tests 
will be used to measure between-cohort differences. 
 Poisson regression analysis will be conducted to compare the number of mental 
health-related physician visits among different cohorts.   
 Control variables in the study will include: age, gender, prescribing physician 
specialty, index year, schizophrenia/bipolar subtype, Charlson Comorbidity Score, pre-
index physician visits, substance abuse, alcohol abuse, and concomitant medication use.  
 Separate analysis will be conducted for schizophrenia and bipolar disorder 
patients.  
Research Question 13 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine with 
risperidone, olanzapine, and typical antipsychotics on psychiatric medication utilization   
 Use of concomitant medications will be categorized into following classes:  
Mood stabilizers, antidepressants, Anxiolytics/Hypnotics/Sedatives, antiparkinsons, 
anticholinergics, antipsychotics (pre-index use), clozapine and benzodiazepine. 
 Proportions of patients from each cohort using concomitant medications will be 
compared using Mantel-Haenszel test.  
Separate analysis will be conducted for schizophrenia and bipolar disorder 
patients.  
Research Question 14 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine with 
risperidone, olanzapine, and typical antipsychotics on patient’s adherence to the index 
medications in the post-index period 
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 Adherence with the index therapy will be compared in terms of Medication 
possession ratio (MPR) 
MPR = the total days supplied for the index drug  
             total days from index date to the date of last prescription  
             of  index drug + days supplied on last claim              
Medicaid prescription claims data does not record claims of medications 
administered to patients in an inpatient setting.  To adjust for this absence of record while 
calculating days of supply of index antipsychotic, the number of days of hospitalizations 
was added to the days supply of drugs for the index antipsychotic if the admit and 
discharge dates of the hospitalization occurred between the first fill date and end of 
follow up period for that index antipsychotic.  
Ordinary Least Squares (OLS) regression models will be used determine the 
impact of choice of index antipsychotic drug on MPR.  Age, gender, prescribing 
physician specialty, index year, schizophrenia/bipolar subtype, Charlson Comorbidity 
Score, schizophrenia/bipolar subtype, other mental illnesses, psychiatric hospitalization, 
psychiatric ER visit, substance abuse, alcohol abuse, and concomitant medication use 
would be considered as covariates.  Separate analysis will be conducted for schizophrenia 
and bipolar disorder patients. 
Research Question 15 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine with 
risperidone, olanzapine, and typical antipsychotics on subsequent index antipsychotic 
therapy modification  
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Persistence or time until treatment change 
 Persistence or time until treatment change will be defined as the total days from 
the index prescription fill date until the occurrence of a filled prescription for any other 
index or a non-index antipsychotic or until discontinuation of therapy with the index 
drug.  
The relative hazard of discontinuation or switch 
 The relative hazard of discontinuation or switch over a follow-up period will be 
analyzed using Cox proportional hazard model.  Age, gender, prescribing physician 
specialty, index year, adherence to index medication, schizophrenia/bipolar subtype, 
Charleston Comorbidity Score, schizophrenia/bipolar subtype, other mental illnesses, 
psychiatric hospitalization, psychiatric ER visit, substance abuse, alcohol abuse, 
concomitant medication use, and time from date of market availability to index date 
would be considered as covariates.  Separate analysis will be conducted for schizophrenia 
and bipolar disorder patients.  
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 CHAPTER FOUR 
RESULTS AND DISCUSSION  
 
 The previous chapter described study objectives and methodology.  This chapter 
presents results and discussion for each of the study objectives.  The results and 
discussion for schizophrenia and bipolar disorder are presented together under each 
research question.  The results are classified into phase 1 and phase 2.  
 Table 1 presents the number of eligible study participants after applying each 
inclusion and exclusion criterion.  A total of 5,297 patients were initiated on 
antipsychotic medications between the index period January 1st, 1999 and December 
31st, 2001 in the WV Medicaid.  Patients with diagnosis of schizophrenia and bipolar 
disorder were identified using the specified criteria.  A total of 1,036 patients with 
schizophrenia and 832 patients with bipolar disorder were initiated on antipsychotics 
during the study index period.  Power analysis carried out for the resulting sample size 
revealed greater than 80% power for the univaraite and multivariate analysis proposed in 
this study. 
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Selection Criteria Sample Size 
N 
1. At least 2 antipsychotic Rx  during the index period 
       (January 1st 1999 –December 31st 2001) 
22,577 
2. Less than or equal to 64 years of age 
 
16,698 




4. Excluding managed care recipients 
 
10,193 
5. No claims of an antipsychotic during a 90 days period 
before the index date 
 
5,384 
6. Excluding patients initiated on clozapine  
 
5,366 
7. Excluding patients initiated on ziprasidone 
 
5,297 
Final Sample 5,297 










Results for research objective 1 
To determine the annual prevalence rate of schizophrenia and bipolar disorder in West 
Virginia Medicaid from 1998 to 2002 
To calculate the annual prevalence rate of schizophrenia and bipolar disorder 
patients, all patients with diagnosis of schizophrenia or bipolar disorder during the year 
(not just patients initiated on antipsychotics) were identified as numerator.  The 
denominator was the number of people eligible under the WV Medicaid for that year. 
Tables 2a and 2b present annual prevalence rates for schizophrenia and bipolar disorder 
in the WV Medicaid population for the years 1998-2002.  Total annual prevalence of 
schizophrenia ranged from 0.9% to 1.5% between the year 1998 and 2002 among WV 
Medicaid eligible population.  Total annual prevalence of bipolar disorder ranged from 
0.6% to 1.7% between the year 1998 and 2002 among WV Medicaid eligible population. 
Annual prevalence of bipolar disorder among patients between 20 and 64 years of age 
increased from 1.3% in 1998 to 3.2% in 2002.  Annual prevalence of bipolar disorder 
among patients less than 14 years of age was 0.02%-0.03% and patients between 14 and 







Table 2a:  Annual prevalence rate for schizophrenia in the WV Medicaid (1998-2002) 
 
 
Nb = Number of patients with diagnosis of schizophrenia in the given one year period 
PR = Prevalence Rate per 1,000 WV eligible patients in the given one year period 





 2002 2001 2000 1999* 1998 
 Nb PR  [95% CI] N
b PR  [95% CI] N
b PR  [95% CI] N
b PR  [95% CI] N
b PR  [95% CI] 
Age Category 
Up to or equal  








77 - 99 0.59 
[0.48, 0.71] 
 
Greater than 14 








114 - 124 2.89 
[2.38, 3.40] 
Greater than 20 







3,154 - 2,854 21.98 
[21.18, 22.79]
Total 
(less than  or  













Table 2b: Annual prevalence rate for bipolar disorder in the WV Medicaid (1998-2002) 
 
Nb = Number of patients with diagnosis of schizophrenia in the given one year period 
PR = Prevalence Rate per 1,000 WV eligible patients in the given one year period 








 2002 2001 2000 1999* 1998 
 Nb PR  [95% CI] N
b PR  [95% CI] N
b PR  [95% CI] N
b PR  [95% CI] N
b PR  [95% CI] 
Age Category 
Up to or equal  







339 - 260 1.56 
[1.37, 1.75] 
Greater than 14 







451 - 347 8.08 
[7.23, 8.93] 
Greater than 20 







2,243 - 1,723 13.27 
[12.64, 13.90]
Total  
(less than  or  














Discussion for research objective 1 
 Information regarding prevalence of schizophrenia and bipolar disorder in WV 
Medicaid is important from a health services planning perspective.  Although it has been 
suggested that the prevalence of these mental health disorders may be higher in low 
income populations, information regarding prevalence of schizophrenia and bipolar 
disorder in Medicaid systems is lacking in literature(Scott, 1993; Goldner, Jones, & 
Waraich, 2003).   
 Based on a survey of 20,291 adults by National Institute of Mental Health 
Epidemiologic Catchment Area Program, one-year prevalence rate of schizophrenia in 
1993 was reported to be 1.1% (Regier et al., 1993).  Our study reports similar prevalence 
rates of schizophrenia (0.9% - 1.5%) from 1998 to 2002 in the WV Medicaid population.   
The rates of prevalence of both schizophrenia and bipolar disorder show steady increase 
from 1998 to 2002 in WV Medicaid, except for the year 2001.  The higher prevalence 
rates in the year 2001 compared to 2002 was due to decrease in the denominator i.e. the 
number of people eligible under the WV Medicaid during the year 2001.   
 Prevalence of bipolar disorder has been estimated to range between 1% and 2% in 
different studies.  The Epidemiologic Catchment Area (ECA) survey reported lifetime 
prevalence of 1.3% whereas the National Comorbidity survey has reported lifetime 
prevalence of 1.6% (Bebbington & Ramana, 1995; Kessler et al., 1994).  A survey of 
representative sample of adult US population in 2000 revealed a very high prevalence 
rate of 3.7% for bipolar disorder (Hirschfeld RMA, Calabrese JR, & Weissman M, 2005).  
Our study also found that the prevalence rate of bipolar disorder had increased to 3.2% in 
2002 among adults.  The prevalence rates in our study may differ from other studies as it 
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was calculated based on the presence of disease specific ICD-9-CM codes in the 
administrative data whereas other studies have reported the prevalence rates based on 
community surveys.  The WV Medicaid patient population differs from the patient 
population used in other studies due to over representation of low-income and women 
population.  
Results for research objective 2 
To determine the medical conditions for which antipsychotics are being prescribed in the 
West Virginia Medicaid population as well as describe patterns of distribution of certain 
demographic factors such as age, gender, and ethnicity in patients using antipsychotics.  
Tables 3a, 3b and 3c present results of an analysis to determine the mental health 
conditions as well as describe patterns of distribution of certain demographic factors such 
as age, gender, and ethnicity in patients who were initiated on antipsychotics in the West 
Virginia Medicaid population during the study period.  
In this analysis, the patients may suffer from multiple mental health conditions. 
Therefore, initiation of an antipsychotic medication cannot be assumed to be indicated for 
the given mental health condition.  However, the tables also provide information on 
proportion of patients within each mental health condition who did not have any other 
psychiatric co-morbidity.  Disease conditions such as autism, non-schizophrenia 
psychosis, major depression, and attention-deficit disorders are of particular interest as 
considerable proportion of patients initiated on antipsychotics during the study period in 
these disease conditions do not have any other mental health co-morbidities.     
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Table 3a:  Exploratory analysis of mental health conditions among patients who 
were initiated on antipsychotics in the West Virginia Medicaid population during 





Table 3a:  Exploratory analysis of mental health conditions among patients who 
were initiated on antipsychotics in the West Virginia Medicaid population during 





Table 3b:  Exploratory analysis of mental health conditions among patients who 
were initiated on antipsychotics in the West Virginia Medicaid population during 




Table 3b:  Exploratory analysis of mental health conditions among patients who 
were initiated on antipsychotics in the West Virginia Medicaid population during 
the study period (contd.) 
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Table 3c: Exploratory analysis of mental health conditions among patients who 
were initiated on antipsychotics in the West Virginia Medicaid population during 
the study period  
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Table 3c: Exploratory analysis of mental health conditions among patients who 
were initiated on antipsychotics in the West Virginia Medicaid population during 
the study period (contd.) 
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For example, a total of 1,112 patients who were initiated on antipsychotics between 1999 
and 2001 had major depression. Of these, about 26% did not have diagnosis of any other 
mental health disorder (except major depression) in the 12-month pre-index period 
suggesting that initiation of antipsychotic may have been for major depression. Similarly, 
more than 50% of patients with autism who were initiated on antipsychotics did not have 
any other co-morbidities.   
For most mental health conditions  (non-schizophrenic psychosis,  attention 
deficit disorder, major depression , mild to moderate, depression, anxiety, other mental 
health disorders), higher proportion of patients who are less than 18 years of age were 
initiated on risperidone compared to any other antipsychotic.   
For most mental health conditions  (non-schizophrenic psychosis,  attention 
deficit disorder, major depression , mild to moderate, depression, anxiety, personality 
disorder, other affective disorders, autism, other mental health disorders), higher 
proportion of patients who are 18 years or older were initiated on olanzapine compared 
to any other antipsychotic.  Results of Chi-square analysis are not presented for cohorts 
with inadequate sample size. 
Discussion for research objective 2 
 The results of our study indicate that a significant proportion of patients were 
probably initiated on antipsychotic therapy for off-label indications such as autism, non-
schizophrenia psychosis, major depression and attention-deficit disorders.  A study by 
Cooper and colleagues reported that greater numbers of adolescents are being initiated on 
atypical antipsychotics for conditions such as attention-deficit/hyperactivity disorder, 
conduct disorder, and affective disorders (Cooper et al., 2004). Other studies have also 
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reported incidences of off-label antipsychotic use for depression, attention-
deficit/hyperactivity disorder, affective disorders, and autism (Barbee et al., 2004; Cooper 
et al., 2004; Liperoti et al., 2003).  These results suggest that the prevalence of 
antipsychotic use in other conditions is present in clinical practice even though clinical 
evidence regarding risks and benefits of this practice is lacking.  It is likely that 
antipsychotics are being used concomitantly along with other psychotropic medications 
indicated with these conditions.   
  It is important to study whether the use of antipsychotics adds any therapeutic 
benefit to the traditional treatment of conditions that are not yet indicated for 
antipsychotic use.  Physicians involved in treating patients using antipsychotics can 
provide more information regarding outcomes of this practice.  Pharmacists should be 
made aware of increasing use of antipsychotics for other indications and encouraged to 
monitor these patients regularly.   
Results for research objective 3 
For schizophrenia and bipolar disorder patients, determine different types of utilization 
pattern of antipsychotics.  
Schizophrenia 
 
Table 4a describes the patterns of antipsychotic use in the 12-month follow-up 
period among schizophrenia patients who are greater than 18 years of age.  The patterns 
of antipsychotic use were classified into mutually exclusive categories: 1) initial 
polytherapy, 2) later polytherapy, 3) switch, 4) interrupted, and 5) continuous therapy.  
Results of chi-square analysis revealed that there are significantly different patterns of 
antipsychotic use prevalent in the schizophrenia population.   
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About 3.6% of patients were initiated on polytherapy (i.e received a combination 
of two or more antipsychotics). About 8.4% of patients switched to polytherapy during 
the course of their treatment.  Therefore, our study population showed 12.0% of patients 
on polytherapy during the 12-month period after initiation of antipsychotic treatment.  
The remaining 88.0% of patients received antipsychotic monotherapy during the 12-
month period after initiation of antipsychotic treatment.   
 About 12.7% of patients switched from the index antipsychotic to another 
antipsychotic. A large proportion of our study population (56.8% ) received less than 
80% days supply of index antipsychotic in the 12-month post index period or interrupted 
therapy.  About 18.5% of patients received continuous therapy, i.e. they received at least 
80% days supply of index antipsychotic in the 12-month post index period.  
Table 4b provides the proportion of patients who continued on index 
antipsychotic of three or more months (trial duration based on recommendations by the 
Texas Medication Algorithm Project (TMAP) guidelines).  About 77.3% of patients 
continued on index antipsychotic prescription for 3 or more months. About 22.7% of 
patients changed or discontinued index antipsychotic prescription within 3 months.  The 






Table 4a:  Pattern of antipsychotic use in the 12-month follow-up period among 





Pattern of antipsychotic use Number of Patients (%) N=1,036 
Antipsychotic Polytherapy  
Initial Polytherapy 37 (3.6%) 
Later Polytherapy 87 (8.4%) 
Antipsychotic Monotherapy 
Switch  132 (12.7%) 
Interrupted   588 (56.8%) 
Continuous  192 (18.5%) 
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* thirty seven patients initiated on polytherapy were deleted from this analysis. 
 N = 999* 






Patients who continued on index antipsychotic 




Patients who changed or discontinued index antipsychotic 




Bipolar Disorder  
 
Table 5 describes the patterns of antipsychotic use in the 12-month follow-up 
period among bipolar patients.  Results of chi-square analysis revealed that there are 
significantly different patterns of antipsychotic use prevalent among bipolar disorder 
patients who are18 years and older and less than 18 years.  Initiation on antipsychotic 
polytherapy was seen in only 0.8% of bipolar patients.  About 7.2% of 18 years and older 
patients and about 10.1% of less than 18 years old patients switched to polytherapy 
during course of their treatment.   
 About 13.3% of patients switched from index antipsychotic use to another 
antipsychotic. About 56.3% of 18 years and older patients and about 66.9% of less than 
18 years old patients had received interrupted therapy.  About 21.6% of 18 years and 
older patients and about 12.2% of less than 18 years old patients received antipsychotic 
adherent therapy during the post-index period.  
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Table 5: Pattern of antipsychotic use in the 12-month follow-up period among 
bipolar disorder patients 
 
 18 years and above n=684 
Less than 18 years 
n=148 
Total 
N = 832 
Antipsychotic Polytherapy  
Initial Polytherapy 6 (0.9%) 1 (0.7%) 7 (0.8%) 
Later Polytherapy 49 (7.2%) 15 (10.1%) 64 (7.7%) 
Antipsychotic Monotherapy 
Switch  96 (14.0%) 15 (10.1%) 111 (13.3%) 
Interrupted   385 (56.3%) 99 (66.9%) 484 (58.2%) 
Continuous  148 (21.6%) 18 (12.2%) 166 (20.0%) 
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Discussion for research objective 3 
Schizophrenia 
 
 Our study reports about 12.0% overall polytherapy among schizophrenia patients 
initiated on antipsychotics between 1999 and 2001 in the WV Medicaid.  Varying rates of 
polytherapy have been found in published literature depending upon study population, 
data used, the year of study, and definitions of polytherapy.  Most studies based on 
outpatient prescription use report lower rates of polytherapy compared to studies based 
on inpatient prescription use indicating that the practice of antipsychotic polytherapy is  
more prevalent during inpatient treatment.  A study by Loosbrock and colleagues 
conducted using am employer claims data from 1997 reported similar polytherapy rates 
as our study (Loosbrock et al., 2003).  They found that about 2% of patients had been 
initiated on polytherapy and 7% patients had switched to polytherapy during one-year 
follow-up period.  About 6.8% antipsychotic polytherapy was reported among 
schizophrenia patients from Veteran Administration in 1999(Leslie et al., 2001).  
Prevalence of antipsychotic polytherapy among Rhode Island Medicaid’s elderly and 
disabled population was about 10% in 2003 (Kogut et al., 2005).  Clark and colleagues 
report increasing rates of polytherapy from 5.7% in 1995 to 24.5% in 1999 among 
schizophrenia patients in the New Hampshire Medicaid(Clark et al., 2002). Ganguly and 
colleagues have reported about 40% antipsychotic polytherapy between 1998 and 2000 in 
the Georgia Medicaid and California Medicaid Schizophrenia patients (Ganguly et al., 
2004).  This is the highest prevalence of polytherapy reported based on an outpatient 
prescription record.  It may be due to identification of polytherapy based on an episode of 
polytherapy anytime between 1998 and 2000.  Studies evaluating antipsychotics using 
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inpatient prescription records have found rates of polytherapy between 16% to 45% 
(Schumacher et al., 2003; Procyshyn et al., 2001; Procyshyn et al., 2004; McCue et al., 
2003). 
 The rate of switching in the 12-month post-index period after initiation on 
antipsychotic was 12.7% in our study.  Loosbrock and colleagues found about 13% rates 
of switching in 1997 among schizophrenia patients from an employer based claims data 
(Loosbrock et al., 2003).  Williams and colleagues have reported a 25% rate of switching 
observed in an indigent Indianapolis community patients who were initiated on 
antipsychotics in 1995 (Williams et al., 1999).  As majority of their patient population 
(88%) were on typical antipsychotics, it is possible that rates of switching increased as 
the use of atypical became more widespread.  McComb and colleagues have reported a 
47% rate of switching to another antipsychotic or augmenting with another antipsychotic 
in the California Medicaid population between 1987 and 1996 (McCombs et al., 1999b).  
The higher rate of switching in their study can be attributed to the episode of care 
methodology and possible differential rates of switching occurring between 1987 and 
1996.   In addition, about 98% of their study population was on typical antipsychotics.  
 Only 18.5% of schizophrenia patients in our study received continuous index 
antipsychotic therapy.  The rate of continuous therapy in our study is comparable to 
11.6% of patients in the McComb study of California Medicaid patients (McCombs et al., 
1999b).  Medication adherence is usually low in the schizophrenia population due to 
reasons such as impaired awareness of disease, alcohol and substance abuse, and 
medication side-effects (Lacro, Dunn, Dolder, Leckband, & Jeste, 2002; Hudson et al., 
2004; Van Putten, 1974).  The 71% monotherapy found in our study is similar to 71.5% 
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reported by William and colleagues and higher than the 52% reported by Loosbrock and 
colleagues (Williams et al., 1999; Loosbrock et al., 2003).  Loosbrock and colleagues 
also reported in their study that 67.1% of patients received interrupted therapy with gaps 
of 1 to 11 months.  Our study defines interrupted therapy in terms of patients who have 
received less than 80% days supply of index antipsychotic in the 12-month post index 
period.  This definition accounts for non-adherence to therapy due to large continuous 
gaps in the therapy or some intermittent missed days of therapy.  We found 56.8% 
patients having interrupted therapy according to our definition.  In general, the 
differences in the patterns of use across the study can be due to the differences in study 
methodology and definition of the pattern, year of study and proportion of patients on 
typical antipsychotics.  
Bipolar Disorder  
 
 Our study reports 7.7% prevalence of antipsychotic polypharmacy among patients 
initiated on antipsychotics during the index period 1999-2001.  A retrospective review of 
psychiatric medications among patients discharged from a tertiary care psychiatric 
facility had revealed 29.9% rate of antipsychotic polytherapy among bipolar patients 
(Procyshyn et al., 2004).  Compared to our study, antipsychotic polypharmacy rates may 
have been higher among patients discharged from hospital due to disease severity.  
Higher rates antipsychotic polypharmacy were also reported by studies based on inpatient 
prescription use among schizophrenia patients(Schumacher et al., 2003; Procyshyn et al., 
2001; Procyshyn et al., 2004; McCue et al., 2003).    
 Rates of interrupted therapy were similar among schizophrenia (56.8%) and adult 
bipolar disorder (56.3%) patients. As in schizophrenia population, non-adherence is a 
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major problem with bipolar disorder patients (Keck, Jr., McElroy, Strakowski, Bourne, & 
West, 1997).   Prevalence of substance abuse disorder and denial of disease condition 
have been cited as the reasons for non-adherence among bipolar disorder patients (Keck, 
Jr. et al., 1997; Lacro et al., 2002; Scott & Pope, 2002).  Though adherence to 
antipsychotics has not been studied in previous studies, the rate of partial or total non-
adherence with mood stabilizers was reported to be about 51% in bipolar disorder 
population (Keck, Jr. et al., 1997).  About one in three patients with bipolar disorder take 
less than 30 percent of their medication (Scott et al., 2002).  However, the rate of 
interrupted therapy was much higher among bipolar disorder patients less than 18 years 
of age.  Since antipsychotics were not approved by the FDA for bipolar disorder at the 
time of study, it is possible that physicians were wary of using antipsychotics for 
extended periods in children and were using them for short periods to control symptoms.  
Results for the research objective 4 
For schizophrenia and bipolar disorder patients, determine the gaps between the refills 
of antipsychotics.  
Schizophrenia 
 
 Table 6 describes treatment gaps among schizophrenia patients in terms of the 
longest continuous gap between refills of antipsychotics for each patient.  About 27.5% 
of patients had no gaps greater than 15 days between refills of antipsychotic therapy.  
About 60.9% of patients had at least 1 gap of greater than 30 days. About 30.4% of 
patients had at least 1 gap of greater than 90 days between refills of antipsychotics. 




 Table 7 describes treatment gaps among schizophrenia patients in terms of the 
longest continuous gap between refills of antipsychotics for each patient.  About 26.8% 
of 18 years and older bipolar disorder patients and about 37.2% of less than 18 years old 
bipolar disorder patients had no gaps greater than 15 days between refills of antipsychotic 
therapy.  About 23.8% of 18 years and older bipolar disorder patients and about 17.6% of 
less than 18 years old bipolar disorder patients had at least 1 gap of greater than 90 days 
between refills of antipsychotics.  Average duration of the longest gap was 64.1 (+ 71.3) 
days for patients 18 years or older and 48 (+ 63.9) days for patients less than 18 years of 
age.  
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Table 6: Study of antipsychotic treatment gaps among schizophrenia patients (18 
years and above) 
 
Duration of gap* in days N = 1,036 
Mean (+std) 
Median   
72.2 (+75.6) 
48.0 
Up to or equal to 15 days 285 (27.5%) 
Greater than 15 days to 30 days 121 (11.7%) 
Greater than 30 days to 60 days 188 (18.2%) 
Greater than 60 days to 90 days 127 (12.3%) 
Greater than 90 days 315 (30.4%) 
 
* The longest continuous gap between refills for each patient 
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Table 7: Study of antipsychotic treatment gaps among bipolar disorder patients  
 
* The longest continuous gap between refills for each patient 
Duration of gap* in 
days 
18 years and above 
n=684 
Less than 18 years 
n=148 
Total 
N = 832 
Mean (+std) 







Up to or equal to 15 
days 
183 (26.8%) 55 (37.2%) 194 (28.6%) 
Greater than 15 days to 
30 days 
117 (17.1%) 31 (20.9%) 148 (17.8%) 
Greater than 30 days to 
60 days 
137 (20.0%) 27 (18.2%) 164 (19.7%) 
Greater than 60 days to 
90 days 
84 (12.2%) 9 (6.08%) 93 (11.2%) 
Greater than 90 days 163 (23.8%) 26 (17.6%) 189 (22.7%) 
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 Discussion for the research objective 4 
Schizophrenia 
 
 Gaps in the antipsychotic therapy are a measure of compliance or adherence to 
therapy.  Poor adherence to antipsychotic therapy among schizophrenia patients can be 
attributed to the nature of disease as well as side-effects to the antipsychotic therapy.  
Large gaps in antipsychotic therapy as found in our study have also been observed in 
other published studies. McCombs and colleagues have noted “drug holidays” among 
schizophrenia patients with only 11.6% of patients received uninterrupted antipsychotic 
therapy. About 30.7% of a treated sample of 2,010 patients had gaps larger than 90 days 
(McCombs, Nichol, Stimmel, Shi, & Smith, 1999a).  Mojtabai and colleagues report that 
about 51% of patients discharged from hospital had gaps of greater than 30 days in 
antipsychotic treatment within a year(Mojtabai et al., 2002).  Weiden and colleagues 
found gaps of greater than 30 days among 25.97% of patients in California Medicaid 
(Weiden, Kozma, Grogg, & Locklear, 2004).  
Bipolar Disorder 
 
 Our study found large gaps in antipsychotic therapy were present among bipolar 
disorder patients as well as schizophrenia patients.  Though few studies have reported the 
problem of non-adherence to mood stabilizer therapy in bipolar disorder patients, gaps in 
the therapy or adherence to antipsychotic therapy has not been explored.  Gaps in 
antipsychotic therapy among bipolar disorder patients may be due to drug side-effects, 
patient denial of illness and alcohol and substance abuse (Keck, Jr. et al., 1997; Lacro et 
al., 2002; Scott et al., 2002). 
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Results for research objective 5 
For schizophrenia and bipolar disorder patients, determine predictors of different 
utilization patterns of antipsychotics    
Schizophrenia 
 
Table 8 presents the results of the multinomial logistic model predicting factors 
associated with patterns of antipsychotic use among schizophrenia patients.  Alcohol and 
substance abuse, and use of typical antipsychotics as index prescription showed 
significant association with all patterns of antipsychotic use.  In addition, Schizophrenia 
subtypes, diagnosis of major depression, prescription of mood stabilizers, antidepressants 
and antipsychotics in the pre-index period were also significantly associated with certain 
patterns of antipsychotic use.  
Patients having diagnosis of alcohol and substance abuse were almost 2 times 
more likely to show either interrupted therapy, switching or polytherapy pattern than 
continuous therapy pattern.  Patients showing mixed diagnosis of schizophrenia and 
schizoaffective disorders were almost 2 times more likely to show continuous therapy 
rather than switching or polytherapy.  Patients having major depression were 2.3 times 
more likely to receive polytherapy rather than continuous monotherapy. 
Compared to patients initiated on quetiapine, patients initiated on typical 
antipsychotic were about 5 times more likely to receive interrupted antipsychotic therapy,  
about 1.1 times more likely to switch, and about 5.6 times more likely to receive 
polytherapy.   
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Table 8: Multinomial logistic regression model determining predictors of pattern of 
antipsychotic use among schizophrenia patients (first-stage sample selection model) 
 






 Coefficient t-ratio Coefficient t-ratio Coefficient t-ratio 
       
Demographic characteristics 
Age (in years) -0.009 -1.192 -0.021 1.926 0.001 0.15 
Males (ref: females) 0.008 0.627 0.751 0.047 0.005 0.246 
Whites (ref: non-
whites) 0.007 0.024 0.293 0.675 -0.111 -0.273 
Metro (ref: non-metro) 0.068 0.291 -0.424 1.408 -0.215 -0.697 
Prescribing physician type 
Psychiatric prescriber  -0.001 -1.871 -0.008 -1.647 -0.005 -1.501 
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective 
disorder 0.219 0.867 0.0844 0.268 -0.384 -1.127 
Both schizoaffective 
disorder and 
schizophrenia 0.162 0.646 -0.777 - 2.309* -0.965 -2.647* 
Pre-index co-morbidities 
Diabetes 0.493 1.464 0.349 0.793 -0.183 -0.357 
Hyperlipidemia 0.021 0.057 -0.349 -0.65 0.099 0.162 
Hypertension 0.122 0.454 0.331 0.949 -0.489 -1.113 
Alcohol and substance 
abuse 0.686 2.676* 0.701 2.193* 0.873 2.614* 
Bipolar disorder  0.547 1.931 0.313 0.873 0.293 0.724 
Major depression 0.195 0.749 0.437 1.348 0.834 2.382* 
Anxiety disorder -0.164 -0.639 -0.178 -0.532 -0.305 -0.802 
Personality disorder -0.160 -0.532 0.086 0.232 -0.120 -0.279 
Non-specified 
psychosis -0.647 -1.497 -1.382 -1.923 -1.182 -1.731 
Other affective 
psychosis -0.797 -1.381 -0.461 -0.597 -1.312 -1.111 
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Table 8: Multinomial logistic regression model determining predictors of pattern of 
antipsychotic use among schizophrenia patients (first-stage sample selection model) 
(contd.) 
 






 Coefficient t-ratio Coefficient t-ratio Coefficient t-ratio 
Attention deficit 
disorders -0.669 -1.238 -0.217 -0.322 -0.056 -0.072 
Mild to moderate 
depression 0.240 0.786 0.351 0.923 0.143 0.325 
Pre-index healthcare utilization and cost 
Number of pre-index 
mental-health related 
ER visits/ 
hospitalizations 0.005 1.558 -0.005 -1.066 -0.002 -0.476 
Number of pre-index 
mental-health related 
physician visits -0.129 -1.345 0.084 0.856 0.062 0.59 
Number of 
psychotherapy visits 0.008 0.398 -0.038 -0.689 0.018 0.645 
Number of medication 
management visits 0.009 0.3 -0.043 -1.012 -0.037 -0.784 
Year of index prescription (ref: 1999) 
• 2000 0.209 0.868 0.217 0.675 -0.251 -0.684 
• 2001 0.190 0.71 0.105 0.286 -0.023 -0.058 
Pre-index period psychiatric medication use ( days of supply) 
Mood stabilizers -0.341 -2.542* -0.869 -0.107 -0.000 -0.128 
Anticholinergics -0.017 -1.386 -0.003 -0.584 0.002 0.303 
Anxiolytics/hypnotics/ 
sedatives 0.004 0.25 0.001 1.004 0.007 0.338 
Antipsychotics -0.125 -2.314* -0.003 -1.007 -0.006 -0.227 
Antidepressants -0.003 -0.489 0.322 2.656* -0.003 -0.332 
Benzodiazepines -0.003 -0.422 -0.001 -1.27 0.001 1.597 
Antiparkinsons 0.006 0.245 0.003 1.08 0.005 0.142 
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Table 8: Multinomial logistic regression model determining predictors of pattern of 
antipsychotic use among schizophrenia patients (first-stage sample selection model) 
(contd.) 
 






 Coefficient t-ratio Coefficient t-ratio Coefficient t-ratio 
Index prescription (ref: quetiapine) 
Risperidone 0.309 1.09 0.144 0.364 0.819 1.580 
Olanzapine 0.025 0.102 0.218 0.422 0.543 1.130 
Typicals 1.628 5.112* 0.108 2.567* 1.730 3.289*
*significant at p<0.05 
 
Model fit statistics: 
 




 Table 9 presents the results of the multinomial logistic model predicting factors 
associated with patterns of antipsychotic use among bipolar disorder patients.  Compared 
to bipolar disorder patients who were less than 18 years of age, bipolar disorder patients 
who were 18 years or older were almost 2 times less likely to have adherent index 
antipsychotic therapy.  Patients having psychiatric prescriber for the index prescription 
were 1.22 times less likely to have interrupted therapy.  Patients having diagnosis of 
alcohol and substance abuse were almost 2.3 times more likely to show interrupted 
therapy, 2.8 times more likely to switch, and 2.7 times more likely to have polytherapy 
pattern than continuous therapy pattern.  Patients using mood stabilizers in the pre-index 
period were 1.3 times more likely to have adherent antipsychotic therapy.  Patients 
initiated on typicals were 1.86 times more likely to have interrupted antipsychotic 
therapy.   
 Patients having mixed bipolar disorder patients were almost 2 times less likely to 
switch.  Patients who have used antidepressants in the pre-index period were almost 1.2 
times more likely to switch index antipsychotic therapy.  Patients who have used typical 
antipsychotics were almost 1.13 times more likely to switch index antipsychotic therapy.  
 Patients who have major depression are 2.5 times more likely to receive 
polytherapy.  Patients who have anxiety are 2.8 times less likely to receive polytherapy.  




Table 9: Multinomial logistic regression model determining predictors of pattern of 
antipsychotic use among bipolar disorder patients (first-stage sample selection 
model) 






 Coefficient t-ratio Coefficient t-ratio Coefficient t-ratio 
Demographic characteristics 
Age (in years) -0.007 -0.730 -0.019 -1.53 0.014 0.956 
18 years or above (ref: 
less than 18 years) 0.719 2.371* -0.338 -0.845 -0.810 -1.942 
Males (ref: females) 0.002 1.417 0.001 0.554 0.108 0.379 
Whites (ref: non-
whites) -0.041 -0.117 0.224 0.462 0.200 0.356 
Metro (ref: non-
metro) 0.146 0.541 -0.347 -1.007 -0.232 -0.596 
Prescribing physician type 
Psychiatric prescriber  -0.200 -2.212* -0.001 -1.036 -0.001 -1.563 
Bipolar Subtype (ref: bipolar disorder I) 
Bipolar disorder II 0.318 1.095 0.181 0.509 -0.144 -0.346 
Mixed 0.260 0.923 -0.742 -2.015* -0.769 -1.824 
Pre-index co-morbidities  
Diabetes 0.409 1.124 0.259 0.533 -0.782 -1.094 
Hyperlipidemia -0.002 -0.005 -0.616 -1.005 0.153 0.199 
Hypertension 0.144 0.496 0.331 0.883 -0.315 -0.608 
Alcohol and substance 
abuse 0.877 2.916* 1.033 2.867* 1.010 2.380* 
Bipolar disorder  0.520 1.656 0.060 0.147 0.076 0.148 
Major depression 0.356 1.234 0.529 1.49 0.925 2.151* 
Anxiety disorder -0.366 -1.273 -0.190 -0.517 -1.058 -1.966* 
Personality disorder -0.091 -0.273 0.066 0.16 -0.227 -0.416 
Non-specified 
psychosis -0.634 -1.248 -1.175 -1.501 -0.378 -0.506 
Other affective 
psychosis -0.788 -1.194 0.003 0.003 -28.058 0.000 
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Table 9: Multinomial logistic regression model determining predictors of pattern of 












 Coefficient t-ratio Coefficient t-ratio Coefficient t-ratio 
Attention deficit 
disorders -0.682 -1.237 -0.285 -0.415 0.133 0.162 
Mild to moderate 
depression 0.148 0.448 0.240 0.58 -0.015 -0.028 
Number of pre-index 
mental-health related 
ER visits/ 
hospitalizations 0.001 1.534 -0.001 -1.18 0.000 -0.224 
Number of pre-index 
mental-health related 
physician visits -0.095 -0.886 0.105 0.958 0.124 1.040 
Number of 
psychotherapy visits -0.019 -0.764 -0.048 -0.789 -0.105 -0.244 
Number of medication 
management visits 0.050 1.461 -0.072 -1.408 -0.177 -0.357 
Year of index prescription (ref: 1999) 
• 2000 0.056 0.213 0.123 0.354 0.000 -0.414 
• 2001 0.025 0.084 -0.016 -0.041 0.006 0.928 
Pre-index period psychiatric medication use ( days of supply)  
Mood stabilizers -0.320 -3.041* 0.000 0.137 0.003 1.250 
Anticholinergics -0.007 -1.298 -0.005 -0.708 0.001 0.248 
Anxiolytics/hypnotics/ 
sedatives 0.001 0.464 0.002 1.04 -0.002 -1.787 
Antipsychotics -0.106 -2.293* -0.005 -1.327 0.001 1.053 
Antidepressants -0.001 -1.219 0.202 2.442* 0.000 -0.028 
Benzodiazepines -0.656 -0.079 -0.001 -1.266 0.017 0.575 
Antiparkinsons -0.001 -0.207 -0.671 -0.016 -0.012 -0.208 
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Table 9: Multinomial logistic regression model determining predictors of pattern of 
antipsychotic use among bipolar disorder patients (first-stage sample selection 
model) (contd.) 
 
* significant at p <0.05 
 
Model fit statistics: 
 
Pseudo R-square = 13.67% 
-2 Log Likelihood = 801.14; χ2 = 253.90; p= 0.00






 Coefficient t-ratio Coefficient  Coefficient t-ratio 
Index prescription (ref: quetiapine)   
Risperidone -0.001 -1.589 -0.001 -1.751 -0.002 -1.237 
Olanzapine -0.001 -1.719 0.000 -1.368 -0.002 -1.536 
Typicals 0.620 3.132* 0.13 2.461* 1.210 2.075* 
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Discussion for research objective 5 
Schizophrenia 
 
 Alcohol and substance abuse is a common co morbidity among schizophrenia 
patients (APA, 1997).   Our study found that alcohol and substance abuse was a 
significant predictor of interrupted therapy, switching, and polytherapy.  Other studies 
have also reported association of substance abuse with non-adherence with medications 
(Hudson et al., 2004; Hunt, Bergen, & Bashir, 2002; Kashner et al., 1991; Kamali et al., 
2001). A study of barriers to medication adherence among schizophrenia patients 
reported patients with substance and alcohol abuse were 3.24 times more likely to be 
non-compliant with the medications (Hudson et al., 2004). As management of disease 
condition may be difficult in these patients, physicians may resort to switching or 
polytherapy to treat patients.  As use of alcohol and drugs are strictly contraindicated 
with use of psychotropic medications, the patients may choose to stop taking medications 
and take alcohol or drugs.  
 Patients with mixed diagnosis of both schizophrenia and schizoaffective disorder 
may be showing range of symptoms.  Physicians may be attempting to control the 
symptoms by changing or augmenting antipsychotic therapy.  According to our study 
results, patients with major depression were 2.3 times more likely to receive polytherapy. 
A study by McCombs and colleagues also reported about 1.9 times greater likelihood of 
switching or polytherapy among schizophrenia patients with diagnosis of major 
depression (McCombs et al., 1999a).  Polytherapy may have been used in these patients 
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to manage greater exacerbation of disease symptoms due to presence of an additional 
mental illness.  
 Compared to patients initiated on quetiapine, patients initiated on typical 
antipsychotic had a high likelihood of interrupted antipsychotic therapy, switching and 
polytherapy.  Typical antipsychotics have been associated with poor adherence due to 
disabling adverse effects such as extrapyramidal symptoms (EPS) (Van Putten, 1974).  
Studies have reported poorer adherence rates with typical antipsychotics (50.1%) 
compared to atypical antipsychotics (54.9%) (Dolder, Lacro, Dunn, & Jeste, 2002). 
Menzin and colleagues found that schizophrenia patients on atypical antipsychotics in the 
California Medicaid population were less likely to switch (OR = 0.37) than typical 
antipsychotics in 1997(Menzin et al., 2003). Compared with quetiapine, olanzapine and 
risperidone did not show any significant difference in the likelihood of interrupted 
therapy, switching, and polytherapy.  Though few studies have reported better persistence 
with index antipsychotic for olanzapine with respect to risperidone (Gibson et al., 2004), 
no studies have compared the typical and atypical antipsychotics in terms of continuous, 
interrupted, switching and polytherapy patterns.  
Bipolar Disorder 
 
 As among schizophrenia patients, we found alcohol and substance abuse was a 
significant predictor of interrupted therapy, switching or polytherapy among bipolar 
patients.  Prevalence of alcohol and substance abuse is about 40% to 60% among bipolar 
disorder patients (Salloum & Thase, 2000).  Other studies have also reported association 
of alcohol and substance abuse with medication non-adherence, especially in 
schizophrenia population (Keck, Jr. et al., 1997).  
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 Patterns of antipsychotic therapy are relatively less studied among bipolar 
disorder patients.  Common factors associated with non-adherence to mood-stabilizers 
medications among bipolar disorder are  mania, personality disorders, alcohol and 
substance abuse, and denial of disorder or need for treatment (Keck, Jr. et al., 1997; 
Loosbrock et al., 2003; Maarbjerg, Aagaard, & Vestergaard, 1988; Schumann, Lenz, 
Berghofer, & Muller-Oerlinghausen, 1999).  In our study, factors such as disease 
subtype, use of mood stabilizers , antidepressants, and typical antipsychotics, alcohol and 
substance abuse were common predictors of patterns of antipsychotic use among bipolar 
and schizophrenia patients.  
 The significant association of use of typical antipsychotics with interrupted 
therapy and switching may be due to side-effects.  Use of mood-stabilizers was 
associated with decreased likelihood of receiving interrupted therapy.   Presence of major 
depression was linked with greater likelihood of receiving polytherapy.  Major depression 
was also associated with polytherapy among schizophrenia patients in our study as well 
as in the McCombs study (McCombs et al., 1999a).    
Results for research objective 6 
For schizophrenia and bipolar disorder patients, determine the relationship between 
utilization pattern of antipsychotics and total health-related healthcare costs.  
 The objective was to determine the effect of pattern of antipsychotic use on total 
healthcare costs among schizophrenia and bipolar patients.  The results of univariate 
analysis show that the post-index total healthcare costs was significantly less for the 
continuous therapy group compared to the interrupted, switch and polytherapy group. 
Multivariate analysis was conducted to test this difference after controlling for patient 
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demographics, disease severity, co morbidities and prior utilization of healthcare 
services.  An important step of this analysis was to adjust for the sample selection bias 
between patients showing different patterns of antipsychotic utilization.  In the first step 
of the analysis, a multinomial logistic regression analysis was carried out using various 
explanatory variables such as patient demographics, co morbidities and healthcare 
utilization variables. This model was same as the model provided in the table 8 for 
schizophrenia patients and table 9 for bipolar disorder patients.  This model allowed for 
calculation of Inverse Mills Ratio (IMR) to adjust for sample selection bias in the second 
step regression models. Individual contrasts were carried out to obtain IMR for 
continuous vs. interrupted therapy, continuous vs. switching therapy, and continuous vs. 
polytherapy.  
 In the second step of the analysis, multivariate regression models were used to 
investigate association of different patterns of antipsychotic use with total healthcare 
costs.  Three semi-log OLS regressions were developed to compare costs associated with 
interrupted therapy, switching and polytherapy with adherent therapy.  IMRs calculated 
from the first stage regression models were added as a covariate in the second stage 
regression models to adjust and test for sample selection bias.  The models were further 
tested for appropriate specifications.  It is possible that multicollinarity resulting due to 
inclusion of IMR in the model may be inflating the standard errors.  Therefore, a semi-
log OLS model was developed without including the IMR and the output was compared 
with the outputs of regression models that included IMR.   
The univariate analysis for total and mental healthcare costs for schizophrenia 
patients are presented in table 10.  The second stage regression models for total and 
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mental healthcare costs for schizophrenia patients are presented in the tables 11 and 12, 
respectively.   
The univariate analysis for total and mental healthcare costs for bipolar disorder 
patients are presented in table 13.   The second stage regression models for total and 




 The results of univariate analysis presented in table 10 show that the post-index 
total healthcare costs was significantly less for the continuous therapy group ($19,960 + 
$32,312) compared to the switching ($21,595 + $24,595) and polytherapy ($27,741 + 
35,334) group.  The multivariate analyses of total costs are presented in tables 11a-11c.  
The results of multivariate analysis presented in table 11a show that patients receiving 
interrupted index antipsychotic therapy incur 7.89% higher total healthcare costs than 
patients receiving continuous antipsychotic therapy.   After controlling for confounding 
variables, there were no significant differences among patients receiving continuous 
antipsychotic therapy and patients switching from index antipsychotic therapy (table 
11b).  Table 11c shows that patients receiving polytherapy incur 28.40% higher total 
costs than patients receiving continuous index antipsychotic therapy.  Also, IMR was not 
significant in all the models indicating possible absence of selection bias between patients 
on different patterns of antipsychotic use cohorts.  
Bipolar disorder  
 
 The results of univariate analysis presented in table 13 show that the post-index 
total healthcare costs was significantly less for the continuous therapy group ($18,383 + 
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$30,283) as compared to the interrupted ($20,486 + $21,513), switching ($20,104 + 
$23,116) and polytherapy ($26,972 + 32,885) groups.  The results of multivariate 
analysis presented in table 14a show that patients receiving interrupted index 
antipsychotic therapy incur 1.5% higher total healthcare costs than patients receiving 
continuous antipsychotic therapy.  Table 14b shows that patients switching from index 
antipsychotic to monotherapy with another antipsychotic incur 17.0% higher total costs 
than patients receiving continuous index antipsychotic therapy.   Table 14c shows that 
patients receiving polytherapy incur 37.71% higher total costs than patients receiving 
continuous index antipsychotic therapy.  
Results for research objective 7 
For schizophrenia and bipolar disorder patients, determine the relationship between 
utilization pattern of antipsychotics and mental health care utilization and costs.  
Schizophrenia 
 
 The results of univariate analysis presented in table 10 show that the post-index 
mental healthcare costs was significantly less for the continuous therapy group ($18,383 
+ $30,283) compared to the interrupted ($12,482 + $24,195), switching ($17,890 + 
$18,330) and polytherapy ($21,006 + $35,334) groups.   The multivariate results in table 
12a show that after controlling for confounding variables, patients receiving interrupted 
index antipsychotic therapy incur 3.44% higher mental healthcare costs than patients 
receiving continuous antipsychotic therapy.   After controlling for confounding variables, 
there were no significant differences among patients receiving continuous antipsychotic 
therapy and patients switching from index antipsychotic therapy (table 12b).  Table 12c 
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shows that patients receiving polytherapy incur 12.74% higher mental health care costs 
than patients receiving continuous index antipsychotic therapy.   
Bipolar  
 
 The results of univariate analysis presented in table 13 show that the post-index 
mental healthcare costs was significantly less for the continuous therapy group ($18,383 
+ $30,283) as compared to the interrupted ($11,134 + $21,901), switching ($17,890 + 
$18,330) and polytherapy ($16,470 +  $15,258) group.   The multivariate results in table 
15a show that after controlling for confounding variables, patients receiving interrupted 
index antipsychotic therapy incur 7.03% higher total healthcare costs than patients 
receiving continuous antipsychotic therapy.   After controlling for confounding variables, 
there were no significant differences among patients receiving continuous antipsychotic 
therapy and patients switching from index antipsychotic therapy (table 15b).  Table 15c 
shows that patients receiving polytherapy incur 16.18% higher total costs than patients 
receiving continuous index antipsychotic therapy.   
Discussion for research objective 6 and 7 
Schizophrenia and bipolar disorder  
 
 Our results show that significant increase in total and mental costs is associated 
with different patterns of antipsychotic use.  Other studies have also found that non-
adherent patients are more costly than adherent patients.  A study by Knapp and 
colleagues conducted among adults living in institutions in the UK reported that non-
adherent patients incurred an additional ₤5000 in total costs than adherent patients 
(Knapp, King, Pugner, & Lapuerta, 2004).  Eaddy and colleagues report 54.5% increase 
in inpatient costs among partially adherent patients (Eaddy et al., 2005).  Gilmer and 
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colleagues found that non-adherent patients incur almost 3 times higher inpatient cost 
than adherent patients in a California Medicaid population.  Risk of hospitalization has 
also been shown to increase with increasing gaps in therapy (Weiden et al., 2004; Gilmer 
et al., 2004). Literature on association of pattern of medication use with healthcare costs 
and utilization are relatively rare in bipolar disorder.  Studies have shown that the risk of 
relapse resulting in hospitalizations increases after discontinuing lithium treatment in 
bipolar disorder patients (Schou, 1997; Suppes, Baldessarini, Faedda, & Tohen, 1991).  
Our study demonstrates that patients with non-adherent or interrupted antipsychotic 
therapy are more likely to incur higher costs.   
 Our results show that switching from index antipsychotic to another antipsychotic 
was associated with significant increase in cost for bipolar disorder patients but not for 
schizophrenia patients.  Other studies in literature have suggested that switching can 
increase costs as it usually occurs when a patient fails the previous treatment or 
experiences severe side-effects (McCombs et al., 2000; Loosbrock et al., 2003). 
McCombs and colleagues reported that antipsychotic switching can increase the annual 
total cost by $9,719 (McCombs et al., 2000). However, they combined the cost of 
switching to antipsychotic monotherapy or polytherapy in their analysis which could 
have overestimated the increase in total costs.  Loosberg and colleagues also found an 
increase of $4,706 associated switching antipsychotics(Loosbrock et al., 2003).  As the 
data used in above two studies is prior to 1997 and a large proportion of the study 
population was on typical antipsychotics, it is likely that increase in cost was mainly due 
to switching from typical to atypical antipsychotics, which are more costly.  Switching 
antipsychotics is advocated by the treatment guidelines when patient fails to respond or 
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stabilize on current medications and may lead to finding the appropriate medication 
regimen for the patients.   
 Significantly greater increase in total and mental costs was associated with 
polytherapy for schizophrenia and bipolar disorder patients.  Results are similar to those 
observed in the Loosbrock study that evaluated total costs differences between 
schizophrenia patients on polytherapy and monotherapy.  The study reported that 
schizophrenia patients on polytherapy incurred an additional $4,244 in total costs as 
compared to schizophrenia patients on monotherapy.  However, it should be noted that in 
our study comparisons are being made between polytherapy and adherent or continuous 
monotherapy.  
 Antipsychotic polytherapy has been associated with increased risk of adverse 
effects and hospitalization (Centorrino et al., 2004).  Utilization of anticholinergics 
among patients on antipsychotics was significantly higher as compared to monotherapy 
(Procyshyn et al., 2001).  The cost of adverse reactions as well as that of utilization of 
additional drug may be driving the cost of polytherapy higher.  It is also likely that the 
patients on polytherapy are more severe or treatment refractory and are utilizing more 
healthcare services.  However, results were significant after controlling for the severity 




Table 10: Total and mental healthcare costs associated with the different 
antipsychotic utilization patterns among schizophrenia patients 
 
 Continuous  
N = 192 
Interrupted  




N = 124 




















Mental Healthcare Cost  
Mean (+std) 
Pre-index $8,513


















I Significant difference between continuous (c) and interrupted cohorts at p<0.05 
S Significant difference between continuous (c) and switch cohorts at p<0.05 
P Significant difference between continuous (c) and polytherapy cohorts at p<0.05 
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Table 11a: Ordinary Least Squares (OLS) regression model for the impact pattern 
of antipsychotic use on total healthcare cost among schizophrenia patients (second 
stage sample selection models): Interrupted vs. Adherent therapy  
 
 Beta S.E t-statistic Significance (p) 
     
Demographic characteristics 
Age (in years) 0.005 0.003 1.376 0.169 
Males (ref: females) 0.571 0.000 0.211 0.833 
Whites (ref: non-whites) 0.120 0.104 1.155 0.248 
Metro (ref: non-metro) -0.152 0.091 -1.669 0.095 
Prescribing physician type 
Psychiatric prescriber  0.798 0.000 0.719 0.472 
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective disorder 0.069 0.096 0.709 0.478 
Both schizoaffective disorder 
and schizophrenia -0.124 0.113 -1.095 0.274 
Pre-index co-morbidities 
Charlson Comorbidity Index 0.215 0.030 7.208 0.000 
Alcohol and substance abuse 0.294 0.107 2.731 0.006 
Bipolar disorder  0.103 0.128 0.804 0.422 
Major depression 0.055 0.112 0.493 0.622 
Other mental comorbidities 0.015 0.088 0.171 0.865 
Pre-index healthcare utilization and cost 
Pre-index total health related 
cost 0.129 0.023 5.683 0.000 
Pre-index  total health related 
ER visits 0.081 0.092 0.880 0.379 
Pre-index  total health related 
hospitalizations 0.187 0.112 1.667 0.096 
Pre-index  total health related 
physician visits 0.005 0.005 1.006 0.315 
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Table 11a: Ordinary Least Squares (OLS) regression model: Interrupted vs. 
Adherent therapy (contd.) 
 
 Beta S.E t-statistic Significance (p) 
     
Year of index prescription (ref: 1999) 
• 2000 -0.010 0.117 -0.088 0.930 
• 2001 -0.438 0.120 -3.656 0.000 
Pre-index period psychiatric medication use ( days of supply) 
Mood stabilizers 0.021 0.010 1.966 0.049 
Antipsychotics -0.002 0.001 -1.710 0.087 
Antidepressants 0.282 0.083 3.404 0.001 
Benzodiazepines 0.082 0.082 1.002 0.317 
Index prescription (ref: quetiapine) 
Risperidone -0.865 0.904 -0.958 0.338 
Olanzapine -0.666 0.000 -0.606 0.544 
Typicals 0.020 0.852 -1.556 0.120 
Interrupted (ref: Adherent) 0.078 0.466 2.314 0.021 
Inverse Mills Ratio 0.403 0.280 1.441 0.150 
 
Model fit statistics: 
 
Adjusted R-square = 29.58% , F = 13.59   , p = 0.00 
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Table 11b: Ordinary Least Squares (OLS) regression model for the impact pattern 
of antipsychotic use on total healthcare cost among schizophrenia patients (second 
stage sample selection models): Switching vs. adherent therapy 
 
 Beta S.E t-statistic Significance (p) 
     
Demographic characteristics 
Age (in years) 0.012 0.004 2.663 0.008 
Males (ref: females) -0.834 0.001 -0.153 0.879 
Whites (ref: non-whites) 0.338 0.190 1.783 0.076 
Metro (ref: non-metro) -0.036 0.136 -0.265 0.791 
Prescribing physician type 
Psychiatric prescriber  0.277 0.000 0.202 0.840 
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective disorder -0.001 0.134 -0.006 0.995 
Both schizoaffective disorder 
and schizophrenia -0.108 0.149 -0.721 0.471 
Charlson Comorbidity Index 0.130 0.039 3.320 0.001 
Pre-index co-morbidities 
Alcohol and substance abuse 0.254 0.137 1.855 0.065 
Bipolar disorder  0.088 0.166 0.530 0.597 
Major depression -0.169 0.136 -1.238 0.217 
Other mental comorbidities 0.152 0.120 1.270 0.205 
Pre-index healthcare utilization and cost 
Pre-index  total health related 
cost 0.128 0.034 3.735 0.000 
Pre-index  total health related 
ER visits -0.121 0.125 -0.962 0.337 
Pre-index  total health related 
hospitalizations -0.105 0.155 -0.679 0.498 
Pre-index  total health related 
physician visits 0.002 0.006 0.292 0.770 
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Table 11b: Ordinary Least Squares (OLS) regression model: Switching vs. adherent 
therapy (contd.) 
 
 Beta S.E t-statistic Significance (p) 
     
Year of index prescription (ref: 1999) 
• 2000 0.209 0.149 1.399 0.163 
• 2001 -0.124 0.142 -0.874 0.383 
Pre-index period psychiatric medication use ( days of supply) 
Mood stabilizers 0.021 0.000 2.971 0.003 
Antipsychotics -0.001 0.001 -0.421 0.674 
Antidepressants 0.039 0.116 0.335 0.738 
Benzodiazepines 0.110 0.108 1.012 0.312 
Index prescription (ref: quetiapine) 
Risperidone 0.001 0.000 1.149 0.252 
Olanzapine 0.001 0.000 0.839 0.402 
Typicals -0.020 0.000 -2.429 0.016 
Switch (ref: Adherent) 0.559 0.331 1.688 0.092 
Inverse Mills Ratio -0.262 0.209 -1.253 0.211 
 
Model fit statistics: 
 
Adjusted R-square = 23.4%, F = 4.84, p = 0.00 
 
130 
Table 11c: Ordinary Least Squares (OLS) regression model for the impact pattern 
of antipsychotic use on total healthcare cost among schizophrenia patients (second 
stage sample selection models): Polytherapy vs. adherent therapy 
 
 Beta S.E t-statistic Significance (p) 
     
Demographic characteristics 
Age (in years) 0.010 0.005 2.007 0.046 
Males (ref: females) -0.002 0.000 -4.055 0.000 
Whites (ref: non-whites) 0.502 0.181 2.778 0.006 
Metro (ref: non-metro) 0.002 0.136 0.017 0.987 
Prescribing physician type 
Psychiatric prescriber  0.000 0.000 -1.406 0.161 
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective disorder 0.049 0.148 0.330 0.742 
Both schizoaffective disorder 
and schizophrenia -0.458 0.171 -2.687 0.008 
Charlson Comorbidity Index 0.117 0.047 2.513 0.013 
Pre-index co-morbidities 
Alcohol and substance abuse 0.440 0.155 2.842 0.005 
Bipolar disorder  0.272 0.195 1.396 0.164 
Major depression 0.133 0.159 0.838 0.403 
Other mental comorbidities 0.171 0.140 1.222 0.223 
Pre-index healthcare utilization and cost 
Pre-index  total health related 
cost 0.107 0.022 4.861 0.000 
Pre-index  total health related 
ER visits -0.125 0.120 -1.040 0.299 
Pre-index  total health related 
hospitalizations -0.041 0.180 -0.228 0.820 
Pre-index  total health related 
physician visits 0.012 0.009 1.293 0.197 
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Table 11c: Ordinary Least Squares (OLS) regression model: Polytherapy vs. 
adherent therapy (contd.) 
 
 Beta S.E t-statistic Significance (p) 
     
Year of index prescription (ref: 1999) 
• 2000 0.000 0.157 0.001 0.999 
• 2001 -0.281 0.162 -1.734 0.084 
Pre-index period psychiatric medication use ( days of supply) 
Mood stabilizers 0.211 0.000 3.487 0.001 
Antipsychotics -0.001 0.001 -1.457 0.146 
Antidepressants 0.073 0.127 0.572 0.568 
Benzodiazepines 0.075 0.120 0.627 0.531 
Index prescription (ref: quetiapine) 
Risperidone 0.133 0.000 1.338 0.182 
Olanzapine 0.078 0.000 0.989 0.324 
Typicals 0.026 0.000 2.935 0.004 
Polytherapy (ref: Adherent) 0.252 0.483 0.523 0.015 
Inverse Mills Ratio 0.466 0.285 1.633 0.104 
 
Model fit statistics: 
 
Adjusted R-square =   28.6%, F = 5.87, p = 0.00 
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Table 12a: Ordinary Least Squares (OLS) regression model for the impact pattern 
of antipsychotic use on mental healthcare cost among schizophrenia patients (second 
stage sample selection models): Interrupted vs. adherent therapy  
 
 Beta S.E t-statistic Significance (p) 
     
Demographic characteristics 
Age (in years) 0.002 0.004 0.498 0.619 
Males (ref: females) 0.002 0.000 3.337 0.001 
Whites (ref: non-whites) 0.092 0.121 0.762 0.446 
Metro (ref: non-metro) -0.141 0.100 -1.400 0.162 
Prescribing physician type 
Psychiatric prescriber  0.000 0.000 1.655 0.098 
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective disorder 0.094 0.106 0.889 0.374 
Both schizoaffective disorder 
and schizophrenia -0.423 0.122 -3.464 0.001 
Charlson Comorbidity Index 0.053 0.045 1.184 0.236 
Pre-index co-morbidities 
Alcohol and substance abuse 0.369 0.132 2.808 0.005 
Bipolar disorder  0.112 0.149 0.754 0.451 
Major depression 0.118 0.122 0.962 0.336 
Other mental comorbidities 0.013 0.099 0.132 0.895 
Pre-index healthcare utilization and cost 
Pre-index mental-health 
related cost 0.192 0.093 2.069 0.039 
Pre-index mental-health 
related ER visits -0.032 0.129 -0.244 0.807 
Pre-index mental-health 
related hospitalizations 0.306 0.103 2.960 0.003 
Pre-index mental-health 
related physician visits 0.379 0.139 2.726 0.006 
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Table 12a: Ordinary Least Squares (OLS) regression model: Interrupted vs. 
adherent therapy (contd.) 
 
 Beta S.E t-statistic Significance (p) 
     
Year of index prescription (ref: 1999) 
• 2000 -0.021 0.126 -0.163 0.870 
• 2001 -0.334 0.133 -2.520 0.012 
Pre-index period psychiatric medication use ( days of supply) 
Mood stabilizers 0.051 0.000 2.472 0.014 
Antipsychotics 0.001 0.002 0.450 0.653 
Antidepressants 0.419 0.227 1.848 0.065 
Benzodiazepines -0.582 0.529 -1.100 0.271 
Index prescription (ref: quetiapine) 
Risperidone 0.735 0.000 0.709 0.478 
Olanzapine 0.024 0.000 2.985 0.303 
Typicals -0.033 0.995 -3.344 0.001 
Interrupted (ref: Adherent) 0.034 0.015 2.318 0.020 
Inverse Mills Ratio 0.038 0.322 0.118 0.906 
 
Model fit statistics: 
 




Table 12b: Ordinary Least Squares (OLS) regression model for the impact pattern 
of antipsychotic use on mental healthcare cost among schizophrenia patients (second 
stage sample selection models): Switch vs. adherent therapy  
 
 Beta S.E t-statistic Significance (p) 
     
Demographic characteristics 
Age (in years) 0.014 0.004 3.167 0.002 
Males (ref: females) 0.001 0.000 1.591 0.113 
Whites (ref: non-whites) 0.373 0.217 1.719 0.087 
Metro (ref: non-metro) 0.008 0.140 0.056 0.955 
Prescribing physician type 
Psychiatric prescriber  0.000 0.000 -1.075 0.283 
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective disorder 0.169 0.147 1.149 0.252 
Both schizoaffective disorder 
and schizophrenia -0.166 0.136 -1.218 0.224 
Charlson Comorbidity Index -0.019 0.049 -0.391 0.696 
Pre-index co-morbidities 
Alcohol and substance abuse 0.274 0.151 1.810 0.071 
Bipolar disorder  0.130 0.161 0.809 0.419 
Major depression -0.237 0.144 -1.648 0.100 
Other mental comorbidities 0.033 0.125 0.263 0.793 
Pre-index healthcare utilization and cost 
Pre-index mental-health 
related cost 0.042 0.017 2.495 0.013 
Pre-index mental-health 
related ER visits -0.243 0.153 -1.592 0.113 
Pre-index mental-health 
related hospitalizations 0.054 0.124 0.431 0.667 
Pre-index mental-health 
related physician visits 0.433 0.065 6.680 0.000 
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Table 12b: Ordinary Least Squares (OLS) regression model: Switch vs. adherent 
therapy (contd.) 
 
 Beta S.E t-statistic Significance (p) 
     
Year of index prescription (ref: 1999) 
• 2000 0.204 0.154 1.327 0.186 
• 2001 -0.122 0.131 -0.925 0.356 
Pre-index period psychiatric medication use ( days of supply) 
Mood stabilizers 0.001 0.000 2.532 0.012 
Antipsychotics -0.001 0.002 -0.557 0.578 
Antidepressants 0.357 0.296 1.205 0.229 
Benzodiazepines -0.014 0.109 -0.130 0.896 
Index prescription (ref: quetiapine) 
Risperidone 0.020 0.000 1.382 0.168 
Olanzapine 0.054 0.000 1.440 0.151 
Typicals -0.020 0.000 -3.105 0.002 
Switch (ref: Adherent) 0.432 0.364 1.188 0.236 
Inverse Mills Ratio -0.181 0.225 -0.804 0.422 
 
Model fit statistics: 
 




Table 12c: Ordinary Least Squares (OLS) regression model for the impact pattern 
of antipsychotic use on mental healthcare cost among schizophrenia patients (second 
stage sample selection models): Polytherapy vs. adherent therapy  
 
 Beta S.E t-statistic Significance (p) 
     
Demographic characteristics 
Age (in years) 0.012 0.005 2.495 0.013 
Males (ref: females) -0.001 0.001 -0.592 0.554 
Whites (ref: non-whites) 0.361 0.203 1.775 0.070 
Metro (ref: non-metro) -0.029 0.133 -0.216 0.829 
Prescribing physician type 
Psychiatric prescriber  0.000 0.000 -1.498 0.135 
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective disorder 0.120 0.146 0.826 0.409 
Both schizoaffective disorder 
and schizophrenia -0.554 0.164 -3.369 0.000 
Charlson Comorbidity Index -0.020 0.057 -0.357 0.721 
Pre-index co-morbidities 
Alcohol and substance abuse 0.471 0.166 2.830 0.005 
Bipolar disorder  0.381 0.199 1.916 0.056 
Major depression 0.028 0.172 0.162 0.871 
Other mental comorbidities 0.151 0.144 1.047 0.295 
Pre-index healthcare utilization and cost 
Pre-index mental-health 
related cost 0.058 0.017 3.339 0.001 
Pre-index mental-health 
related ER visits 0.058 0.152 0.381 0.703 
Pre-index mental-health 
related hospitalizations -0.137 0.129 -1.059 0.290 
Pre-index mental-health 
related physician visits 0.058 0.518 0.112 0.911 
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Table 12c: Ordinary Least Squares (OLS) regression model: Polytherapy vs. 
adherent therapy (contd.) 
 
 Beta S.E t-statistic Significance (p) 
     
Year of index prescription (ref: 1999) 
• 2000 0.114 0.164 0.695 0.487 
• 2001 -0.180 0.149 -1.211 0.220 
Pre-index period psychiatric medication use ( days of supply) 
Mood stabilizers 0.021 0.000 1.787 0.070 
Antipsychotics -0.001 0.001 -1.173 0.241 
Antidepressants 0.104 0.132 0.787 0.431 
Benzodiazepines -0.071 0.123 -0.572 0.567 
Index prescription (ref: quetiapine) 
Risperidone 0.030 0.000 1.452 0.147 
Olanzapine 0.034 0.000 1.683 0.093 
Typicals -0.095 0.000 -3.013 0.002 
Polytherapy (ref: Adherent) 0.128 0.045 2.833 0.005 
Inverse Mills Ratio 0.349 0.306 1.139 0.256 
 
Model fit statistics: 
 
Adjusted R-square =    28.8%, F = 5.57, p = 0.00 
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Table 13: Total and mental healthcare costs associated with the different 
antipsychotic utilization patterns among bipolar disorder patients 
 
 Continuous 
N = 166 
Interrupted 




N = 64 
Total Healthcare Cost 
 Mean (+std) 





































I Significant difference between continuous (c) and interrupted cohorts at p<0.05 
S Significant difference between continuous (c) and switch cohorts at p<0.05 
P Significant difference between continuous (c) and polytherapy cohorts at p<0.05
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Table 14a: Ordinary Least Squares (OLS) regression model for the impact pattern 
of antipsychotic use on total healthcare cost among bipolar disorder patients 
(second stage sample selection models): Interrupted vs. adherent therapy  
 
 Beta S.E t-statistic Significance (p) 
Age (in years) 0.006 0.004 1.575 0.115 
18 years or above (ref: less 
than 18 years) 0.398 0.140 1.135 0.344 
Males (ref: females) 0.512 0.000 0.015 0.988 
Whites (ref: non-whites) 0.253 0.121 2.090 0.037 
Metro (ref: non-metro) -0.134 0.104 -1.278 0.201 
Psychiatric prescriber  0.000 0.000 1.014 0.311 
Bipolar Subtype (ref: bipolar disorder I) 
Bipolar disorder II 0.130 0.111 1.165 0.244 
Mixed -0.084 0.127 -0.657 0.511 
Pre-index co-morbidities 
Charlson Comorbidity Index 0.213 0.032 6.744 0.000 
Alcohol and substance abuse 0.309 0.126 2.449 0.014 
Bipolar disorder  0.010 0.140 0.072 0.943 
Major depression 0.113 0.123 0.919 0.358 
Other mental comorbidities 0.056 0.096 0.584 0.559 
Pre-index mental-health 
related cost 0.137 0.024 5.778 0.000 
Pre-index mental-health 
related ER visits 0.042 0.099 0.428 0.669 
Pre-index mental-health 
related hospitalizations 0.158 0.122 1.294 0.196 
Pre-index mental-health 
related physician visits 0.007 0.006 1.289 0.197 
Year of index prescription (ref: 1999) 
• 2000 -0.001 0.126 -0.010 0.992 
• 2001 -0.481 0.129 -3.712 0.000 
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Table 14a: Ordinary Least Squares (OLS) regression model: Interrupted vs. 
adherent therapy (contd.) 
 
 Beta S.E t-statistic Significance (p) 
Pre-index period psychiatric medication use ( days of supply) 
Mood stabilizers 0.001 0.000 1.613 0.107 
Antipsychotics -0.002 0.002 -1.282 0.200 
Antidepressants 0.262 0.090 2.927 0.003 
Benzodiazepines 0.052 0.090 0.583 0.560 
Index prescription (ref: quetiapine)   
Risperidone -0.951 0.000 -0.919 0.358 
Olanzapine -0.997 0.000 -0.794 0.427 
Typicals 0.000 0.917 -1.687 0.092 
Interrupted (ref: Adherent) 0.016 0.451 2.126 0.034 
Inverse Mills Ratio -0.295 0.271 -1.088 0.276 
 
Model fit statistics: 
 
Adjusted R-square =   30.20%, F = 23.45, p = 0.000 
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Table 14b: Ordinary Least Squares (OLS) regression model for the impact pattern 
of antipsychotic use on total healthcare cost among bipolar disorder patients 
(second stage sample selection models): Switching vs. adherent therapy 
 
 Beta S.E t-statistic Significance (p) 
Demographic characteristics 
Age (in years) 0.011 0.005 2.251 0.025 
18 years or above (ref: less 
than 18 years) 0.568 0.130 1.135 0.524 
Males (ref: females) 0.000 0.001 -0.183 0.855 
Whites (ref: non-whites) 0.423 0.218 1.942 0.053 
Metro (ref: non-metro) -0.164 0.144 -1.141 0.255 
Prescribing physician type 
Psychiatric prescriber  -0.170 0.000 -0.012 0.990 
Bipolar Subtype (ref: bipolar disorder I) 
Bipolar disorder II -0.049 0.150 -0.324 0.746 
Mixed -0.167 0.158 -1.057 0.292 
Pre-index co-morbidities 
Charlson Comorbidity Index 0.125 0.041 3.070 0.002 
Alcohol and substance abuse 0.185 0.161 1.151 0.251 
Bipolar disorder  0.112 0.189 0.593 0.553 
Major depression -0.228 0.155 -1.475 0.141 
Other mental comorbidities 0.173 0.128 1.353 0.177 
Pre-index mental-health 
related cost 0.123 0.031 3.963 0.000 
Pre-index mental-health 
related ER visits -0.105 0.129 -0.811 0.418 
Pre-index mental-health 
related hospitalizations -0.178 0.156 -1.144 0.254 
Pre-index mental-health 
related physician visits 0.007 0.007 0.958 0.339 
Year of index prescription (ref: 1999) 
• 2000 0.197 0.160 1.237 0.217 
• 2001 -0.150 0.153 -0.978 0.329 
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Table 14b: Ordinary Least Squares (OLS) regression model: Switching vs. adherent 
therapy (contd.) 
 
 Beta S.E t-statistic Significance (p) 
Pre-index period psychiatric medication use ( days of supply) 
Mood stabilizers 0.001 0.000 2.477 0.014 
Antipsychotics -0.001 0.001 -0.819 0.414 
Antidepressants 0.097 0.118 0.821 0.412 
Benzodiazepines 0.016 0.116 0.140 0.889 
Index prescription (ref: quetiapine) 
Risperidone 0.631 0.000 0.532 0.596 
Olanzapine 0.830 0.000 0.629 0.530 
Typicals 0.030 0.000 2.451 0.015 
Switch (ref: Adherent) 0.163 0.373 2.517 0.030 
Inverse Mills Ratio -0.293 0.235 -1.245 0.214 
 
Model fit statistics: 
 




Table 14c: Ordinary Least Squares (OLS) regression model for the impact pattern 
of antipsychotic use on total healthcare cost among bipolar disorder patients 
(second stage sample selection models): Polytherapy vs. adherent therapy 
 
 Beta S.E t-statistic Significance (p) 
Demographic characteristics 
Age (in years) 0.011 0.006 1.905 0.058 
18 years or above (ref: less 
than 18 years) 0.244 0.135 1.156 0.444 
Males (ref: females) -0.001 0.001 -1.999 0.047 
Whites (ref: non-whites) 0.604 0.223 2.712 0.007 
Metro (ref: non-metro) 0.062 0.162 0.380 0.705 
Prescribing physician type 
Psychiatric prescriber  0.020 0.010 -1.193 0.234 
Bipolar Subtype (ref: bipolar disorder I) 
Bipolar disorder II 0.087 0.167 0.519 0.605 
Mixed -0.344 0.192 -1.798 0.074 
Pre-index co-morbidities 
Charlson Comorbidity Index 0.115 0.057 2.018 0.045 
Alcohol and substance abuse 0.376 0.166 2.263 0.025 
Bipolar disorder  0.154 0.190 0.810 0.419 
Major depression 0.066 0.172 0.383 0.702 
Other mental comorbidities 0.202 0.153 1.318 0.189 
Pre-index mental-health 
related cost 0.108 0.025 4.366 0.000 
Pre-index mental-health 
related ER visits -0.118 0.137 -0.859 0.391 
Pre-index mental-health 
related hospitalizations -0.056 0.213 -0.263 0.793 
Pre-index mental-health 
related physician visits 0.016 0.011 1.480 0.140 
Year of index prescription (ref: 1999) 
• 2000 0.027 0.180 0.152 0.879 
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Table 14c: Ordinary Least Squares (OLS) regression model: Polytherapy vs. 
adherent therapy (contd.) 
 
 Beta S.E t-statistic Significance (p) 
• 2001 -0.345 0.184 -1.876 0.062 
Pre-index period psychiatric medication use ( days of supply) 
Mood stabilizers 0.021 0.000 2.305 0.022 
Antipsychotics -0.001 0.001 -1.350 0.179 
Antidepressants 0.111 0.148 0.752 0.453 
Benzodiazepines -0.055 0.138 -0.399 0.690 
Index prescription (ref: quetiapine) 
Risperidone 0.002 0.020 1.402 0.162 
Olanzapine 0.002 0.001 1.057 0.292 
Typicals 0.036 0.010 2.452 0.021 
Polytherapy (ref: Adherent) 0.320 0.504 2.154 0.007 
Inverse Mills Ratio -0.298 0.309 -0.963 0.337 
 
Model fit statistics: 
 
Adjusted R-square =   25.7%, F = 4.02, p = 0.000 
145 
Table 15a: Ordinary Least Squares (OLS) regression model for the impact pattern 
of antipsychotic use on mental healthcare cost among bipolar disorder patients 
(second stage sample selection models): Interrupted vs. adherent therapy  
 
 Beta S.E t-statistic Significance (p) 
Demographic characteristics 
Age (in years) 0.002 0.004 0.418 0.676 
18 years or above (ref: less 
than 18 years) 0.543 0.342 1.360 0.561 
Males (ref: females) 0.002 0.001 3.898 0.000 
Whites (ref: non-whites) 0.163 0.139 1.174 0.241 
Metro (ref: non-metro) -0.073 0.115 -0.638 0.524 
Psychiatric prescriber  0.000 0.000 2.007 0.045 
Bipolar Subtype (ref: bipolar disorder I) 
Bipolar disorder II 0.047 0.124 0.378 0.706 
Mixed -0.408 0.136 -2.999 0.003 
Pre-index co-morbidities 
Charlson Comorbidity Index 0.066 0.047 1.391 0.164 
Alcohol and substance abuse 0.381 0.156 2.441 0.015 
Bipolar disorder  0.059 0.158 0.371 0.711 
Major depression 0.198 0.129 1.527 0.127 
Other mental comorbidities 0.016 0.107 0.153 0.879 
Pre-index mental-health 
related cost 0.030 0.015 1.965 0.050 
Pre-index mental-health 
related ER visits -0.020 0.141 -0.141 0.888 
Pre-index mental-health 
related hospitalizations 0.319 0.111 2.884 0.004 
Pre-index mental-health 
related physician visits 0.364 0.151 2.414 0.016 
Year of index prescription (ref: 1999) 
• 2000 -0.059 0.134 -0.438 0.661 
• 2001 -0.420 0.143 -2.947 0.003 
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Table 15a: Ordinary Least Squares (OLS) regression model: Interrupted vs. 
adherent therapy (contd.) 
 
 Beta S.E t-statistic Significance (p) 
Pre-index period psychiatric medication use ( days of supply) 
Mood stabilizers 0.051 0.000 2.217 0.027 
Antipsychotics 0.001 0.002 0.557 0.578 
Antidepressants 0.245 0.250 0.981 0.327 
Benzodiazepines 0.213 0.103 2.075 0.038 
Index prescription (ref: quetiapine) 
Risperidone 0.000 0.000 1.233 0.218 
Olanzapine 0.001 0.000 1.139 0.072 
Typicals 0.041 0.000 3.317 0.001 
Interrupted (ref: Adherent) 0.069 0.503 2.330 0.015 
Inverse Mills Ratio -0.103 0.305 -0.336 0.737 
 
Model fit statistics: 
 
Adjusted R-square =   28.18%, F = 10.43, p = 0.000 
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Table 15b: Ordinary Least Squares (OLS) regression model for the impact pattern 
of antipsychotic use on mental healthcare cost among bipolar disorder patients 
(second stage sample selection models): Switch vs. adherent therapy  
 
 Beta S.E t-statistic Significance (p) 
Demographic characteristics 
Age (in years) 0.012 0.005 2.514 0.013 
18 years or above (ref: less 
than 18 years) 0.348 0.341 1.432 0.356 
Males (ref: females) 0.001 0.000 1.674 0.095 
Whites (ref: non-whites) 0.435 0.249 1.750 0.081 
Metro (ref: non-metro) -0.039 0.142 -0.272 0.786 
Psychiatric prescriber  0.000 0.000 -1.058 0.291 
Bipolar Subtype (ref: bipolar disorder I) 
Bipolar disorder II 0.075 0.158 0.474 0.636 
Mixed -0.205 0.149 -1.375 0.170 
Pre-index co-morbidities 
Charlson Comorbidity Index -0.018 0.049 -0.358 0.720 
Alcohol and substance abuse 0.201 0.182 1.101 0.272 
Bipolar disorder  0.079 0.161 0.492 0.623 
Major depression -0.229 0.136 -1.684 0.093 
Other mental comorbidities 0.009 0.128 0.070 0.944 
Pre-index mental-health 
related cost 0.041 0.016 2.502 0.013 
Pre-index mental-health 
related ER visits -0.259 0.160 -1.617 0.107 
Pre-index mental-health 
related hospitalizations 0.068 0.127 0.535 0.593 
Pre-index mental-health 
related physician visits 0.519 0.070 7.457 0.000 
Year of index prescription (ref: 1999) 
• 2000 0.162 0.162 0.997 0.320 
• 2001 -0.209 0.130 -1.603 0.110 
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Table 15b: Ordinary Least Squares (OLS) regression model: Switch vs. adherent 
therapy (contd.) 
 
 Beta S.E t-statistic Significance (p) 
Pre-index period psychiatric medication use ( days of supply) 
Mood stabilizers 0.001 0.000 2.253 0.025 
Antipsychotics -0.002 0.002 -0.889 0.375 
Antidepressants 0.208 0.334 0.622 0.535 
Benzodiazepines -0.090 0.116 -0.769 0.443 
Index prescription (ref: quetiapine) 
Risperidone 0.040 0.000 1.172 0.242 
Olanzapine 0.021 0.000 1.344 0.180 
Typicals 0.040 0.000 2.753 0.006 
Switch (ref: Adherent) 0.517 0.402 1.286 0.200 
Inverse Mills Ratio -0.322 0.242 -1.332 0.184 
 
Model fit statistics: 
 




Table 15c: Ordinary Least Squares (OLS) regression model for the impact pattern 
of antipsychotic use on mental healthcare cost among bipolar disorder patients 
(second stage sample selection models): Polytherapy vs. adherent therapy  
 
 Beta S.E t-statistic Significance (p) 
Demographic characteristics 
Age (in years) 0.012 0.005 2.219 0.028 
18 years or above (ref: less 
than 18 years) 0.345 0.432 2.265 0.044 
Males (ref: females) 0.002 0.001 2.760 0.006 
Whites (ref: non-whites) 0.445 0.282 1.580 0.116 
Metro (ref: non-metro) 0.079 0.156 0.507 0.613 
Psychiatric prescriber  0.000 0.000 -1.667 0.097 
Bipolar Subtype (ref: bipolar disorder I) 
Bipolar disorder II 0.163 0.161 1.010 0.314 
Mixed -0.434 0.174 -2.497 0.013 
Pre-index co-morbidities 
Charlson Comorbidity Index 0.038 0.051 0.739 0.461 
Alcohol and substance abuse 0.432 0.186 2.316 0.022 
Bipolar disorder  0.290 0.173 1.669 0.097 
Major depression -0.023 0.170 -0.133 0.895 
Other mental comorbidities 0.137 0.157 0.872 0.384 
Pre-index mental-health 
related cost 0.044 0.016 2.686 0.008 
Pre-index mental-health 
related ER visits 0.110 0.166 0.661 0.510 
Pre-index mental-health 
related hospitalizations -0.073 0.138 -0.528 0.598 
Pre-index mental-health 
related physician visits 0.116 0.043 2.689 0.008 
Year of index prescription (ref: 1999) 
• 2000 0.108 0.184 0.586 0.558 
• 2001 -0.285 0.154 -1.848 0.066 
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Table 15c: Ordinary Least Squares (OLS) regression model: Polytherapy vs. 
adherent therapy (contd.) 
 
 Beta S.E t-statistic Significance (p) 
Pre-index period psychiatric medication use ( days of supply) 
Mood stabilizers 0.004 0.020 0.732 0.465 
Antipsychotics -0.002 0.001 -1.300 0.195 
Antidepressants 0.059 0.157 0.377 0.707 
Benzodiazepines -0.127 0.146 -0.871 0.385 
Index prescription (ref: quetiapine) 
Risperidone 0.031 0.023 1.688 0.093 
Olanzapine 0.050 0.017 2.029 0.084 
Typicals 0.032 0.000 2.293 0.023 
Polytherapy (ref: Adherent) 0.153 0.503 2.304 0.002 
Inverse Mills Ratio -0.168 0.298 -0.561 0.575 
 
Model fit statistics: 
 
Adjusted R-square =   26.91%, F = 4.22, p = 0.000 
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PHASE 2 - Results 
 Schizophrenia patients initiated on multiple antipsychotics (n = 37) were excluded 
from the analysis in the phase 2.  This resulted in sample size of 999 schizophrenia 
patients. Schizophrenia patients initiated on study antipsychotics were divided into the 
following study cohorts based on the first prescription of the index antipsychotic:  
 Patients initiated on olanzapine: 346 (34.63%) 
 Patients initiated on risperidone: 201 (20.12%) 
 Patients initiated on quetiapine: 149 (14.91%) 
 Patients initiated on typical antipsychotics: 303 (30.33%) 
 There were 7 bipolar disorder patients who were initiated on multiple 
antipsychotics. After excluding these patients, the resulting sample size of bipolar 
disorder patients was 825.  Bipolar disorder patients initiated on study antipsychotics 
were divided into the following study cohorts based on the first prescription of the index 
antipsychotic:  
 Patients initiated on olanzapine: 283 (34.30%) 
 Patients initiated on risperidone: 231 (28.00%) 
 Patients initiated on quetiapine: 106 (12.85%) 
 Patients initiated on typical antipsychotics: 205 (24.85%) 
Demographic characteristics of patients initiated on antipsychotics 
Schizophrenia  
 
 Table 16 provides information on demographic characteristics and co-morbidities 
among schizophrenia patients initiated on antipsychotics.  Wilcoxon rank sum test was 
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used to compare continuous variables like age and Charlson comorbidity index. Chi-
square analysis was used to compare the categorical variables.  
 Patients initiated on quetiapine did not differ significantly from patients initiated 
on other antipsychotics based on age, gender and race.  Significantly higher proportion of 
patients initiated on quetiapine (79.2%) were from non-metro areas compared to patients 
initiated on olanzapine (66.8%) and typical antipsychotics (67.7%).  In addition, 
significantly higher proportion of patients initiated on quetiapine (68.3%) had a 
psychiatric prescriber for the index prescription compared to patients initiated on 
olanzapine (55.7%), risperidone (55.3%), and typical antipsychotic (42.5%).   
 Significantly higher proportion of patients initiated on quetiapine showed ‘dual 
diagnosis’ (claims associated with both diagnosis in the 12-months pre-index period) of 
schizophrenia and schizoaffective disorder (57.7%) as compared to initiated olanzapine 
(39.6%), risperidone (37.3%) and typical antipsychotics (31.3%).  There were 
significantly a higher proportion of patients with alcohol and substance abuse in the 
quetiapine cohort (24.8%) as compared to the risperidone (14.9%) cohort.  There was 
significantly greater proportion of patients with mild to moderate depression among the 
quetiapine cohort (13.4%) as compared to the typical antipsychotic cohort (7.6%).   
Bipolar Disorder 
 
 Table 17 provides information on demographic characteristics and co-morbidities 
among schizophrenia patients initiated on antipsychotics.  Significantly greater 
proportions of patients initiated on quetiapine (90.6%) were 18 years or older compared 
to patients initiated on risperidone (63.2%).   Significantly higher proportion of patients 
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initiated on quetiapine (84.0%) were from non-metro areas compared to patients initiated 
on olanzapine (70.6%), risperidone (71.8%) and typical antipsychotics (73.6%).   
There were no significant differences between the patients initiated on quetiapine and 
other antipsychotics based on gender and race.  Significantly higher proportion of 
patients initiated on quetiapine (65.2%) had a psychiatric prescriber for index prescription 
as compared to patients initiated on typical antipsychotic (34.0%).   
  A significantly higher proportion of patients initiated on quetiapine showed a 
mixed diagnosis (68.9%) as compared to patients initiated olanzapine (48.1%), 
risperidone (32.5%) or typical antipsychotics (46.3%).  There was significantly a higher 
proportion of patients with alcohol and substance abuse in the quetiapine cohort (21.6%) 
as compared to the risperidone (15.2%) cohort.  There was significantly a lesser 
proportion of patients with major depression in the quetiapine cohort (13.3%) as 
compared to the olanzapine (35.8%), risperidone (29.4%) or typical antipsychotics 
(21.3%) cohorts.  Also, there were significantly lesser proportion of patients with mild to 
moderate depression, anxiety and personality disorder in the quetiapine cohort as 




Table 16: Demographic characteristics of schizophrenia patients (18 years and 
older) who were initiated on study antipsychotics between January 1, 1999 and 
December 31, 2001 (N = 999) 
 
 Olanzapine 
N = 346 
Risperidone 
N = 201 
Quetiapine 
N = 149 
Typical 
N = 303 
Demographics 
Age in years  
(Mean/+SD)     
40.0 (+11.8) 38.8 (+14.2) 41.0 (+11.5) 43.9(+11.0) 
Gender 





































































Year of Index Prescription  

































Table 16: Demographic characteristics of schizophrenia patients (18 years and 
older) who were initiated on study antipsychotics between January 1, 1999 and 
December 31, 2001 (N = 999) 
 
 Olanzapine 
N = 346 
Risperidone 
N = 201 
Quetiapine 
N = 149 
Typical 

















































































































































Table 16: Demographic characteristics of schizophrenia patients (18 years and 
older) who were initiated on study antipsychotics between January 1, 1999 and 
December 31, 2001 (N = 999) 
 
 Olanzapine 
N = 346 
Risperidone 
N = 201 
Quetiapine 
N = 149 
Typical 













O Significant difference between quetiapine and olanzapine cohorts at p<0.05 
R Significant difference between quetiapine and risperidone cohorts at p<0.05 






Table 17: Demographic characteristics of bipolar disorder patients who were 
initiated on study antipsychotics between January 1, 1999 and December 31, 2001 
(N = 825) 
 
 Olanzapine 
N = 283 
Risperidone 
N = 231 
Quetiapine 
N = 106 
Typical 
N = 205 
Age category 






























Age in years  





















264 (93.3%) 210 (90.9%) 97 (91.5%) 181 (88.4%) 
Others 
 
19 (6.7%) 21 (9.0%) 9 (8.5%) 24 (11.7%) 
Residence 

















Psychiatric  135 
















Table 17: Demographic characteristics of bipolar disorder patients who were 
initiated on study antipsychotics between January 1, 1999 and December 31, 2001 
(N = 825) (contd.) 
 
 Olanzapine 
N = 283 
Risperidone 
N = 231 
Quetiapine 
N = 106 
Typical 
N = 205 
Year of Index Prescription  
























Bipolar Disorder Subtype 










































































































Table 17: Demographic characteristics of bipolar disorder patients who were 
initiated on study antipsychotics between January 1, 1999 and December 31, 2001 
(N = 825) (contd.) 
 
 Olanzapine 
N = 283 
Risperidone 
N = 231 
Quetiapine 
N = 106 
Typical 














































O Significant difference between quetiapine and olanzapine cohorts at p<0.05 
R Significant difference between quetiapine and risperidone cohorts at p<0.05 
T Significant difference between quetiapine and typicals cohorts at p<0.05 
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Results for research objective 8 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine 




 Results for univariate analysis comparing differences in total and mental costs 
between each of the index antipsychotics are reported in table 18.  There were no 
significant differences in total healthcare costs of quetiapine cohort compared to other 
index antipsychotic cohorts.  Total post-index mental health-related costs for quetiapine 
($15,318 + $20,343) were significantly lesser compared to olanzapine ($17,919 + 
$25,660) and typical cohorts ($18,342 + $26,730).  
  It is possible that various factors such as patient demographics, comorbidities, 
disease severity, or sample selection bias could have confounded the results of univariate 
analysis. Therefore, a multivariate analysis controlling for various confounders was 
conducted to determine the impact of index antipsychotic use on total healthcare costs.   
 The first step involved developing a multinomial logistic regression model 
predicting treatment selection.  This model allowed for calculation of Inverse Mills Ratio 
(IMR) to adjust for sample selection bias in the second step regression models. Individual 
contrasts were carried out to obtain IMR for quetiapine vs. olanzapine, quetiapine vs. 
risperidone, and quetiapine vs. typicals.  The results of this multinomial logistic 
regression model are presented in table 19.  
 In the second step of the analysis, three semi-log OLS regressions were developed 
to compare costs associated with olanzapine, risperidone and typical with quetiapine 
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therapy.  IMRs calculated from the first stage regression models were added as a 
covariate in the second stage regression models to adjust and test for sample selection 
bias.  The second stage regression models are presented in tables 20a to 21c. Variables 
were dropped from the model if data was sparse for a variable. Certain variables such as 
pre-index ECT, pre-index clozapine use, pre-index suicides, and pre-index arrhythmia 
were dropped due to sparse data.  Variables were also dropped from the model if they 
were highly collinear with other variables.  Variance inflation factors were less than 3. 
Wherever needed, White’s correction for heteroskedasity was used.  
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Table 18: Healthcare costs comparison among schizophrenia patients: (Quetiapine 
versus other antipsychotics)  
 Olanzapine 
N = 346 
Risperidone 
N = 201 
Quetiapine 
N = 149 
Typical 
N = 303 





















Mental health-related Costs 






































$5,418  Q 
(+$15,787) 
Outpatient 









































Table 18: Healthcare costs comparison among schizophrenia patients: (Quetiapine 
versus other antipsychotics) (contd.) 
 
 Olanzapine 
N = 346 
Risperidone 
N = 201 
Quetiapine 
N = 149 
Typical 





















O Significant difference between quetiapine and olanzapine cohorts at p<0.05 
R Significant difference between quetiapine and risperidone cohorts at p<0.05 
T Significant difference between quetiapine and typicals cohorts at p<0.05 
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Table 19: Multinomial logistic regression model determining predictors of index 
antipsychotic use among schizophrenia patients (first-stage sample selection model) 
 






 Coefficient t-ratio Coefficient t-ratio Coefficient t-ratio 
Demographic characteristics 
Age (in years) 0.004 0.418 -0.004 -0.324 0.033 3.161* 
Males (ref: females) 0.088 0.581 0.002 1.204 0.001 0.877 
Whites (ref: non-
whites) 0.230 0.592 -0.069 -0.168 -0.413 -1.069 
Metro (ref: non-
metro) 0.211 0.710 -0.435 -1.335 -0.044 -0.141 
Prescribing physician type 
Psychiatric prescriber  -0.001* -3.805* -0.001 -3.908* -0.001 -3.95* 
Schizophrenia subtype  (ref: only schizophrenia) 
Schizoaffective 
disorder -0.402 -1.303 -0.248 -0.746 -0.860 -2.619* 
Both schizoaffective 
disorder and 
schizophrenia -0.709 -2.289* -1.105 -3.284* -1.152 -3.532* 
Pre-index co-morbidities 
Diabetes 0.123 0.321 0.418 1.001 0.627 1.604 
Hyperlipidemia -0.395 -1.021 -0.906 -1.879 -0.105 -0.256 
Hypertension -0.242 -0.837 0.078 0.240 -0.133 -0.420 
Alcohol and substance 
abuse -0.402 -1.571 -0.868 -2.859* -0.068 -0.250 
Bipolar disorder  -0.277 -0.942 -0.347 -1.033 -0.054 -0.166 
Major depression 0.307 1.097 -0.064 -0.199 0.012 0.037 
Anxiety disorder -0.081 -0.287 -0.525 -1.560 -0.090 -0.286 
Personality disorder 0.024 0.070 -0.257 -0.670 -0.331 -0.887 
Non-specified 
psychosis 0.931 1.384 0.925 1.227 0.312 0.418 
Other affective 
psychosis -0.477 -0.685 -0.122 -0.161 -0.866 -0.936 
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Table 19: Multinomial logistic regression model determining predictors of index 
antipsychotic use among schizophrenia patients (first-stage sample selection model) 
 






 Coefficient t-ratio Coefficient t-ratio Coefficient t-ratio 
Attention deficit 
disorders -0.041 -0.055 1.082 1.504 0.653 0.803 
Mild to moderate 
depression 0.110 0.336 0.415 1.142 -0.217 -0.575 
Pre-index healthcare utilization and cost 
Number of pre-index 
mental-health related 
ER visits 0.000 1.196 0.000 1.111 0.184 0.045 
Number of pre-index 
mental-health related 
hospitalizations 0.064 0.574 -0.025 -0.199 -0.176 -1.287 
Number of 
psychotherapy visits 0.014 0.651 -0.019 -0.558 -0.001 -0.050 
Number of medication 
management visits -0.064 -2.024* -0.047 -1.285 -0.095 -2.509* 
Year of index prescription (ref: 1999) 
• 2000 -0.102 -0.371 0.364 1.169 -0.524 -1.760 
• 2001 -0.312 -1.051 0.054 0.158 -1.130 -3.326* 
Pre-index period psychiatric medication use ( days of supply) 
Mood stabilizers 0.001 0.710 0.000 0.125 -0.002 -1.991 
Anticholinergics -0.005 -1.131 -0.021 -1.547 -0.010 -1.214 
Anxiolytics/hypnotics/ 
sedatives 0.001 0.755 0.002 1.015 0.001 0.802 
Antipsychotics -0.001 -0.101 0.018 3.077* 0.0164* 2.937* 
Antidepressants 0.000 0.268 0.000 -0.542 -0.001 -1.086 
Benzodiazepines -0.002 -2.829* -0.002 -1.860 -0.002 -2.046* 
Antiparkinsons -0.002 -0.756 -0.006 -1.466 0.001 0.243 
*significant at p<0.05 
Model fit statistics: 
Pseudo R-square = 12.43% 
-2 Log Likelihood = 1128.21; χ2  = 331.90; p= 0.00 
(contd.) 
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Table 20a: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on total healthcare cost among schizophrenia patients (second stage 
sample selection models): Olanzapine vs.  quetiapine 
 Beta S.E t-statistic Significance (p) 
Demographic characteristics 
Age (in years) 0.005 0.004 1.386 0.166 
Males (ref: females) -0.979 0.001 -0.130 0.896 
Whites (ref: non-whites) 0.089 0.161 0.552 0.582 
Metro (ref: non-metro) 0.005 0.114 0.044 0.965 
Prescribing physician type 
Psychiatric prescriber  0.000 0.000 2.702 0.007 
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective disorder -0.064 0.120 -0.536 0.592 
Both schizoaffective disorder 
and schizophrenia -0.112 0.137 -0.817 0.414 
Pre-index co-morbidities 
Charlson Comorbidity Index 0.150 0.045 3.341 0.001 
Alcohol and substance abuse 0.257 0.103 2.492 0.013 
Bipolar disorder  0.206 0.135 1.527 0.128 
Major depression -0.016 0.108 -0.144 0.886 
Other mental comorbidities -0.020 0.100 -0.201 0.841 
Pre-index healthcare utilization and cost  
Pre-index total health related 
cost 0.174 0.032 5.413 0.000 
Pre-index total health related 
ER visits -0.121 0.128 -0.941 0.347 
Pre-index total health related 
hospitalizations 0.006 0.108 0.051 0.960 
Pre-index total health related 
physician visits 0.005 0.006 0.786 0.432 
Year of index prescription (ref: 1999) 
• 2000 -0.093 0.117 -0.795 0.427 
• 2001 -0.278 0.137 -2.034 0.043 
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Model fit statistics: 
 
Adjusted R-square =     22.14% , F =  6.85 , p = 0.00 
Table 20a: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on total healthcare cost among schizophrenia patients (second stage 
sample selection models): Olanzapine vs.  quetiapine (contd.) 
 Beta S.E t-statistic Significance (p) 
Antipsychotics 0.003 0.002 1.739 0.083 
Antidepressants 0.000 0.000 1.001 0.317 
Benzodiazepines 0.179 0.104 1.717 0.087 
Index prescription (ref: quetiapine) 
Olanzapine  0.499 0.442 1.129 0.259 
Inverse Mills Ratio -0.211 0.267 -0.787 0.432 
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Table 20b: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on total healthcare cost among schizophrenia patients (second stage 
sample selection models): Risperidone vs.  quetiapine 
 Beta S.E t-statistic Significance (p) 
Demographic characteristics 
Age (in years) 0.012 0.005 2.403 0.017
Males (ref: females) 0.000 0.001 0.363 0.717
Whites (ref: non-whites) 0.360 0.192 1.878 0.061
Metro (ref: non-metro) -0.119 0.148 -0.805 0.422
Prescribing physician type  
Psychiatric prescriber  0.000 0.000 1.184 0.238
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective disorder 0.077 0.153 0.505 0.614
Both schizoaffective disorder 
and schizophrenia -0.242 0.182 -1.332 0.184
Pre-index co-morbidities  
Charlson Comorbidity Index 0.162 0.050 3.219 0.001
Alcohol and substance abuse 0.346 0.160 2.170 0.031
Bipolar disorder  0.229 0.171 1.336 0.183
Major depression -0.009 0.150 -0.057 0.954
Other mental comorbidities -0.100 0.131 -0.764 0.446
Pre-index healthcare utilization and cost  
Pre-index total health related 
cost 0.091 0.021 4.295 0.000
Pre-index total health related 
ER visits 0.211 0.166 1.272 0.204
Pre-index total health related 
hospitalizations -0.012 0.130 -0.092 0.927
Pre-index total health related 
physician visits 0.004 0.009 0.422 0.673
Year of index prescription (ref: 1999) 
• 2000 -0.199 0.153 -1.295 0.196
• 2001 -0.506 0.177 -2.859 0.005
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Model fit statistics: 
 
Adjusted R-square =    27.5%  , F =  6.52, p = 0.00 
Table 20b: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on total healthcare cost among schizophrenia patients (second stage 
sample selection models): Risperidone vs.  quetiapine (contd.) 
 Beta S.E t-statistic Significance 
(p) 
Pre-index period psychiatric medication use ( days of supply) 
Mood stabilizers 0.001 0.000 2.834 0.005
Antipsychotics -0.001 0.002 -0.666 0.506
Antidepressants 0.001 0.000 2.197 0.029
Benzodiazepines 0.100 0.133 0.752 0.453
Index prescription (ref: quetiapine) 
Risperidone 0.207 0.394 0.526 0.599
Inverse Mills Ratio -0.040 0.246 -0.161 0.873
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Table 20c: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on total healthcare cost among schizophrenia patients (second stage 
sample selection models): Typicals vs.  quetiapine 
 Beta S.E t-statistic Significance (p) 
Demographic characteristics 
Age (in years) 0.004 0.005 0.700 0.485
Males (ref: females) 0.000 0.001 0.440 0.661
Whites (ref: non-whites) 0.166 0.163 1.021 0.308
Metro (ref: non-metro) -0.228 0.140 -1.626 0.105
Prescribing physician type  
Psychiatric prescriber  0.000 0.000 1.428 0.154
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective disorder 0.152 0.164 0.929 0.354
Both schizoaffective disorder 
and schizophrenia -0.076 0.177 -0.426 0.670
Pre-index co-morbidities  
Charlson Comorbidity Index 0.208 0.045 4.631 0.000
Alcohol and substance abuse 0.255 0.133 1.913 0.057
Bipolar disorder  -0.107 0.184 -0.580 0.562
Major depression 0.071 0.154 0.463 0.644
Other mental comorbidities 0.188 0.133 1.416 0.157
Pre-index healthcare utilization and cost  
Pre-index total health related 
cost 0.238 0.053 4.478 0.000
Pre-index total health related 
ER visits 0.291 0.184 1.581 0.115
Pre-index total health related 
hospitalizations 0.146 0.153 0.957 0.339
Pre-index total health related 
physician visits 0.000 0.009 0.030 0.976
Year of index prescription (ref: 1999) 
• 2000 -0.064 0.173 -0.369 0.712
• 2001 -0.311 0.227 -1.370 0.172
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Model fit statistics: 
 
Adjusted R-square =    27.92%, F =   8.28, p = 0.00 
Table 20c: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on total healthcare cost among schizophrenia patients (second stage 
sample selection models): Typicals vs.  quetiapine 
 Beta S.E t-statistic Significance (p) 
Mood stabilizers 0.021 0.000 2.153 0.032
Antipsychotics -0.011 0.001 -0.441 0.659
Antidepressants 0.000 0.000 0.853 0.394
Benzodiazepines 0.171 0.135 1.268 0.205
Index prescription (ref: quetiapine) 
Typical -0.355 0.000 -0.077 0.939




Table 21a: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare cost among schizophrenia patients (second stage 
sample selection models): Olanzapine vs.  quetiapine 
 Beta S.E t-statistic Significance (p) 
Demographic characteristics 
Age (in years) 0.004 0.004 1.035 0.301
Males (ref: females) 0.001 0.001 1.235 0.218
Whites (ref: non-whites) 0.173 0.175 0.991 0.322
Metro (ref: non-metro) -0.092 0.124 -0.739 0.460
Prescribing physician type  
Psychiatric prescriber  0.000 0.000 2.592 0.010
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective disorder -0.101 0.130 -0.773 0.440
Both schizoaffective disorder 
and schizophrenia -0.337 0.150 -2.251 0.025
Pre-index co-morbidities  
Charlson Comorbidity Index 0.108 0.047 2.301 0.022
Alcohol and substance abuse 0.365 0.112 3.256 0.001
Bipolar disorder  0.095 0.147 0.647 0.518
Major depression 0.041 0.117 0.345 0.730
Other mental comorbidities 0.053 0.109 0.488 0.626
Pre-index healthcare utilization and cost  
Pre-index mental-health 
related cost 0.071 0.016 4.533 0.000
Pre-index mental-health 
related ER visits -0.212 0.135 -1.568 0.118
Pre-index mental-health 
related hospitalizations 0.202 0.112 1.798 0.073
Pre-index mental-health 
related physician visits -0.024 0.027 -0.894 0.372
Year of index prescription (ref: 1999) 
• 2000 -0.035 0.127 -0.272 0.786





Model fit statistics: 
 
Adjusted R-square =     19.97%, F = 6.14, p = 0.00 
 
Table 21a: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare cost among schizophrenia patients (second stage 
sample selection models): Olanzapine vs.  quetiapine (contd.) 
 Beta S.E t-statistic Significance (p) 
Pre-index period psychiatric medication use ( days of supply) 
Mood stabilizers 0.001 0.000 1.472 0.142
Antipsychotics 0.004 0.002 1.870 0.062
Antidepressants 0.000 0.000 1.207 0.228
Benzodiazepines 0.126 0.114 1.104 0.270
Index prescription (ref: quetiapine) 
Olanzapine 0.482 0.478 1.008 0.314
Inverse Mills Ratio -0.169 0.290 -0.583 0.560
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Table 21b: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare cost among schizophrenia patients (second stage 
sample selection models): Risperidone vs.  quetiapine 
 Beta S.E t-statistic Significance (p) 
Demographic characteristics 
Age (in years) 0.011 0.005 1.966 0.050
Males (ref: females) 0.001 0.001 0.986 0.325
Whites (ref: non-whites) 0.304 0.218 1.393 0.165
Metro (ref: non-metro) -0.150 0.167 -0.901 0.368
Prescribing physician type  
Psychiatric prescriber  0.000 0.000 1.645 0.101
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective disorder -0.059 0.174 -0.340 0.734
Both schizoaffective disorder 
and schizophrenia -0.465 0.206 -2.255 0.025
Pre-index co-morbidities  
Charlson Comorbidity Index 0.035 0.055 0.640 0.523
Alcohol and substance abuse 0.547 0.181 3.029 0.003
Bipolar disorder  0.228 0.194 1.173 0.242
Major depression 0.056 0.170 0.331 0.741
Other mental comorbidities -0.013 0.150 -0.088 0.930
Pre-index healthcare utilization and cost  
Pre-index mental-health 
related cost 0.045 0.017 2.611 0.010
Pre-index mental-health 
related ER visits 0.171 0.178 0.959 0.338
Pre-index mental-health 
related hospitalizations 0.017 0.150 0.112 0.911
Pre-index mental-health 
related physician visits -0.009 0.040 -0.224 0.823
Year of index prescription (ref: 1999) 
• 2000 -0.244 0.173 -1.411 0.159
• 2001 -0.436 0.197 -2.216 0.027
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Model fit statistics: 
 
Adjusted R-square =    18.19, F =   4.24, p = 0.00 
Table 21b: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare cost among schizophrenia patients (second stage 
sample selection models): Risperidone vs.  quetiapine  (contd.) 
 Beta S.E t-statistic Significance 
(p) 
Pre-index period psychiatric medication use ( days of supply) 
Mood stabilizers 0.011 0.000 2.204 0.028
Antipsychotics 0.001 0.002 0.297 0.767
Antidepressants 0.031 0.000 2.804 0.005
Benzodiazepines -0.090 0.149 -0.605 0.546
Index prescription (ref: quetiapine) 
Risperidone 0.084 0.448 0.187 0.852
Inverse Mills Ratio -0.031 0.280 -0.112 0.911
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Table 21c: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare cost among schizophrenia patients (second stage 
sample selection models): Typicals vs.  quetiapine  
 Beta S.E t-statistic Significance (p) 
Demographic characteristics 
Age (in years) -0.004 0.007 -0.644 0.520
Males (ref: females) 0.002 0.001 2.461 0.014
Whites (ref: non-whites) 0.199 0.205 0.974 0.331
Metro (ref: non-metro) -0.299 0.176 -1.695 0.091
Prescribing physician type  
Psychiatric prescriber  0.000 0.000 1.451 0.148
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective disorder 0.019 0.208 0.093 0.926
Both schizoaffective disorder 
and schizophrenia -0.955 0.228 -4.182 0.000
Pre-index co-morbidities  
Charlson Comorbidity Index 0.033 0.052 0.642 0.521
Alcohol and substance abuse 0.547 0.168 3.264 0.001
Bipolar disorder  -0.004 0.232 -0.017 0.986
Major depression 0.205 0.194 1.054 0.293
Other mental comorbidities 0.142 0.168 0.848 0.397
Pre-index healthcare utilization and cost  
Pre-index mental-health 
related cost 0.012 0.022 0.561 0.575
Pre-index mental-health 
related ER visits 0.027 0.221 0.122 0.903
Pre-index mental-health 
related hospitalizations 0.434 0.174 2.495 0.013
Pre-index mental-health 
related physician visits -0.017 0.051 -0.332 0.740
Year of index prescription (ref: 1999) 
• 2000 -0.016 0.218 -0.074 0.941




Model fit statistics: 
 
Adjusted R-square =    20.0%, F =   5.71, p = 0.00 
Table 21c: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare cost among schizophrenia patients (second stage 
sample selection models): Typicals vs.  quetiapine  
 Beta S.E t-statistic Significance 
(p) 
Pre-index period psychiatric medication use ( days of supply) 
Mood stabilizers 0.045 0.001 1.789 0.074
Antipsychotics 0.002 0.002 1.125 0.261
Antidepressants 0.021 0.000 2.866 0.004
Benzodiazepines 0.127 0.169 0.754 0.452
Index prescription (ref: quetiapine) 
Typical 0.001 0.001 1.450 0.148




 Results for the OLS regression models for the impact of index antipsychotics on 
total and mental healthcare costs are presented in the tables 20a-20c for total and tables 
21a-21c for mental healthcare costs, respectively.  The results showed that there were no 
significant differences in total and mental healthcare-related costs between quetiapine and 
other index antipsychotics.  The model was further tested for appropriate specifications.  
It was possible that multicollinarity resulting due to inclusion of IMR in the model may 
be inflating the standard errors.  Therefore, a semi-log OLS model was developed 
without including the IMR and the output was compared with the outputs of regression 
models that included IMR. As the direction and significance of variables in all these 
outputs were similar, it was concluded that there were no significant differences in the 
total and mental healthcare costs between these cohorts.  
Bipolar disorder 
 
 Results for univariate analysis comparing differences in total and mental costs for 
bipolar disorder patients are reported in table 22.  Total post-index costs for quetiapine 
($13,227 + $18,862) were significantly lesser compared to risperidone ($17,539 + 
$17,570) and typical antipsychotics ($17,570 + $23,842).  Total post-index mental 
health-related costs for quetiapine ($8,064 + $7,368) were significantly lesser than for 
olanzapine ($10,203 + $17,203).   
 The results of the first-stage multinomial logistic regression model are presented 
in table 23. Results of multivariate analysis show that there were no significant 
differences in total healthcare costs of the quetiapine cohort as compared to other index 
atypical antipsychotic cohorts.  However, typical antipsychotics had 28.4% greater total 
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cost and 8.7% greater mental health-related costs than quetiapine.  Results for the OLS 
regression models for the impact of index antipsychotics on total and mental healthcare 
costs are presented in tables 24a-24c for total and table 25a-25c for mental health-related 
costs, respectively.  
Results for research objective 9 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine 
with risperidone, olanzapine, and typical antipsychotics on components of mental 
healthcare costs (costs associated with mental health-related inpatient, emergency room, 
outpatient and pharmacy services)  
Schizophrenia  
 Univariate analysis for mental health-related inpatient, outpatient, ER, and 
pharmacy costs are reported in table18.  The results indicated that the post-index inpatient 
costs were significantly higher for typical antipsychotics ($5,418 + $15,787) compared to 
quetiapine ($4,865+ $11,285).  The post-index outpatient costs were also significantly 
higher for risperidone ($4,247 + $10,209) and olanzapine ($4,136 + $16,349) as 
compared to quetiapine ($2,071 + $3,479).  The post-index ER costs were significantly 
lower for risperidone ($152 + $415) as compared to quetiapine ($231 + $531).  
Compared to quetiapine ($2470 + 1789), the post-index prescription costs were 
significantly higher for olanzapine ($3,072 + 2,285) and significantly lower for typical 
antipsychotics ($1,421 + $1,898).  
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Table 22: Healthcare costs comparison among bipolar disorder patients: 





N = 283 
Risperidone 
N = 201 
Quetiapine 
N = 106 
Typical 
N = 205 
Total Healthcare Costs 
Total  
Mean (+std) 
















Mental health-related Costs 
















































































O Significant difference between quetiapine and olanzapine cohorts at p<0.05 
R Significant difference between quetiapine and risperidone cohorts at p<0.05 
T Significant difference between quetiapine and typicals cohorts at p<0.05 
Prescription  
Mean (+std) 
Table 22: Healthcare costs comparison among bipolar disorder patients: (Quetiapine 
versus other antipsychotics) (contd.) 
 Olanzapine 
N = 283 
Risperidone 
N = 201 
Quetiapine 
N = 106 
Typical 





















Table 23: Multinomial logistic regression model determining predictors of index 
antipsychotic use among bipolar disorder patients (first-stage sample selection 
model) 






 Coefficient t-ratio Coefficient t-ratio Coefficient t-ratio 
Demographic characteristics 
Age (in years) -0.001 -0.074 0.001 0.101 0.029 2.329 
Age category -0.687 -1.688 -0.979 -2.355 -1.352 -3.211 
Males (ref: females) 0.070 0.419 0.002 1.002 0.001 0.431 
Whites (ref: non-
whites) 0.435 0.964 0.051 0.113 -0.167 -0.360 
Metro (ref: non-
metro) 0.304 0.774 -0.236 -0.594 0.148 0.351 
Prescribing physician type  
Psychiatric prescriber  -0.012 -3.223* -0.011 -3.408* -0.011 -3.372* 
Bipolar disorder subtype (ref: only bipolar disorder) 
Bipolar Disorder II -0.976 -2.331* -0.851 -2.032* -1.457 -3.212* 
Bipolar Disorder 
Mixed -1.150 -2.788* -2.132 -5.038* -1.426 -3.265* 
Pre-index co-morbidities  
Diabetes 0.509 1.082 0.706 1.455 0.974 1.993* 
Hyperlipidemia -0.316 -0.639 -0.193 -0.373 0.318 0.621 
Hypertension -0.266 -0.792 0.181 0.510 0.102 0.276 
Alcohol and substance 
abuse -0.435 -1.454 -0.870 -2.634* -0.198 -0.596 
Bipolar disorder  0.112 0.307 -0.207 -0.527 -0.050 -0.119 
Major depression 0.241 0.742 -0.110 -0.313 -0.186 -0.485 
Anxiety disorder 0.026 0.073 -0.203 -0.532 -0.149 -0.369 
Personality disorder -0.042 -0.104 -0.081 -0.190 -0.300 -0.656 
Non-specified 
psychosis 0.661 0.810 0.840 0.985 0.477 0.531 
Other affective 
psychosis -0.356 -0.436 0.313 0.379 -28.865 0.000 
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Table 23: Multinomial logistic regression model determining predictors of index 
antipsychotic use among bipolar disorder patients (first-stage sample selection 
model) 






 Coefficient t-ratio Coefficient t-ratio Coefficient t-ratio 
Attention deficit 
disorders -0.43 8 -0.554 1.196 1.624 0.727 0.862 
Mild to moderate 
depression 0.091 0.236 0.311 0.765 -0.382 -0.814 
Pre-index healthcare utilization and cost  
Number of pre-index 
mental-health related 
ER visits 0.000 0.936 0.000 0.327 0.000 -0.631 
Number of pre-index 
mental-health related 
hospitalizations 0.003 0.023 -0.069 -0.543 -0.254 -1.593 
Number of 
psychotherapy visits 0.002 0.070 -0.037 -1.015 0.012 0.408 
Number of medication 
management visits -0.087 -2.383* -0.058 -1.464 -0.158 -3.350* 
Year of index prescription (ref: 1999) 
• 2000 -0.119 -0.363 0.220 0.633 -0.396 -1.109 
• 2001 -0.292 -0.844 -0.120 -0.320 -1.256 -3.032* 
Pre-index period psychiatric medication use ( days of supply) 
Mood stabilizers 0.001 0.652 0.000 -0.129 -0.002 -1.948 
Anticholinergics -0.006 -1.291 -0.020 -1.560 -0.007 -0.971 
Anxiolytics/hypnotics/ 
sedatives 0.897 0.052 0.000 -0.058 0.001 0.354 
Antipsychotics -0.004 -0.707 0.011 2.005* 0.012 2.119* 
Antidepressants 0.001 0.866 0.000 0.197 -0.316 -0.035 
Benzodiazepines -0.012 -2.178* -0.002 -1.816 -0.001 -1.341 
Antiparkinsons -0.002 -0.587 -0.006 -1.406 -0.001 -0.389 
*significant at p<0.05 level 
Model fit statistics: 




Table 24a: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on total healthcare cost among bipolar disorder patients (second stage 
sample selection models): Olanzapine vs.  quetiapine 
 Beta S.E t-statistic Significance (p) 
Demographic characteristics 
Age (in years) 0.006 0.004 1.432 0.153 
Agecat  0.063 0.144 0.438 0.662 
Males (ref: females) 0.502 0.001 0.049 0.961 
Whites (ref: non-whites) 0.199 0.176 1.129 0.260 
Metro (ref: non-metro) -0.028 0.127 -0.217 0.828 
Prescribing physician type  
Psychiatric prescriber  0.012 0.000 1.972 0.049 
Bipolar disorder subtype (ref: bipolar disorder I) 
Bipolar disorder II disorder -0.163 0.141 -1.154 0.249 
Mixed  -0.189 0.174 -1.085 0.279 
Pre-index co-morbidities  
Charlson Comorbidity Index 0.135 0.049 2.758 0.006 
Alcohol and substance abuse 0.226 0.115 1.959 0.051 
Bipolar disorder  0.100 0.147 0.681 0.496 
Major depression 0.011 0.117 0.096 0.923 
Other mental comorbidities 0.049 0.109 0.454 0.650 
Pre-index healthcare utilization and cost  
Pre-index total health related 
cost 0.229 0.042 5.422 0.000 
Pre-index  total health related 
ER visits -0.254 0.138 -1.842 0.066 
Pre-index  total health related 
hospitalizations -0.097 0.120 -0.806 0.421 
Pre-index  total health related 
physician visits 0.008 0.006 1.266 0.206 
Year of index prescription (ref: 1999) 
• 2000 -0.006 0.124 -0.044 0.965 




Model fit statistics: 
 
Adjusted R-square =    22.22%  , F =  5.77 , p = 0.000 
 
Table 24a: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on total healthcare cost among bipolar disorder patients (second stage 
sample selection models): Olanzapine vs.  quetiapine 
 Beta S.E t-statistic Significance (p) 
Pre-index period psychiatric medication use ( days of supply) 
Mood stabilizers 0.041 0.000 2.317 0.021 
Antipsychotics 0.003 0.002 1.581 0.115 
Antidepressants 0.000 0.000 0.654 0.513 
Benzodiazepines 0.050 0.114 0.437 0.663 
Index prescription (ref: quetiapine) 
Olanzapine 0.261 0.495 0.527 0.059 
Inverse Mills Ratio -0.058 0.295 -0.197 0.844 
(contd.) 
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Table 24b: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on total healthcare cost among bipolar disorder patients (second stage 
sample selection models): Risperidone vs.  quetiapine  
 Beta S.E t-statistic Significance (p) 
Demographic characteristics 
Age (in years) 0.012 0.005 2.382 0.018 
agecat 0.115 0.173 0.661 0.509 
Males (ref: females) 0.000 0.001 0.368 0.714 
Whites (ref: non-whites) 0.481 0.206 2.34 0.020 
Metro (ref: non-metro) -0.266 0.160 -1.657 0.099 
Prescribing physician type 
Psychiatric prescriber  0.506 0.000 0.293 0.770 
Bipolar disorder subtype (ref:  Bipolar disorder I) 
Bipolar disorder II  -0.001 0.174 -0.005 0.996 
Mixed  -0.509 0.234 -2.174 0.031 
Pre-index co-morbidities 
Charlson Comorbidity Index 0.178 0.055 3.266 0.001 
Alcohol and substance abuse 0.235 0.184 1.277 0.203 
Bipolar disorder  0.194 0.193 1.006 0.315 
Major depression 0.019 0.165 0.114 0.909 
Other mental comorbidities -0.019 0.141 -0.135 0.892 
Pre-index healthcare utilization and cost 
Pre-index  total health related 
cost 0.089 0.022 4.007 0.000 
Pre-index  total health related 
ER visits 0.230 0.182 1.265 0.207 
Pre-index  total health related 
hospitalizations -0.134 0.141 -0.95 0.343 
Pre-index  total health related 
physician visits 0.010 0.010 0.993 0.322 
Year of index prescription (ref: 1999) 
• 2000 -0.119 0.168 -0.711 0.478 




Model fit statistics: 
 
Adjusted R-square =    27.58%  , F =  5.66 , p = 0.000 
 
 
Table 24b: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on total healthcare cost among bipolar disorder patients (second stage 
sample selection models): Risperidone vs.  quetiapine (contd.) 
 Beta S.E t-statistic Significance (p) 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers 0.031 0.000 2.877 0.004 
Antipsychotics -0.001 0.001 -0.368 0.713 
Antidepressants 0.507 0.387 1.309 0.192 
Benzodiazepines 0.032 0.141 0.226 0.822 
Index prescription (ref: quetiapine) 
Risperidone -0.329 0.439 -0.751 0.454 
Inverse Mills Ratio 0.314 0.268 1.171 0.243 
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Table 24c: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on total healthcare cost among bipolar disorder patients (second stage 
sample selection models): Typicals vs.  quetiapine 
 Beta S.E t-statistic Significance (p) 
Demographic characteristics 
Age (in years) 0.002 0.006 0.348 0.728 
agecat 0.278 0.179 1.553 0.122 
Males (ref: females) 0.000 0.001 0.324 0.746 
Whites (ref: non-whites) 0.431 0.211 2.04 0.042 
Metro (ref: non-metro) -0.280 0.193 -1.451 0.148 
Prescribing physician type 
Psychiatric prescriber  0.000 0.000 1.384 0.168 
Bipolar disorder  subtype (ref:  Bipolar disorder I ) 
Bipolar disorder II  0.389 0.221 1.758 0.080 
Mixed  0.020 0.213 0.095 0.924 
Pre-index co-morbidities 
Charlson Comorbidity Index 0.212 0.049 4.306 0.000 
Alcohol and substance abuse 0.215 0.175 1.23 0.220 
Bipolar disorder  -0.272 0.236 -1.153 0.250 
Major depression 0.176 0.197 0.896 0.371 
Other mental comorbidities 0.360 0.162 2.23 0.027 
Pre-index healthcare utilization and cost 
Pre-index  total health related 
cost 0.244 0.066 3.727 0.000 
Pre-index  total health related 
ER visits 0.304 0.221 1.378 0.169 
Pre-index  total health related 
hospitalizations 0.185 0.191 0.97 0.333 
Pre-index  total health related 
physician visits 0.004 0.011 0.353 0.725 
Year of index prescription (ref: 1999) 
• 2000 -0.053 0.201 -0.262 0.794 



























Table 24c: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on total healthcare cost among bipolar disorder patients (second stage 
sample selection models): Typicals vs.  quetiapine (contd.) 
 Beta S.E t-statistic Significance (p) 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers 0.001 0.001 1.015 0.311 
Antipsychotics -0.001 0.002 -0.548 0.584 
Antidepressants 0.001 0.000 1.032 0.303 
Benzodiazepines 0.045 0.157 0.285 0.776 
Index prescription (ref: quetiapine) 
Typical 0.250 0.417 2.30 0.028 
Inverse Mills Ratio 0.083 0.260 0.319 0.750 
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Table 25a: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare cost among bipolar disorder patients (second 
stage sample selection models): Olanzapine vs.  quetiapine  
 
 Beta S.E t-statistic Significance (p) 
Demographic characteristics 
Age (in years) 0.004 0.005 0.829 0.407 
Agecat  0.104 0.157 0.665 0.506 
Males (ref: females) 0.002 0.001 1.581 0.115 
Whites (ref: non-whites) 0.293 0.192 1.525 0.128 
Metro (ref: non-metro) -0.122 0.139 -0.878 0.380 
Prescribing physician type 
Psychiatric prescriber  0.000 0.000 1.831 0.068 
Bipolar disorder subtype (ref: Bipolar disorder I) 
Bipolar disorder II  -0.219 0.154 -1.420 0.156 
Mixed  -0.444 0.189 -2.346 0.020 
Pre-index co-morbidities 
Charlson Comorbidity Index 0.117 0.051 2.285 0.023 
Alcohol and substance abuse 0.363 0.126 2.890 0.004 
Schizophrenia   0.006 0.160 0.036 0.971 
Major depression 0.067 0.128 0.519 0.604 
Other mental comorbidities 0.114 0.119 0.956 0.340 
Pre-index healthcare utilization and cost 
Pre-index mental-health 
related cost 0.074 0.017 4.366 0.000 
Pre-index mental-health 
related ER visits -0.302 0.146 -2.064 0.040 
Pre-index mental-health 
related hospitalizations 0.158 0.122 1.296 0.196 
Pre-index mental-health 
related physician visits 0.001 0.031 0.024 0.981 
Year of index prescription (ref: 1999) 
• 2000 0.019 0.136 0.139 0.890 
• 2001 -0.143 0.157 -0.907 0.365 
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Model fit statistics: 
 
Adjusted R-square =   20.33%, F = 5.27, p = 0.00 
 
 
Table 25a: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare cost among bipolar disorder patients (second 
stage sample selection models): Olanzapine vs.  quetiapine (contd.) 
 Beta S.E t-statistic Significance (p) 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers 0.001 0.000 1.676 0.095 
Antipsychotics 0.004 0.002 1.737 0.083 
Antidepressants 0.000 0.000 0.890 0.374 
Benzodiazepines 0.020 0.124 0.160 0.873 
Index prescription (ref: quetiapine) 
Olanzapine 0.203 0.539 0.377 0.070 
Inverse Mills Ratio -0.024 0.322 -0.074 0.941 
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Table 25b: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare cost among bipolar disorder patients (second 
stage sample selection models): Risperidone vs.  quetiapine 
 Beta S.E t-statistic Significance (p) 
Demographic characteristics 
Age (in years) 0.011 0.006 1.900 0.058 
agecat 0.026 0.194 0.135 0.893 
Males (ref: females) 0.001 0.001 1.007 0.315 
Whites (ref: non-whites) 0.409 0.233 1.758 0.080 
Metro (ref: non-metro) -0.195 0.180 -1.080 0.281 
Prescribing physician type 
Psychiatric prescriber  0.535 0.000 0.276 0.783 
Bipolar disorder subtype (ref: Bipolar disorder I) 
Bipolar disorder II  -0.227 0.196 -1.155 0.249 
Mixed  -0.849 0.264 -3.212 0.002 
Pre-index co-morbidities 
Charlson Comorbidity Index 0.069 0.059 1.183 0.238 
Alcohol and substance abuse 0.482 0.208 2.324 0.021 
Schizophrenia   0.180 0.219 0.820 0.413 
Major depression 0.088 0.186 0.471 0.638 
Other mental comorbidities 0.046 0.161 0.285 0.776 
Pre-index healthcare utilization and cost 
Pre-index mental-health 
related cost 0.038 0.018 2.057 0.041 
Pre-index mental-health 
related ER visits 0.193 0.195 0.990 0.323 
Pre-index mental-health 
related hospitalizations -0.131 0.163 -0.799 0.425 
Pre-index mental-health 
related physician visits 0.009 0.048 0.194 0.846 
Year of index prescription (ref: 1999) 
• 2000 -0.179 0.187 -0.953 0.341 
• 2001 -0.438 0.216 -2.025 0.044 
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Table 25b: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare cost among bipolar disorder patients (second 
stage sample selection models): Risperidone vs.  quetiapine 
 Beta S.E t-statistic Significance (p) 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers 0.081 0.000 1.864 0.063 
Antipsychotics 0.001 0.002 0.315 0.753 
Antidepressants 0.051 0.000 2.759 0.006 
Benzodiazepines -0.234 0.159 -1.472 0.142 
Index prescription (ref: quetiapine) 
Risperidone -0.647 0.502 -1.288 0.199 
Inverse Mills Ratio 0.405 0.307 1.322 0.187 
 
Model fit statistics: 
 






Table 25c: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare cost among bipolar disorder patients (second 
stage sample selection models): Typicals vs.  quetiapine 
 Beta S.E t-statistic Significance (p) 
Demographic characteristics 
Age (in years) -0.011 0.008 -1.366 0.173 
agecat 0.114 0.227 0.499 0.618 
Males (ref: females) 0.002 0.001 2.403 0.017 
Whites (ref: non-whites) 0.342 0.269 1.273 0.204 
Metro (ref: non-metro) -0.239 0.245 -0.974 0.331 
Prescribing physician type 
Psychiatric prescriber  0.000 0.000 1.738 0.083 
Bipolar Disorder subtype (ref: Bipolar disorder I) 
Bipolar disorder II  0.155 0.282 0.550 0.583 
Mixed  -0.919 0.276 -3.332 0.001 
Pre-index co-morbidities 
Charlson Comorbidity Index 0.072 0.057 1.275 0.203 
Alcohol and substance abuse 0.587 0.221 2.649 0.009 
Schizophrenia -0.117 0.301 -0.388 0.699 
Major depression 0.437 0.251 1.742 0.083 
Other mental comorbidities 0.196 0.205 0.954 0.341 
Pre-index healthcare utilization and cost 
Pre-index mental-health 
related cost -0.018 0.024 -0.735 0.463 
Pre-index mental-health 
related ER visits -0.027 0.269 -0.099 0.921 
Pre-index mental-health 
related hospitalizations 0.592 0.218 2.719 0.007 
Pre-index mental-health 
related physician visits 0.024 0.062 0.387 0.699 
Year of index prescription (ref: 1999) 
• 2000 -0.014 0.252 -0.054 0.957 
• 2001 -0.213 0.319 -0.668 0.505 
(contd.) 
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Table 25c: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare cost among bipolar disorder patients (second 
stage sample selection models): Typicals vs.  quetiapine 
 Beta S.E t-statistic Significance (p) 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers 0.001 0.001 0.856 0.393 
Antipsychotics 0.001 0.002 0.412 0.681 
Antidepressants 0.062 0.001 3.348 0.001 
Benzodiazepines 0.039 0.198 0.195 0.845 
Index prescription (ref: quetiapine) 
Typical 0.083 0.535 2.568 0.008 
Inverse Mills Ratio 0.357 0.332 1.076 0.283 
 
Model fit statistics: 
 





Multivariate analysis results for mental health-related inpatient costs 
 The results of the two-part model used to estimate the impact of antipsychotic on 
mental health-related inpatient costs are presented in the tables 26a and 26b.  The first-
part logistic regression model comparing the risk of incurring any inpatient cost to no 
inpatient costs showed no significant difference between quetiapine and other 
antipsychotics.  The second-part semi-log OLS regression which was carried out only on 
those patients who had incurred any mental health-related inpatient costs showed that 
patients initiated on typical antipsychotics incurred 3.7% higher costs than patients 
initiated on quetiapine.   
Multivariate analysis results for mental health-related ER costs  
 The results of two part model estimating the impact of index antipsychotic 
therapy on mental health-related ER costs are presented in table 27a and 27b.  The first 
part logistic regression analysis revealed that there were no significant differences in the 
likelihood of incurring any ER cost between quetiapine and other cohorts.  The 
subsequent semi-log OLS analysis carried out using only the patients who have incurred 
ER costs also showed no significant differences in mental health-related ER costs 
between quetiapine and other antipsychotics.  
Multivariate analysis results for mental health-related pharmacy costs  
 The results show that patients initiated on olanzapine incur 27.88% higher mental 
healthcare-related pharmacy cost than patients initiated on quetiapine.  Patients initiated 
on typical antipsychotics incur 53.92% lesser mental healthcare-related pharmacy cost 
than patients initiated on quetiapine.  Results for the OLS regression models for the 
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impact of index antipsychotics on mental-health related pharmacy healthcare costs are 
presented in table 28.   
Multivariate analysis results for mental health-related outpatient costs  
 The results of semi-log regression analysis show that the patients initiated on 
typical antipsychotics incur 3.0% higher outpatient costs than patients initiated on 
quetiapine.  Results for the OLS regression models for the impact of index antipsychotics 
on mental-health related outpatient healthcare costs are presented in table 29.    
Bipolar Disorder 
 Univariate analysis for mental health-related inpatient, outpatient, ER, and 
pharmacy costs are reported in table 23.  There were no significant differences in mental-
health related inpatient and outpatient costs between quetiapine and other antipsychotics.  
The post-index ER costs were significantly lower for risperidone ($129 + $352) 
compared to quetiapine ($200 + $486).  The post-index prescription costs were 
significantly lower for typicals ($1,118 + $1,118) compared to quetiapine ($2,084 + 
1,578).  
Multivariate analysis results for mental health-related inpatient costs 
 The results of the two-part model used to estimate the impact of antipsychotic on 
mental health-related inpatient costs are presented in tables 30a and 30b.  Results of the 
two part model show that there were no significant differences in the mental health-
related inpatient costs between quetiapine and other antipsychotics.  
Multivariate analysis results for mental health-related ER costs  
 The results of two part model estimating the impact of index antipsychotic 
therapy on mental health-related ER costs are presented in tables 31a and 31b.  The first 
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part logistic regression analysis and the subsequent semi-log OLS analysis revealed that 
there were no significant differences in the mental health-related ER cost between 
quetiapine and other cohorts.  
Multivariate analysis results for mental health-related pharmacy costs  
 Patients initiated on typical antipsychotics incur 52.76% lesser mental healthcare-
related pharmacy cost than patients initiated on quetiapine.  Patients initiated on 
olanzapine incur 12.41% greater mental healthcare-related pharmacy cost than patients 
initiated on quetiapine.  Results for the OLS regression models for the impact of index 
antipsychotics on mental-health related pharmacy healthcare costs are presented in table 
32.   
Multivariate analysis results for mental health-related outpatient costs  
 The results of semi-log regression analysis show that the patients initiated patients 
initiated on typical antipsychotics incur 7.78% higher outpatient costs than patients 
initiated on quetiapine.  Results for the OLS regression models for the impact of index 
antipsychotics on mental-health related outpatient healthcare costs are presented in table 
33.    
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TWO-PART MODEL-PART 1 
Table 26a: Logistic regression model for the impact of index antipsychotic on having 
a mental health-related hospitalization episode among schizophrenia patients 
 
 Beta SE Sig. (p) Odds ratio 95% CI for odds ratio 





Age (in years) -0.008 0.007 0.266 0.992 0.978 1.006 
Males (ref: females) -0.005 0.008 0.495 0.995 0.980 1.010 
Whites (ref: non-
whites) -0.562 0.286 0.049 0.570 0.326 0.998 
Metro (ref: non-
metro) 0.361 0.195 0.065 1.435 0.979 2.105 
Prescribing physician type 
Psychiatric 
prescriber  0.000 0.000 0.730 1.000 1.000 1.000 
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective 
disorder 0.366 0.207 0.077 1.441 0.962 2.160 
Both schizoaffective 
disorder and 
schizophrenia 0.758 0.219 0.001 2.135 1.391 3.276 
Pre-index co-morbidities 
Alcohol and 
substance abuse -0.888 0.181 <.0001 0.411 0.289 0.586 
Bipolar disorder -0.362 0.244 0.138 0.697 0.432 1.123 
Major depression -0.229 0.206 0.268 0.796 0.531 1.192 
Mild to Moderate 
depression -0.246 0.236 0.297 0.782 0.492 1.242 
Other mental 
comorbidities -0.083 0.187 0.656 0.920 0.638 1.327 
diabetes -0.385 0.267 0.150 0.680 0.403 1.149 
hyperlipedemia 0.298 0.328 0.364 1.347 0.709 2.559 
hypertension 0.245 0.226 0.279 1.278 0.820 1.990 
Charlson 
Comorbidity Index -0.197 0.063 0.002 0.821 0.726 0.930 
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Table 26a: Logistic regression model for the impact of index antipsychotic on having 
a mental health-related hospitalization episode among schizophrenia patients 
 
 Beta SE Sig. (p) Odds ratio 95% CI for odds ratio 




Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers 0.000 0.001 0.722 1.000 0.999 1.001 
Antipsychotics -0.002 0.002 0.387 0.998 0.995 1.002 
Antidepressants -0.001 0.001 0.049 0.999 0.998 1.000 
Benzodiazepines -0.001 0.001 0.345 0.999 0.998 1.001 
Pre-index healthcare utilization and cost 
Number of 
psychotherapy visits -0.005 0.017 0.777 0.995 0.962 1.029 
Number of 
medication 
management visits 0.076 0.030 0.011 1.079 1.018 1.143 
Any pre-index 
mental-health 
related ER visits -0.329 0.288 0.252 0.719 0.410 1.264 
Pre-index mental-
health related 




hospitalizations -0.752 0.169 <.0001 0.471 0.339 0.656 
Year of index prescription (ref: 1999) 
• 2000 -0.127 0.216 0.555 0.880 0.577 1.343 
• 2001 0.260 0.261 0.318 1.297 0.778 2.161 
Index prescription (ref: quetiapine) 
Risperidone 0.356 0.276 0.197 1.428 0.831 2.453 
Olanzapine 0.103 0.241 0.670 1.108 0.691 1.776 
Typicals 0.202 0.260 0.436 1.224 0.736 2.037 
 
Model Statistics: 
-2 Log Likehood =  1207.17 , chi-square =   161.00         , p < 0.0001 
(contd.) 
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TWO-PART MODEL-PART 2 
Table 26b: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare-related hospitalization cost among 
schizophrenia patients 
 
 Beta S.E t-statistic Significance 
(p) 
Demographic characteristics 
Age (in years) 0.003 0.005 0.670 0.506 
Males (ref: females) 0.000 0.107 0.000 0.997 
Whites (ref: non-whites) 0.315 0.199 1.590 0.114 
Metro (ref: non-metro) 0.114 0.131 0.870 0.384 
Prescribing physician type 
Psychiatric prescriber  0.000 0.000 -0.380 0.705 
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective disorder -0.084 0.129 -0.650 0.515 
Both schizoaffective disorder 
and schizophrenia -0.122 0.206 -0.590 0.554 
Pre-index co-morbidities 
Alcohol and substance abuse 0.301 0.107 2.800 0.006 
Bipolar disorder -0.001 0.145 -0.010 0.992 
Major depression 0.153 0.126 1.210 0.226 
Mild to Moderate depression 0.262 0.138 1.900 0.059 
Other mental comorbidities 0.147 0.118 1.250 0.214 
diabetes 0.036 0.161 0.230 0.821 
hyperlipedemia -0.116 0.206 -0.560 0.576 
hypertension 0.177 0.141 1.250 0.212 
Charlson Comorbidity Index 0.024 0.041 0.590 0.553 
Pre-index period psychiatric medication use`(days of supply) 
Mood stabilizers 0.000 0.000 -1.290 0.199 
Antipsychotics 0.001 0.001 0.880 0.378 
Antidepressants 0.000 0.000 0.090 0.929 
Benzodiazepines 0.000 0.000 -1.060 0.289 
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Table 26b: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare-related hospitalization cost among 
schizophrenia patients 
 
 Beta S.E t-statistic Significance 
(p) 
 
Pre-index healthcare utilization and cost 
Number of psychotherapy 
visits -0.006 0.009 -0.660 0.510 
Number of medication 
management visits -0.011 0.020 -0.540 0.593 
Number of pre-index mental-
health related ER visits -0.025 0.073 -0.340 0.731 
Pre-index mental-health 
related physician visits -0.060 0.033 -1.830 0.068 
Number of pre-index mental-
health related hospitalizations 0.015 0.006 2.590 0.010 
Pre-index mental health-
related cost 0.256 0.134 1.910 0.058 
Year of index prescription (ref: 1999) 
• 2000 -0.187 0.166 -1.120 0.263 
• 2001 -0.111 0.175 -0.640 0.526 
Index prescription (ref: quetiapine) 
Risperidone -0.269 0.154 -1.750 0.081 
Olanzapine -0.174 0.164 -1.060 0.290 
Typicals 0.036 0.015 0.670 0.026 
 
Model fit statistics: 
 





TWO-PART MODEL-PART 1 
Table 27a: Logistic regression model for the impact of index antipsychotic on having 
a mental health-related ER episode among schizophrenia patients 
 
 Beta SE Sig. (p) Odds ratio 95% CI for odds ratio 





Age (in years) -0.003 0.007 0.655 0.997 0.983 1.011 
Males (ref: females) 0.000 0.001 0.675 1.000 0.997 1.002 
Whites (ref: non-
whites) -0.909 0.293 0.002 0.403 0.227 0.716 
Metro (ref: non-
metro) 0.487 0.198 0.014 1.628 1.105 2.398 
Prescribing physician type 
Psychiatric 
prescriber  0.000 0.000 0.034 1.000 0.999 1.000 
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective 
disorder 0.900 0.216 <.0001 2.460 1.611 3.755 
Both schizoaffective 
disorder and 
schizophrenia 0.772 0.212 0.000 2.163 1.427 3.280 
Pre-index co-morbidities 
Alcohol and 
substance abuse -1.242 0.181 <.0001 0.289 0.203 0.412 
Bipolar disorder -0.229 0.241 0.340 0.795 0.496 1.274 
Major depression -0.170 0.207 0.413 0.844 0.562 1.267 
Mild to Moderate 
depression -0.384 0.236 0.104 0.681 0.429 1.083 
Other mental 
comorbidities -0.395 0.183 0.031 0.674 0.470 0.965 
diabetes -0.504 0.266 0.058 0.604 0.359 1.017 
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Table 27a: Logistic regression model for the impact of index antipsychotic on having 
a mental health-related ER episode among schizophrenia patients 
 
 Beta SE Sig. (p) Odds ratio 95% CI for odds ratio 




hyperlipedemia 0.155 0.315 0.624 1.167 0.629 2.165 
hypertension -0.132 0.219 0.547 0.876 0.571 1.346 
Charlson 
Comorbidity Index -0.062 0.064 0.331 0.940 0.829 1.065 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers -0.001 0.001 0.053 0.999 0.998 1.000 
Antipsychotics 0.000 0.002 0.799 1.000 0.997 1.004 
Antidepressants 0.000 0.001 0.537 1.000 0.999 1.001 
Benzodiazepines -0.001 0.001 0.362 0.999 0.998 1.001 
Pre-index healthcare utilization and cost 
Number of 
psychotherapy visits -0.015 0.016 0.367 0.985 0.955 1.017 
Number of 
medication 
management visits 0.032 0.028 0.246 1.033 0.978 1.090 
Any pre-index 
mental-health 
related ER visits -0.717 0.286 0.012 0.488 0.279 0.854 
Pre-index mental-
health related 




hospitalizations -0.308 0.171 0.072 0.735 0.525 1.028 
Year of index prescription (ref: 1999) 
• 2000 0.395 0.219 0.071 1.484 0.967 2.278 
• 2001 0.349 0.254 0.169 1.418 0.862 2.331 
(contd.) 
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Table 27a: Logistic regression model for the impact of index antipsychotic on having 
a mental health-related ER episode among schizophrenia patients 
 
 Beta SE Sig. (p) Odds ratio 95% CI for odds ratio 





Index prescription (ref: quetiapine) 
Risperidone 0.211 0.271 0.437 1.234 0.726 2.100 
Olanzapine 0.118 0.240 0.623 1.125 0.703 1.800 
Typicals -0.100 0.258 0.698 0.905 0.546 1.499 
 
Model fit statistics: 
 
-2 Log Likehood = 1057.6       , chi-square =   178.25         , p < 0.0001 
(contd.) 
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TWO-PART MODEL-PART 2 
Table 27b: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare-related ER cost among schizophrenia patients 
 
 Beta S.E t-statistic Significance 
(p) 
Demographic characteristics 
Age (in years) -0.006 0.007 -0.750 0.456 
Males (ref: females) 0.000 0.001 -0.200 0.844 
Whites (ref: non-whites) -0.076 0.306 -0.250 0.803 
Metro (ref: non-metro) 0.158 0.188 0.840 0.402 
Prescribing physician type 
Psychiatric prescriber  0.000 0.000 -0.520 0.606 
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective disorder -0.063 0.205 -0.310 0.759 
Both schizoaffective disorder 
and schizophrenia -0.256 0.199 -1.290 0.199 
Pre-index co-morbidities 
Alcohol and substance abuse 0.281 0.157 1.790 0.074 
Bipolar disorder 0.096 0.207 0.460 0.645 
Major depression 0.368 0.191 1.930 0.055 
Mild to Moderate depression 0.244 0.206 1.190 0.236 
Other mental comorbidities 0.035 0.172 0.200 0.840 
Diabetes 0.435 0.245 1.780 0.077 
Hyperlipedemia -0.177 0.302 -0.590 0.558 
Hypertension 0.106 0.205 0.520 0.606 
Charlson Comorbidity Index 0.155 0.074 2.100 0.037 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers 0.000 0.001 0.380 0.706 
Antipsychotics -0.003 0.002 -1.450 0.147 
Antidepressants 0.000 0.001 0.850 0.395 
Benzodiazepines -0.001 0.001 -1.800 0.073 
Number of psychotherapy 
visits -0.031 0.012 -2.730 0.007 
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Table 27b: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare-related ER cost among schizophrenia patients 
 
 Beta S.E t-statistic Significance 
(p) 
Pre-index healthcare utilization and cost 
Number of medication 
management visits -0.010 0.028 -0.350 0.723 
Number of pre-index mental-
health related ER visits -0.030 0.109 -0.280 0.782 
Pre-index mental-health 
related physician visits -0.019 0.044 -0.440 0.663 
Number of pre-index mental-
health related hospitalizations 0.150 0.250 0.460 0.651 
Pre-index mental health-
related cost 0.006 0.012 0.460 0.644 
Year of index prescription (ref: 1999) 
• 2000 0.234 0.202 1.160 0.248 
• 2001 0.071 0.233 0.310 0.760 
Index prescription (ref: quetiapine) 
Risperidone -0.535 0.259 -2.060 0.060 
Olanzapine -0.390 0.227 -1.720 0.086 
Typicals -0.375 0.239 -1.570 0.118 
 
Model fit statistics: 
 




Table 28: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare-related pharmacy cost among schizophrenia 
patients 
 Beta S.E t-statistic Significance 
(p) 
Demographic characteristics 
Age (in years) 0.001 0.003 0.46 0.643 
Males (ref: females) 0.000 0.000 0.47 0.639 
Whites (ref: non-whites) -0.007 0.115 -0.06 0.948 
Metro (ref: non-metro) -0.042 0.088 -0.48 0.630 
Prescribing physician type 
Psychiatric prescriber  0.000 0.000 5.26 <.0001 
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective disorder 0.006 0.093 0.07 0.946 
Both schizoaffective disorder 
and schizophrenia -0.222 0.097 -2.29 0.022 
Pre-index co-morbidities 
Alcohol and substance abuse -0.139 0.086 -1.61 0.107 
Bipolar disorder 0.005 0.113 0.04 0.966 
Major depression 0.056 0.095 0.58 0.560 
Mild to Moderate depression 0.010 0.112 0.09 0.927 
Other mental comorbidities 0.027 0.083 0.33 0.742 
Diabetes 0.098 0.127 0.77 0.444 
Hyperlipedemia 0.010 0.141 0.07 0.945 
Hypertension -0.040 0.102 -0.4 0.692 
Charlson Comorbidity Index -0.066 0.030 -2.19 0.029 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers 0.091 0.000 5.45 <.0001 
Antipsychotics 0.001 0.001 1.36 0.174 
Antidepressants 0.072 0.000 5.14 <.0001 
Benzodiazepines 0.034 0.000 2.82 0.005 
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Table 28: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare-related pharmacy cost among schizophrenia 
patients 
 Beta S.E t-statistic Significance 
(p) 
Pre-index healthcare utilization and cost 
Number of psychotherapy 
visits 0.001 0.008 0.13 0.894 
Number of medication 
management visits -0.010 0.012 -0.88 0.380 
Number of pre-index mental-
health related ER visits -0.038 0.073 -0.53 0.599 
Pre-index mental-health 
related physician visits -0.00073 0.025 -0.03 0.976 
Number of pre-index mental-
health related hospitalizations 0.043 0.036 1.18 0.237 
Pre-index psychiatric drug 
cost 0.003 0.005 0.54 0.586 
Year of index prescription (ref: 1999) 
• 2000 -0.043 0.095 -0.45 0.654 
• 2001 0.022 0.110 0.2 0.845 
Index prescription (ref: quetiapine) 
Risperidone 0.032 0.121 0.26 0.794 
Olanzapine 0.246 0.108 2.28 0.023 
Typicals -0.775 0.116 -6.65 <.0001 
 
Model fit statistics: 
 




Table 29: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare-related outpatient cost among schizophrenia 
patients 
 Beta S.E t-statistic Significance 
(p) 
Demographic characteristics 
Age (in years) 0.009 0.013 0.67 0.504 
Males (ref: females) 0.004 0.002 2.06 0.040 
Whites (ref: non-whites) 0.203 0.486 2.48 0.013 
Metro (ref: non-metro) -0.637 0.369 -1.73 0.085 
Prescribing physician type 
Psychiatric prescriber  0.001 0.000 2.76 0.006 
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective disorder 0.567 0.391 1.45 0.147 
Both schizoaffective disorder 
and schizophrenia -0.649 0.425 -6.23 <.0001 
Pre-index co-morbidities 
Alcohol and substance abuse 0.991 0.366 2.71 0.007 
Bipolar disorder 0.626 0.476 1.31 0.189 
Major depression -0.083 0.400 -0.21 0.836 
Mild to Moderate depression 0.626 0.473 1.32 0.186 
Other mental comorbidities -1.166 0.351 -3.32 0.001 
diabetes 0.182 0.536 0.34 0.734 
hyperlipedemia -0.277 0.593 -0.47 0.641 
hypertension -0.210 0.428 -0.49 0.624 
Charlson Comorbidity Index -0.193 0.127 -1.52 0.129 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers -0.001 0.001 -0.85 0.396 
Antipsychotics -0.002 0.004 -0.64 0.520 
Antidepressants 0.000 0.001 -0.24 0.811 
Benzodiazepines -1.318 0.490 2.69 0.007 
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Table 29: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare-related outpatient cost among schizophrenia 
patients 
 Beta S.E t-statistic Significance 
(p) 
Pre-index healthcare utilization and cost 
Number of psychotherapy 
visits 0.000 0.033 0.01 0.990 
Number of medication 
management visits 0.082 0.051 1.6 0.110 
Number of pre-index mental-
health related ER visits -0.207 0.306 -0.68 0.499 
Pre-index mental-health 
related physician visits -0.064 0.106 -0.6 0.547 
Number of pre-index mental-
health related hospitalizations 0.320 0.153 2.09 0.037 
Pre-index outpatient drug 
cost 0.365 0.025 14.51 <.0001 
Year of index prescription (ref: 1999) 
• 2000 -0.047 0.401 -0.12 0.907 
• 2001 -0.365 0.465 -0.79 0.432 
Index prescription (ref: quetiapine) 
Risperidone -0.540 0.508 -1.06 0.288 
Olanzapine -0.412 0.455 -0.91 0.365 
Typicals 0.03 0.001 2.3 0.022 
 
Model fit statistics: 
 





TWO-PART MODEL-PART 1 
Table 30a: Logistic regression model for the impact of index antipsychotic on having 
a mental health-related hospitalization episode   
 Beta SE Sig. (p) Odds ratio 95% CI for odds ratio 
     Lower Upper 
Demographic characteristics 
Age (in years) -0.012 0.008 0.121 0.988 0.972 1.003 
18 years or above 
(ref: less than 18 
years) -0.277 0.241 0.250 0.758 0.473 1.215 
Males (ref: females) -0.005 0.008 0.533 0.995 0.979 1.011 
Whites (ref: non-
whites) -0.763 0.350 0.029 0.466 0.235 0.927 
Metro (ref: non-
metro) 0.421 0.230 0.068 1.523 0.970 2.391 
Prescribing physician type 
Psychiatric 
prescriber  0.000 0.000 0.506 1.000 0.999 1.000 
Bipolar disorder subtype (ref: Bipolar disorder I) 
Bipolar disorder II  0.448 0.241 0.064 1.565 0.975 2.511 
Mixed   0.835 0.243 0.001 2.305 1.432 3.712 
Pre-index co-morbidities 
Alcohol and 
substance abuse -0.889 0.206 <.0001 0.411 0.275 0.615 
Schizophrenia  -0.228 0.275 0.407 0.796 0.464 1.364 
Major depression -0.153 0.232 0.509 0.858 0.545 1.351 
Mild to Moderate 
depression -0.069 0.268 0.797 0.933 0.552 1.578 
Other mental 
comorbidities -0.192 0.207 0.354 0.825 0.550 1.238 
Diabetes -0.363 0.297 0.221 0.696 0.389 1.244 
Hyperlipedemia 0.228 0.359 0.525 1.256 0.622 2.536 
Hypertension 0.219 0.246 0.375 1.245 0.768 2.017 
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Table 30a: Logistic regression model for the impact of index antipsychotic on having 
a mental health-related hospitalization episode   
 Beta SE Sig. (p) Odds ratio 95% CI for odds ratio 
     Lower Upper 
Charlson 
Comorbidity Index -0.189 0.066 
0.004 
0.828 0.727 0.942 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers 0.000 0.001 0.731 1.000 0.998 1.001 
Antipsychotics -0.002 0.002 0.302 0.998 0.994 1.002 
Antidepressants -0.001 0.001 0.083 0.999 0.998 1.000 
Benzodiazepines -0.001 0.001 0.459 0.999 0.998 1.001 
Pre-index healthcare utilization and cost 
Number of 
psychotherapy visits -0.001 0.024 0.977 0.999 0.953 1.048 
Number of 
medication 
management visits 0.100 0.036 0.006 1.105 1.029 1.186 
Any pre-index 
mental-health 
related ER visits -0.190 0.321 0.553 0.827 0.441 1.550 
Pre-index mental-
health related 




hospitalizations -0.749 0.190 <.0001 0.473 0.326 0.686 
Year of index prescription (ref: 1999) 
• 2000 -0.198 0.233 0.396 0.821 0.520 1.296 
• 2001 0.233 0.287 0.417 1.263 0.719 2.216 
Index prescription (ref: quetiapine) 
Risperidone 0.268 0.316 0.397 1.307 0.704 2.426 
Olanzapine 0.082 0.286 0.774 1.086 0.620 1.903 
Typicals 0.078 0.315 0.806 1.081 0.583 2.003 
Model fit statistics: 




TWO-PART MODEL-PART 2 
Table 30b: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare-related hospitalization cost among bipolar 
disorder patients 
 Beta S.E t-statistic Significance 
(p) 
Demographic characteristics 
Age (in years) 0.005 0.005 0.930 0.354 
18 years or above (ref: less 
than 18 years) 0.100 0.163 0.610 0.541 
Males (ref: females) -0.030 0.119 -0.250 0.801 
Whites (ref: non-whites) 0.484 0.245 1.970 0.050 
Metro (ref: non-metro) 0.082 0.158 0.520 0.606 
Prescribing physician type 
Psychiatric prescriber  0.000 0.000 -0.730 0.465 
Bipolar disorder subtype (ref: Bipolar disorder I) 
Bipolar disorder II -0.056 0.151 -0.370 0.711 
Mixed  -0.181 0.206 -0.880 0.382 
Pre-index co-morbidities 
Alcohol and substance abuse 0.318 0.123 2.590 0.010 
Bipolar disorder 0.031 0.166 0.180 0.854 
Major depression 0.171 0.143 1.200 0.232 
Mild to Moderate depression 0.039 0.160 0.250 0.806 
Other mental comorbidities 0.125 0.130 0.970 0.335 
diabetes -0.043 0.170 -0.250 0.800 
hyperlipedemia -0.190 0.219 -0.870 0.387 
hypertension 0.179 0.152 1.180 0.241 
Charlson Comorbidity Index 0.044 0.042 1.050 0.295 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers -0.021 0.000 -1.670 0.096 
Antipsychotics 0.000 0.001 0.380 0.702 
Antidepressants 0.000 0.000 -0.320 0.750 
Benzodiazepines 0.000 0.000 -0.630 0.528 
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Table 30b: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare-related hospitalization cost among bipolar 
disorder patients 
 Beta S.E t-statistic Significance 
(p) 
Pre-index healthcare utilization and cost 
Number of psychotherapy 
visits 0.013 0.014 0.920 0.357 
Number of medication 
management visits -0.020 0.026 -0.770 0.445 
Number of pre-index mental-
health related ER visits -0.008 0.078 -0.100 0.919 
Pre-index mental-health 
related physician visits -0.048 0.037 -1.300 0.195 
Number of pre-index mental-
health related hospitalizations 0.094 0.206 0.460 0.647 
Pre-index mental health-
related cost 0.020 0.007 2.960 0.004 
Year of index prescription (ref: 1999) 
• 2000 0.300 0.143 2.110 0.036 
• 2001 -0.186 0.184 -1.010 0.314 
Index prescription (ref: quetiapine) 
Risperidone -0.201 0.200 -1.010 0.315 
Olanzapine -0.414 0.184 -2.250 0.225 
Typicals -0.343 0.201 -1.710 0.089 
 
Model fit statistics: 
 




TWO-PART MODEL-PART 1 
Table 31a: Logistic regression model for the impact of index antipsychotic on having 
a mental health-related ER episode among bipolar disorder patients 
 Beta SE Sig. (p) Odds ratio 95% CI for odds ratio 





Age (in years) -0.003 0.008 0.709 0.997 0.982 1.013 
18 years or above 
(ref: less than 18 
years) -0.526 0.242 0.030 0.591 0.368 0.950 
Males (ref: females) 0.000 0.001 0.919 1.000 0.997 1.002 
Whites (ref: non-
whites) -0.866 0.342 0.011 0.421 0.215 0.823 
Metro (ref: non-
metro) 0.487 0.230 0.035 1.627 1.036 2.554 
Prescribing physician type 
Psychiatric 
prescriber  0.000 0.000 0.164 1.000 0.999 1.000 
Bipolar disorder subtype (ref: bipolar disorder I) 
Bipolar disorder I 0.827 0.247 0.001 2.287 1.408 3.713 
Mixed  0.846 0.237 0.000 2.330 1.465 3.706 
Pre-index co-morbidities 
Alcohol and 
substance abuse -1.093 0.204 <.0001 0.335 0.225 0.500 
Schizophrenia  -0.332 0.266 0.211 0.717 0.426 1.207 
Major depression -0.181 0.228 0.429 0.835 0.534 1.306 
Mild to Moderate 
depression -0.217 0.262 0.408 0.805 0.481 1.346 
Other mental 
comorbidities -0.420 0.203 0.038 0.657 0.442 0.977 
diabetes -0.513 0.293 0.080 0.598 0.337 1.063 
hyperlipedemia 0.100 0.345 0.771 1.106 0.562 2.175 
hypertension -0.144 0.237 0.542 0.866 0.544 1.376 
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Table 31a: Logistic regression model for the impact of index antipsychotic on having 
a mental health-related ER episode among bipolar disorder patients 
 Beta SE Sig. (p) Odds ratio 95% CI for odds ratio 





Comorbidity Index -0.047 0.067 0.481 0.954 
0.836 
1.088 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers -0.001 0.001 0.130 0.999 0.998 1.000 
Antipsychotics 0.002 0.002 0.502 1.002 0.997 1.006 
Antidepressants 0.000 0.001 0.377 1.000 0.998 1.001 
Benzodiazepines -0.001 0.001 0.353 0.999 0.998 1.001 
Pre-index healthcare utilization and cost 
Number of 
psychotherapy visits -0.010 0.021 0.644 0.990 0.950 1.032 
Number of 
medication 
management visits 0.033 0.032 0.300 1.034 0.971 1.100 
Any pre-index 
mental-health 
related ER visits -0.758 0.314 0.016 0.469 0.253 0.868 
Pre-index mental-
health related 




hospitalizations -0.403 0.190 0.034 0.668 0.460 0.971 
Year of index prescription (ref: 1999) 
• 2000 0.214 0.234 0.360 1.239 0.783 1.959 
• 2001 0.297 0.277 0.284 1.346 0.782 2.317 
Index prescription (ref: quetiapine) 
Risperidone 0.161 0.308 0.601 1.175 0.642 2.150 
Olanzapine 0.044 0.281 0.876 1.045 0.602 1.813 




Model fit statistics: 
 
-2 Log Likehood =   866.29      , chi-square =   142.48             , p <0.0001  
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TWO-PART MODEL-PART 2 
Table 31b: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare-related ER cost among bipolar disorder patients 
 
 Beta S.E t-statistic Significance 
(p) 
Demographic characteristics 
Age (in years) 0.001 0.008 0.180 0.858 
18 years or above (ref: less 
than 18 years) 0.197 0.243 0.810 0.419 
Males (ref: females) 0.000 0.001 0.170 0.863 
Whites (ref: non-whites) -0.129 0.346 -0.370 0.709 
Metro (ref: non-metro) -0.038 0.222 -0.170 0.864 
Prescribing physician type 
Psychiatric prescriber  0.000 0.000 -0.730 0.465 
Bipolar disorder subtype (ref: Bipolar disorder I) 
Bipolar disorder I -0.056 0.231 -0.240 0.807 
Mixed  -0.488 0.216 -2.260 0.025 
Pre-index co-morbidities 
Alcohol and substance abuse 0.382 0.175 2.180 0.030 
Schizophrenia  0.115 0.232 0.500 0.619 
Major depression 0.402 0.206 1.950 0.052 
Mild to Moderate depression 0.307 0.231 1.330 0.186 
Other mental comorbidities -0.118 0.193 -0.610 0.539 
diabetes 0.466 0.258 1.810 0.072 
hyperlipedemia -0.370 0.320 -1.160 0.249 
hypertension 0.041 0.217 0.190 0.849 
Charlson Comorbidity Index 0.158 0.080 1.970 0.050 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers 0.051 0.001 1.170 0.244 
Antipsychotics -0.004 0.002 -1.560 0.121 
Antidepressants 0.004 0.001 0.340 0.732 




Model fit statistics: 
 
Adjusted R-square =    19.95%  , F =  2.47, p < 0.000 
Table 31b: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare-related ER cost among bipolar disorder patients 
 
 Beta S.E t-statistic Significance 
(p) 
Pre-index healthcare utilization and cost 
Number of psychotherapy 
visits -0.029 0.016 -1.850 0.065 
Number of medication 
management visits -0.007 0.032 -0.210 0.831 
Number of pre-index mental-
health related ER visits -0.040 0.114 -0.350 0.726 
Pre-index mental-health 
related physician visits -0.021 0.049 -0.440 0.663 
Number of pre-index mental-
health related hospitalizations 0.028 0.063 0.650 0.910 
Pre-index mental health-
related cost 0.000 0.013 0.030 0.978 
Year of index prescription (ref: 1999) 
• 2000 0.229 0.211 1.080 0.280 
• 2001 0.005 0.257 0.020 0.984 
Index prescription (ref: quetiapine) 
Risperidone -0.681 0.293 -2.320 0.071 
Olanzapine -0.494 0.264 -1.870 0.063 




Table 32: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare-related pharmacy cost among bipolar disorder 
patients 
 Beta S.E t-statistic Significance (p) 
     
Demographic characteristics 
Age (in years) 0.001 0.003 0.37 0.714 
18 years or above (ref: less than 18 
years) 0.034 0.101 0.34 0.735 
Males (ref: females) 0.000 0.001 0.66 0.507 
Whites (ref: non-whites) 0.026 0.134 0.19 0.848 
Metro (ref: non-metro) -0.005 0.102 -0.05 0.961 
Prescribing physician type 
Psychiatric prescriber 0.000 0.000 4.66 <.0001 
Bipolar disorder subtype (ref: bipolar disorder I) 
Bipolar disorder I 0.039 0.108 0.36 0.717 
Mixed -0.249 0.107 -2.32 0.021 
Pre-index co-morbidities 
Alcohol and substance abuse -0.198 0.099 -2 0.045 
Schizophrenia -0.069 0.127 -0.54 0.590 
Major depression 0.079 0.106 0.74 0.458 
Mild to Moderate depression -0.022 0.125 -0.17 0.863 
Other mental comorbidities 0.084 0.092 0.92 0.360 
Diabetes 0.124 0.142 0.88 0.381 
Hyperlipedemia 0.025 0.158 0.16 0.876 
Hypertension -0.092 0.112 -0.82 0.411 
Charlson Comorbidity Index -0.044 0.032 -1.4 0.161 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers 0.041 0.000 4.73 <.0001 
Antipsychotics 0.001 0.001 0.61 0.539 
Antidepressants 0.045 0.000 5.3 <.0001 
Benzodiazepines 0.032 0.000 2.34 0.020 
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Table 32: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare-related pharmacy cost among bipolar disorder 
patients 
 Beta S.E t-statistic Significance (p) 
Pre-index healthcare utilization and cost 
Number of psychotherapy visits 0.016 0.010 1.61 0.108 
Number of medication management 
visits -0.026 0.013 -1.93 0.054 
Number of pre-index mental-health 
related ER visits -0.068 0.078 -0.87 0.383 
Pre-index mental-health related 
physician visits 0.014 0.028 0.48 0.632 
Number of pre-index mental-health 
related hospitalizations 0.022 0.039 0.56 0.575 
Pre-index mental health-related 
pharmacy cost 0.305 -0.060 0.9546 0.028 
Year of index prescription (ref: 1999) 
• 2000 -0.044 0.103 -0.43 0.670 
• 2001 0.016 0.121 0.13 0.898 
Index prescription (ref: quetiapine) 
Risperidone -0.002 0.137 -0.02 0.986 
Olanzapine 0.117 0.126 2.22 0.035 
Typicals -0.859 0.139 -6.17 <.0001 
 
Model fit statistics: 
 




Table 33: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare-related outpatient cost  
 




Age (in years) 0.003 0.015 0.17 0.865 
18 years or above (ref: less 
than 18 years) -0.194 0.431 -0.45 0.653 
Males (ref: females) 0.005 0.002 2.08 0.038 
Whites (ref: non-whites) 1.653 0.574 2.88 0.004 
Metro (ref: non-metro) -0.896 0.438 -2.05 0.041 
Prescribing physician type 
Psychiatric prescriber 0.001 0.000 2.29 0.022 
Bipolar disorder subtype (ref: bipolar disorder I) 
Bipolar disorder II 0.524 0.462 1.13 0.258 
Mixed  -0.929 0.481 -2.89 <.0001 
Pre-index co-morbidities 
Alcohol and substance abuse 1.048 0.425 2.46 0.014 
Schizophrenia  0.747 0.543 1.37 0.170 
Major depression 0.101 0.452 0.22 0.823 
Mild to Moderate depression 0.785 0.535 1.47 0.143 
Other mental comorbidities -1.456 0.394 -3.7 0.000 
diabetes -0.068 0.607 -0.11 0.911 
hyperlipedemia -0.441 0.678 -0.65 0.516 
hypertension -0.335 0.478 -0.7 0.483 
Charlson Comorbidity Index -0.153 0.135 -1.13 0.257 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers -0.001 0.001 -0.84 0.399 
Antipsychotics -0.006 0.004 -1.29 0.197 
Antidepressants 0.000 0.001 -0.26 0.794 
Benzodiazepines 0.003 0.001 2.51 0.012 
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Table 33: Ordinary Least Squares (OLS) regression model for the impact of index 
antipsychotic on mental healthcare-related outpatient cost  
 
 Beta S.E t-statistic Significance 
(p) 
Pre-index healthcare utilization and cost 
Number of psychotherapy 
visits -0.017 0.042 -0.41 0.683 
Number of medication 
management visits 0.053 0.059 0.9 0.368 
Number of pre-index mental-
health related ER visits -0.307 0.332 -0.92 0.356 
Pre-index mental-health 
related physician visits 0.015 0.121 0.12 0.903 
Number of pre-index mental-
health related hospitalizations 0.374 0.168 2.23 0.026 
Pre-index mental health-
related outpatient cost 0.371 0.027 13.63 <.0001 
Year of index prescription (ref: 1999) 
• 2000 -0.323 0.442 -0.73 0.466 
• 2001 -0.623 0.518 -1.2 0.230 
Index prescription (ref: quetiapine) 
Risperidone -0.806 0.584 -1.38 0.168 
Olanzapine -0.629 0.537 -1.17 0.241 
Typicals 0.075 0.597 2.95 0.003 
 
Model fit statistics: 
 
Adjusted R-square =    38.22%  , F =  16.93, p < 0.0001 
(contd.) 
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Results for research objective 10 
For schizophrenia and bipolar patients, to compare the impact of quetiapine with 
risperidone, olanzapine, and typical antipsychotics on mental health-related healthcare 
hospitalizations.  
Schizophrenia  
 Results of univariate analysis of mental-health inpatient utilization are presented 
in table 34.  Though there were significantly greater proportion of patients with pre-index 
mental health-related hospitalizations and number of inpatient visits in the quetiapine 
cohort as compared to the typical antipsychotic cohort, there were no significant 
differences in the proportion of patients having post-index hospitalization and the post-
index length of stay between quetiapine and other atypical antipsychotics.  Though the 
length of stay among pre-index hospitalized patients in olanzapine cohort was 
significantly longer compared to quetiapine cohort, there were no significant differences 
in the length of stay between quetiapine and other atypical antipsychotic cohorts.  
However, length of stay in the post-index period was significantly shorter for quetiapine 
(9.9 + 12.6) as compared to typical antipsychotics (13.4 + 11.0).   
Multivariate analysis for the number of hospitalization visits 
 As number of hospitalization is count data, poisson or negative binomial model 
was used to compare the impact of index antipsychotic on number of mental health-
related hospitalizations.  Poisson regression assumes that the conditional mean of the 
outcome is equal to conditional variance.  Poisson regression model carried out for 
estimating the number of hospitalizations was found to be overdispersed ie. the variance 
was greater than the conditional mean.  This was due to high proportion of patients with 
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zero count.  Therefore, a negative binomial model was used for estimation of number of 
hospitalization as it relaxes the assumption that the conditional mean should be equal to 
the variance.  The model statistics and the results are presented in table 35.  The results 
show that there is no significant impact of receiving quetiapine as index antipsychotic 
compared to other index antipsychotics on number of mental health-related 
hospitalizations.  
Time to the first-mental health-related hospitalization 
 Univariate Kaplan Meier analysis revealed that time to the first mental health-
related hospitalization was not significantly different among the index cohorts as 
indicated by log rank statistics of 1.43 (p = 0.696).  The Kaplan Meier survival curves are 
presented in figure 4. 
 A multivariate Cox proportional model that controlled for confounders did not 
show any significant impact of using quetiapine as index antipsychotic on time to first 
mental health-related hospitalization (table 36).  
Bipolar Disorder 
 Results of univariate analysis of mental-health inpatient utilization in bipolar 
disorder patients are presented in table 37.  There were no significant differences between 
quetiapine and other antipsychotics in terms of post-index proportion of patients with 
mental health-related inpatient visits, number of inpatient visits and length of stay.   
 The results of the negative binomial model show that there is no significant 
impact of receiving quetiapine as index antipsychotic compared to other index 
antipsychotics on number of mental health-related hospitalizations (table 38).  
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Table 34: Mental health-related hospitalization comparison (Quetiapine versus 
other antipsychotics) among schizophrenia patients 
 
O Significant difference between quetiapine and olanzapine cohorts at p<0.05 
R Significant difference between quetiapine and risperidone cohorts at p<0.05 
T Significant difference between quetiapine and typicals cohorts at p<0.05 
 
 Olanzapine N = 346 
Risperidone 
N = 201 
Quetiapine 
N = 149 
Typical 
N = 303 
Patients hospitalized  
N (%) 














Number of Inpatient Visits  
Mean (+std) 


































Table 35: Negative binomial model for the impact of index antipsychotic therapy of 
number of mental health-related hospitalization among schizophrenia patients 
 
 Beta S.E t-statistic Significance 
(p) 
Demographic characteristics 
Age (in years) 0.004 0.006 0.590 0.442 
Males (ref: females) 0.005 0.007 0.540 0.464 
Whites (ref: non-whites) 0.610 0.234 6.780 0.009 
Metro (ref: non-metro) -0.131 0.153 0.740 0.390 
Prescribing physician type 
Psychiatric prescriber  0.000 0.000 0.160 0.691 
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective disorder -0.501 0.164 9.370 0.002 
Both schizoaffective disorder 
and schizophrenia -0.695 0.176 15.640 <.0001 
Pre-index co-morbidities 
Alcohol and substance abuse 0.859 0.134 41.120 <.0001 
Bipolar disorder 0.227 0.185 1.500 0.220 
Major depression 0.147 0.162 0.820 0.366 
Mild to Moderate depression 0.390 0.176 4.900 0.027 
Other mental comorbidities 0.173 0.146 1.400 0.236 
diabetes 0.435 0.201 4.700 0.030 
hyperlipedemia -0.229 0.251 0.830 0.362 
hypertension -0.062 0.175 0.120 0.724 
Charlson Comorbidity Index 0.169 0.051 11.160 0.001 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers 0.000 0.001 0.300 0.585 
Antipsychotics 0.001 0.002 0.280 0.597 
Antidepressants 0.001 0.000 1.810 0.178 
Benzodiazepines 0.001 0.001 0.880 0.348 
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Table 35: Negative binomial model for the impact of index antipsychotic therapy of 
number of mental health-related hospitalization among schizophrenia patients 
 
 Beta S.E t-statistic Significance 
(p) 
Pre-index healthcare utilization and cost 
Number of psychotherapy 
visits -0.002 0.013 0.030 0.866 
Number of medication 
management visits -0.066 0.024 7.390 0.007 
Number of pre-index mental-
health related ER visits -0.096 0.117 0.670 0.413 
Pre-index mental-health 
related physician visits -0.049 0.043 1.270 0.261 
Number of pre-index mental-
health related hospitalizations 0.291 0.059 24.010 <.0001 
Year of index prescription (ref: 1999) 
• 2000 0.203 0.166 1.490 0.222 
• 2001 -0.170 0.205 0.690 0.406 
Index prescription (ref: quetiapine) 
Risperidone -0.276 0.219 1.590 0.208 
Olanzapine -0.307 0.194 2.510 0.113 
Typicals -0.167 0.203 0.670 0.412 
 
Model fit statistics: 
 
-2 Log Likehood = 1008.08, χ2 = 220.39, p = 0.0001 
Dispersion estimate = 1.36, p = 0.00 
(contd.) 
230 
Figure 4: Kaplan Meier Survival Curves for time to first mental health-related 










































  Chi-Square df Sig. 
Log Rank (Mantel-Cox) 1.439 3 .696
Test of equality of survival distributions for the different levels of index class
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Table 36: Cox Proportional hazard model for the impact of index antipsychotic 
therapy on time to the first mental health-related hospitalization among 
schizophrenia patients 
 Beta SE Sig. (p) Hazards 
Ratio 
95% CI for hazards 
ratio 





Age (in years) 0.003 0.007 0.727 1.003 0.988 1.017 
Males (ref: females) -0.461 0.161 0.004 0.631 0.461 0.864 
Whites (ref: non-
whites) 0.488 0.305 0.110 1.628 0.896 2.959 
Metro (ref: non-
metro) -0.279 0.186 0.134 0.757 0.526 1.089 
Prescribing physician type 
Psychiatric 
prescriber  -0.105 0.186 0.574 0.901 0.625 1.298 
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective 
disorder -0.392 0.195 0.045 0.675 0.461 0.990 
Both schizoaffective 
disorder and 
schizophrenia -0.699 0.209 0.001 0.497 0.330 0.748 
Pre-index co-morbidities 
Alcohol and 
substance abuse 0.658 0.163 <.0001 1.931 1.403 2.657 
Bipolar disorder 0.357 0.218 0.101 1.429 0.933 2.190 
Major depression 0.170 0.191 0.373 1.185 0.815 1.724 
Mild to Moderate 
depression 0.241 0.195 0.216 1.273 0.869 1.866 
Other mental 
comorbidities 0.076 0.188 0.688 1.078 0.746 1.559 
diabetes 0.303 0.233 0.192 1.354 0.859 2.136 
hyperlipedemia -0.490 0.317 0.123 0.613 0.329 1.141 
hypertension -0.235 0.208 0.259 0.791 0.526 1.189 
(contd.) 
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Table 36: Cox Proportional hazard model for the impact of index antipsychotic 
therapy on time to the first mental health-related hospitalization among 
schizophrenia patients 
 Beta SE Sig. (p) Hazards 
Ratio 
95% CI for hazards 
ratio 







0.168 0.051 0.001 1.183 1.071 1.306 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers 0.000 0.001 0.959 1.000 0.999 1.001 
Antipsychotics -0.002 0.003 0.448 0.998 0.992 1.003 
Antidepressants 0.000 0.000 0.672 1.000 0.999 1.001 
Benzodiazepines 0.000 0.001 0.673 1.000 0.999 1.001 
Pre-index healthcare utilization and cost 
Number of 
psychotherapy visits 0.004 0.012 0.738 1.004 0.981 1.027 
Number of 
medication 
management visits -0.072 0.029 0.014 0.931 0.879 0.986 
Any pre-index 
mental-health 
related ER visits -0.011 0.091 0.904 0.989 0.828 1.181 
Pre-index mental-
health related 




hospitalizations 0.154 0.059 0.008 1.167 1.040 1.309 
Year of index prescription (ref: 1999) 
• 2000 0.131 0.186 0.480 1.140 0.792 1.641 
• 2001 -0.110 0.229 0.631 0.896 0.571 1.404 
Index prescription (ref: quetiapine) 
Risperidone -0.273 0.251 0.277 0.761 0.465 1.245 
Olanzapine -0.160 0.205 0.436 0.852 0.570 1.274 




Model fit statistics: 
-2 Log Likelihood = 2349.62, χ2 =   100.91, p < 0.0001 
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Table 37: Mental health-related hospitalization comparison (Quetiapine versus 
other antipsychotics) among bipolar disorder patients 
 
 Olanzapine N = 283 
Risperidone 
N = 231 
Quetiapine 
N = 106 
Typical 
N = 205 
 
Patients hospitalized  
N (%) 














Number of Inpatient Visits  
Mean (std) 














Length of Stay  
Mean (+std) 















O Significant difference between quetiapine and olanzapine cohorts at p<0.05 
R Significant difference between quetiapine and risperidone cohorts at p<0.05 
T Significant difference between quetiapine and typicals cohorts at p<0.05 
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Table 38: Negative binomial model for the impact of index antipsychotic therapy of 
number of mental health-related hospitalization among bipolar disorder patients 
 
 Beta S.E t-statistic Significance 
(p) 
Demographic characteristics 
Age (in years) 0.009 0.006 2.190 0.139 
18 years or above (ref: less 
than 18 years) 0.292 0.194 2.280 0.131 
Males (ref: females) 0.005 0.008 0.460 0.499 
Whites (ref: non-whites) 0.772 0.287 7.240 0.007 
Metro (ref: non-metro) -0.119 0.177 0.460 0.500 
Prescribing physician type 
Psychiatric prescriber  0.000 0.000 0.080 0.775 
Bipolar disorder subtype (ref: bipolar disorder I) 
Bipolar disorder II -0.477 0.188 6.450 0.011 
Mixed -0.732 0.191 14.620 0.000 
Pre-index co-morbidities 
Alcohol and substance abuse 0.898 0.150 35.910 <.0001 
Bipolar disorder 0.212 0.207 1.050 0.305 
Major depression 0.108 0.181 0.350 0.552 
Mild to Moderate depression 0.221 0.200 1.230 0.268 
Other mental comorbidities 0.189 0.162 1.360 0.243 
diabetes 0.357 0.215 2.760 0.097 
hyperlipedemia -0.209 0.267 0.620 0.433 
hypertension 0.008 0.187 0.000 0.966 
Charlson Comorbidity Index 0.171 0.051 11.120 0.001 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers 0.000 0.001 0.170 0.679 
Antipsychotics 0.001 0.002 0.150 0.698 
Antidepressants 0.000 0.001 0.530 0.465 
Benzodiazepines 0.001 0.001 1.450 0.228 
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Table 38: Negative binomial model for the impact of index antipsychotic therapy of 
number of mental health-related hospitalization among bipolar disorder patients 
 
 Beta S.E t-statistic Significance 
(p) 
Pre-index healthcare utilization and cost 
Number of psychotherapy 
visits 0.009 0.016 0.310 0.579 
Number of medication 
management visits -0.084 0.029 8.360 0.004 
Number of pre-index mental-
health related ER visits -0.084 0.123 0.470 0.493 
Pre-index mental-health 
related physician visits -0.026 0.047 0.300 0.585 
Number of pre-index mental-
health related hospitalizations 0.263 0.063 17.690 <.0001 
Year of index prescription (ref: 1999) 
• 2000 0.306 0.176 3.010 0.083 
• 2001 -0.186 0.226 0.680 0.410 
Index prescription (ref: quetiapine) 
Risperidone -0.158 0.242 0.430 0.514 
Olanzapine -0.371 0.228 2.650 0.104 
Typicals -0.158 0.242 0.430 0.514 
 
Model fit statistics: 
 
  -2 Log Likehood = 880.56, χ2 =  323.98 , p < 0.0001 




 The univariate Kaplan Meier analysis revealed that time to the first mental health-
related hospitalization was not significantly different between the index cohorts as 
indicated by log rank statistics of 0.577 (p = 0.902).  The Kaplan Meier survival curves 
are presented in figure 5.  
 A multivariate Cox proportional model that controlled for confounders did not 
show any significant impact of using quetiapine as index antipsychotic on time to first 
mental health-related hospitalization (table 39).  
Results for research objective 11 
For schizophrenia patients, to compare the impact of quetiapine with risperidone, 
olanzapine, and typical antipsychotics on mental healthcare-related emergency room 
visits. 
Schizophrenia  
 Results of univariate analysis of mental-health-related ER utilization are 
presented in table 40.  Univariate analysis revealed that there were significantly greater 
proportion of patients with pre-index mental health related ER visits and significantly 
greater number of pre-index mental health related ER visits in the quetiapine cohort as 
compared to typical cohort.  However, there were no significant differences in the post-
index comparisons.  
Multivariate analysis of number of mental health-related ER visit 
 If the proportion of zeroes is disproportionately large, negative binomial 
regression has to be replaced by zero inflated models.  Zero inflated poisson models 
allows for proportion of zero values to be higher than poisson or negative binomial 
regression.  As there were many patients with no mental health-related ER visit, zero 
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inflated model was used for multivariate comparisons.  The model statistics and results 
are presented in the table 41.  Vuong statistic is significant and positive supporting the 
use of zero inflated model.  Patients initiated on quetiapine did not have any significant 
difference in mental health related ER visits compared to patients initiated on other index 
antipsychotics.  
Bipolar Disorder 
 Results of univariate analysis of mental-health-related ER utilization are 
presented in table 42.  Univariate analysis reveals that there were significantly a greater 
proportion of patients with pre-index mental health related ER visits in the quetiapine 
cohort (11.3%) as compared to the typical cohort (1.9%).  Also, there was a significantly 
greater proportion of patients with pre-index mental health related ER visits in the 
risperidone cohort (15.1%) compared to quetiapine cohort (11.3%).  However, there were 
no significant differences in the post-index comparisons.   
 The multivariate zero inflated model also did not show any significant differences 
in the mental health related ER visits among patients initiated on Quetiapine as compared 
to patients initiated on other index antipsychotics (Table 43).  
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Figure 5: Kaplan Meier Survival Curves for time to first mental health-related 
hospitalization among bipolar disorder patients  
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 Overall Comparisons 
 
  Chi-Square df Sig. 
Log Rank (Mantel-Cox) .577 3 .902
Test of equality of survival distributions for the different levels of index class. 
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Table 39: Cox Proportional hazard model for the impact of index antipsychotic 
therapy on time to the first mental health-related hospitalization among bipolar 
disorder patients 
 
 Beta SE Sig. (p) Hazards 
Ratio 
95% CI for hazards 
ratio 





Age (in years) 0.008 0.008 0.363 1.008 0.991 1.024 
18 years or above 
(ref: less than 18 
years) 0.039 0.234 0.866 1.040 0.658 1.646 
Males (ref: females) -0.490 0.179 0.006 0.613 0.431 0.871 
Whites (ref: non-
whites) 0.722 0.374 0.054 2.058 0.988 4.287 
Metro (ref: non-
metro) -0.284 0.218 0.192 0.753 0.492 1.153 
Prescribing physician type  
Psychiatric 
prescriber  -0.239 0.209 0.253 0.787 0.523 1.186 
Bipolar disorder subtype (ref:  Bipolar disorder I) 
Bipolar disorder II -0.487 0.231 0.035 0.614 0.390 0.967 
Mixed -0.926 0.238 0.000 0.396 0.248 0.632 
Pre-index co-morbidities 
Alcohol and 
substance abuse 0.760 0.189 <.0001 2.139 1.475 3.101 
Bipolar disorder 0.194 0.250 0.438 1.214 0.743 1.984 
Major depression 0.174 0.213 0.414 1.191 0.784 1.809 
Mild to Moderate 
depression 0.053 0.226 0.814 1.054 0.677 1.641 
Other mental 
comorbidities 0.246 0.209 0.240 1.279 0.849 1.927 
Diabetes 0.371 0.253 0.143 1.449 0.882 2.380 
Hyperlipedemia -0.288 0.336 0.392 0.750 0.388 1.449 
Hypertension -0.304 0.227 0.180 0.738 0.473 1.151 
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Table 39: Cox Proportional hazard model for the impact of index antipsychotic 
therapy on time to the first mental health-related hospitalization among bipolar 
disorder patients 
 
 Beta SE Sig. (p) Hazards 
Ratio 
95% CI for hazards 
ratio 





Comorbidity Index 0.168 0.054 0.002 1.182 1.064 1.314 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers 0.000 0.001 0.691 1.000 0.999 1.002 
Antipsychotics -0.002 0.003 0.555 0.998 0.992 1.004 
Antidepressants 0.000 0.001 0.468 1.000 0.999 1.001 
Benzodiazepines 0.000 0.001 0.805 1.000 0.999 1.001 
Pre-index healthcare utilization and cost 
Number of 
psychotherapy visits 0.020 0.022 0.364 1.020 0.977 1.064 
Number of 
medication 
management visits -0.104 0.036 0.004 0.901 0.840 0.967 
Any pre-index 
mental-health 
related ER visits -0.051 0.111 0.647 0.950 0.764 1.182 
Pre-index mental-
health related 




hospitalizations 0.132 0.067 0.049 1.142 1.001 1.303 
Year of index prescription (ref: 1999) 
• 2000 0.119 0.211 0.571 1.127 0.746 1.702 
• 2001 -0.130 0.262 0.618 0.878 0.526 1.465 
Index prescription (ref: quetiapine) 
Risperidone -0.312 0.289 0.279 0.732 0.416 1.288 
Olanzapine -0.227 0.248 0.361 0.797 0.490 1.297 
(contd.) 
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Table 39: Cox Proportional hazard model for the impact of index antipsychotic 
therapy on time to the first mental health-related hospitalization among bipolar 
disorder patients 
 
 Beta SE Sig. (p) Hazards 
Ratio 
95% CI for hazards 
ratio 




Typicals -0.179 0.293 0.541 0.836 0.471 1.484 
 
Model fit statistics: 
 
-2 Log Likelihood =  1822.14, χ2 =   94.26, p < 0.0001 
(contd.) 
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Table 40: Mental health-related ER visits comparison (Quetiapine versus other 
antipsychotics) among schizophrenia patients 
O Significant difference between quetiapine and olanzapine cohorts at p<0.05 
R Significant difference between quetiapine and risperidone cohorts at p<0.05 
T Significant difference between quetiapine and typicals cohorts at p<0.05 
 
 Olanzapine N = 346 
Risperidone 
N = 201 
Quetiapine 
N = 149 
Typical 
N = 303 










































Table 41: Zero-inflated poisson regression model for the impact of index 
antipsychotic therapy of number of mental health-related ER visit among 
schizophrenia patients 
 Beta S.E t-statistic Significance 
(p) 
Demographic characteristics 
Age (in years) 0.010 0.006 1.755 0.079
Males (ref: females) 0.125 0.125 1.005 0.315
Whites (ref: non-whites) 0.989 0.299 3.304 0.001
Metro (ref: non-metro) 0.107 0.138 0.775 0.438
Prescribing physician type 
Psychiatric prescriber  0.001 0.000 4.673 0.000
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective disorder -0.690 0.164 -4.210 0.000
Both schizoaffective disorder 
and schizophrenia -0.745 0.171 -4.344 0.000
Pre-index co-morbidities 
Alcohol and substance abuse 0.668 0.127 5.265 0.000
Bipolar disorder 0.151 0.166 0.909 0.363
Major depression 0.455 0.141 3.232 0.001
Mild to Moderate depression 0.338 0.149 2.260 0.024
Other mental comorbidities 0.363 0.139 2.604 0.009
diabetes -0.153 0.218 -0.699 0.485
hyperlipedemia -0.315 0.282 -1.119 0.263
hypertension -0.144 0.169 -0.852 0.394
Charlson Comorbidity Index 0.036 0.050 0.720 0.472
Pre-index period psychiatric medication use  
( days of supply) 
Mood stabilizers -0.001 0.001 -1.862 0.063
Antipsychotics -0.014 0.004 -3.410 0.001
Antidepressants 0.000 0.000 -0.660 0.509
Benzodiazepines 0.000 0.001 0.613 0.540
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Table 41: Zero-inflated poisson regression model for the impact of index 
antipsychotic therapy of number of mental health-related ER visit among 
schizophrenia patients 
 Beta S.E t-statistic Significance 
(p) 
Pre-index healthcare utilization and cost 
Number of psychotherapy 
visits -0.013 0.012 -1.126 0.260
Number of medication 
management visits -0.021 0.022 -0.950 0.342
Number of pre-index mental-
health related ER visits 0.366 0.064 5.680 0.000
Pre-index mental-health 
related physician visits 0.013 0.008 1.574 0.116
Number of pre-index mental-
health related hospitalizations -0.138 0.065 -2.136 0.033
Year of index prescription (ref: 1999) 
• 2000 -0.006 0.154 -0.041 0.967
• 2001 -0.276 0.189 -1.459 0.145
Index prescription (ref: quetiapine) 
Risperidone -0.500 0.225 -2.218 0.087
Olanzapine 0.039 0.176 0.224 0.823
Typicals -0.103 0.196 -0.524 0.600
 
Model fit statistics: 
 
Log Likelihood = -702.84, χ2 =   331.27, p = 0.0001 




Table 42: Mental health-related ER visits comparison (Quetiapine versus other 
antipsychotics) among bipolar disorder patients 
 
O Significant difference between quetiapine and olanzapine cohorts at p<0.05 
R Significant difference between quetiapine and risperidone cohorts at p<0.05 
T Significant difference between quetiapine and typicals cohorts at p<0.05 
 Olanzapine N = 283 
Risperidone 
N = 231 
Quetiapine 
N = 106 
Typical 
N = 205 
Patients with Mental-Health Related ER visits 









































Table 43: Zero-inflated poisson regression model for the impact of index 
antipsychotic therapy of number of mental health-related ER visit among bipolar 
disorder patients 
 Beta S.E t-statistic Significance 
(p) 
Demographic characteristics 
Age (in years) 0.019 0.006 2.920 0.004 
Males (ref: females) 0.298 0.196 1.525 0.127 
Whites (ref: non-whites) 0.169 0.138 1.218 0.223 
Metro (ref: non-metro) 1.029 0.333 3.089 0.002 
Prescribing physician type 
Psychiatric prescriber  0.006 0.158 0.036 0.972 
Bipolar disorder subtype (ref:  bipolar disorder I) 
Bipolar disorder II 0.001 0.000 4.808 0.000 
Mixed -0.756 0.187 -4.035 0.000 
Pre-index co-morbidities 
Alcohol and substance abuse -0.962 0.188 -5.117 0.000 
Bipolar disorder 0.596 0.145 4.112 0.000 
Major depression 0.208 0.182 1.146 0.252 
Mild to Moderate depression 0.560 0.153 3.646 0.000 
Other mental comorbidities 0.158 0.173 0.912 0.362 
diabetes 0.565 0.156 3.625 0.000 
hyperlipedemia -0.189 0.231 -0.817 0.414 
hypertension -0.104 0.293 -0.356 0.722 
Charlson Comorbidity Index -0.177 0.180 -0.984 0.325 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers 0.019 0.055 0.342 0.733 
Antipsychotics -0.001 0.001 -1.997 0.046 
Antidepressants -0.012 0.004 -2.835 0.005 
Benzodiazepines -0.001 0.000 -1.242 0.214 
Pre-index healthcare utilization and cost 
Number of psychotherapy 
visits 0.001 0.001 0.886 0.376 
(contd.) 
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Table 43: Zero-inflated poisson regression model for the impact of index 
antipsychotic therapy of number of mental health-related ER visit among bipolar 
disorder patients 
 Beta S.E t-statistic Significance 
(p) 
Number of medication 
management visits 0.000 0.014 0.022 0.982 
Number of pre-index mental-
health related ER visits -0.034 0.025 -1.348 0.178 
Pre-index mental-health 
related physician visits 0.332 0.072 4.625 0.000 
Number of pre-index mental-
health related hospitalizations 0.017 0.008 2.037 0.042 
Year of index prescription (ref: 1999) 
• 2000 -0.138 0.072 -1.922 0.055 
• 2001 -0.063 0.171 -0.371 0.711 
Index prescription (ref: quetiapine) 
Risperidone -0.193 0.205 -0.940 0.347 
Olanzapine -0.273 0.208 -1.313 0.189 
Typicals 0.627 0.244 2.566 0.110 
 
Model fit statistics: 
 
Log Likelihood = -570.92, χ2 =   283.47, p = 0.0001 
Vuong statistic = 1.59, p = 0.00 
(contd.) 
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Results for research objective 12 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine with 
risperidone, olanzapine, and typical antipsychotics on mental healthcare-related physician 
visits.  
Schizophrenia  
 Results of univariate analysis of mental-health-related outpatient utilization are 
presented in table 44.  Patients in quetiapine cohort had a greater number of pre-index 
mental health-related physician office visits, psychotherapy sessions, and medication 
management visits than patients in other cohorts.  Univariate analysis revealed the 
average number of post-index mental health-related physician office visits and 
medication management visits were significantly greater for quetiapine patients 
compared to other antipsychotics.  The average number of psychotherapy sessions was 
significantly greater among risperidone patients (1.25 + 7.83) as compared to quetiapine 
patients (0.77 + 2.68).   
 Multivariate analysis to assess the impact of index antipsychotic was performed 
only for the mental health-related physician office visits.  Results of negative binomial 
model revealed that mental health related physician office visit was not significantly 
different among patients initiated on quetiapine and other index antipsychotics (Table 
45).  
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Table 44: Physician office-visits, psychotherapy, and medication management 
psychotherapy sessions comparison (Quetiapine versus other antipsychotics) among 
schizophrenia patients 
 
O Significant difference between quetiapine and olanzapine cohorts at p<0.05 
R Significant difference between quetiapine and risperidone cohorts at p<0.05 
T Significant difference between quetiapine and typicals cohorts at p<0.05 
 Olanzapine N = 346 
Risperidone 
N = 201 
Quetiapine 
N = 149 
Typical 
N = 303 
Number of Mental Health-Related physician office visits  
Mean (+std) 


























































Table 45: Negative binomial model for the impact of index antipsychotic therapy of 
number of mental health-related physician visit among schizophrenia patients 
 Beta S.E t-statistic Significance 
(p) 
Demographic characteristics 
Age (in years) -0.005 0.008 0.310 0.577 
Males (ref: females) 0.000 0.001 0.110 0.736 
Whites (ref: non-whites) 0.365 0.342 1.140 0.286 
Metro (ref: non-metro) 0.283 0.233 1.470 0.225 
Prescribing physician type 
Psychiatric prescriber  0.000 0.000 2.120 0.146 
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective disorder -0.226 0.262 0.750 0.388 
Both schizoaffective disorder 
and schizophrenia -0.082 0.271 0.090 0.763 
Pre-index co-morbidities 
Alcohol and substance abuse 0.155 0.226 0.470 0.491 
Bipolar disorder 0.376 0.289 1.690 0.194 
Major depression 0.675 0.240 7.900 0.005 
Mild to Moderate depression -0.100 0.287 0.120 0.729 
Other mental comorbidities -0.007 0.215 0.000 0.974 
diabetes 0.303 0.334 0.820 0.364 
hyperlipedemia -0.407 0.390 1.090 0.296 
hypertension 0.308 0.263 1.370 0.242 
Charlson Comorbidity Index -0.166 0.102 2.660 0.103 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers 0.000 0.001 0.350 0.554 
Antipsychotics -0.001 0.003 0.040 0.849 
Antidepressants 0.001 0.001 1.980 0.160 
Benzodiazepines 0.001 0.001 0.650 0.419 
Pre-index healthcare utilization and cost 
Number of psychotherapy 
visits -0.002 0.026 0.000 0.944 
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Table 45: Negative binomial model for the impact of index antipsychotic therapy of 
number of mental health-related physician visit among schizophrenia patients 
 Beta S.E t-statistic Significance 
(p) 
Number of medication 
management visits -0.104 0.034 9.330 
0.002 
Number of pre-index mental-
health related ER visits 0.135 0.185 0.530 0.467 
Pre-index mental-health 
related physician visits 0.325 0.073 20.150 <.0001 
Number of pre-index mental-
health related hospitalizations 0.022 0.098 0.050 0.824 
Year of index prescription (ref: 1999) 
• 2000 0.365 0.256 2.030 0.154 
• 2001 0.230 0.306 0.570 0.451 
Index prescription (ref: quetiapine) 
Risperidone -0.147 0.282 0.270 0.602 
Olanzapine 0.364 0.243 2.250 0.134 
Typicals 0.554 0.305 3.290 0.070 
  
Model fit statistics: 
 
-2 Log Likelihood = 1074.08, χ2 = 179.09, p = 0.0001 




 Results of univariate analysis of mental-health-related outpatient utilization are 
presented in table 46.  The average number of post-index mental health-related physician 
office visits were significantly greater for quetiapine patients (0.92 + 2.21) as compared 
to risperidone (0.41 + 1.05) and typical antipsychotic (0.48 + 1.43) patients.  The average 
pre- and post-index numbers of psychotherapy sessions were significantly higher for 
quetiapine patients compared to typical antipsychotic cohort.  The average numbers of 
medication management sessions were significantly higher for patients on quetiapine 
compared to patients on other antipsychotics.  
 Results of negative binomial model revealed that mental health related physician 
office visit was not significantly different among patients initiated on quetiapine and 
other index antipsychotics (Table 47).  
Results for research objective 13 
For schizophrenia patients, to compare the impact of quetiapine with risperidone, 
olanzapine, and typical antipsychotics on psychiatric medication utilization.  
Schizophrenia  
 Results of univariate analysis of mental-health-related pharmacy utilization are 
presented in table 48.  Results of Mantel Hansel tests show that significantly greater 
proportions of patients in quetiapine cohort (39.6%) were using mood stabilizers as 
compared to the olanzapine cohort (27.5%), risperidone cohort (24.9%) and typicals 
cohort (16.8%) in the pre-index period.  However, post-index comparisons showed 
significant differences only among quetiapine (55.0%) and typical antipsychotic (32.3%) 
cohort.   
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Table 46: Physician office-visits, psychotherapy, and medication management 
psychotherapy sessions comparison (Quetiapine versus other antipsychotics) among 
bipolar disorder patients 
 
 Olanzapine N = 283 
Risperidone 
N = 231 
Quetiapine 
N = 106 
Typical 
N = 205 
Number of Mental Health-Related physician office visits  
Mean (+std) 














Number of Psychotherapy Sessions  
Mean (+std) 














Number of Medication Management Sessions  
Mean (+std) 

















O Significant difference between quetiapine and olanzapine cohorts at p<0.05 
R Significant difference between quetiapine and risperidone cohorts at p<0.05 
T Significant difference between quetiapine and typicals cohorts at p<0.05 
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Table 47: Negative binomial model for the impact of index antipsychotic therapy of 
number of mental health-related physician visit among bipolar disorder patients 




Age (in years) -0.006 0.009 -0.500 0.479 
18 years or above (ref: less 
than 18 years) -0.404 0.251 -2.590 0.107 
Males (ref: females) 0.000 0.001 0.000 0.969 
Whites (ref: non-whites) 0.434 0.388 1.250 0.264 
Metro (ref: non-metro) 0.195 0.262 0.550 0.457 
Prescribing physician type 
Psychiatric prescriber  0.000 0.000 1.770 0.183 
Bipolar disorder subtype (ref:  Bipolar disorder I) 
Bipolar disorder II 0.279 0.291 0.920 0.339 
Mixed -0.083 0.296 -0.080 0.780 
Pre-index co-morbidities 
Alcohol and substance abuse 0.195 0.253 0.590 0.441 
Bipolar disorder 0.274 0.320 0.730 0.392 
Major depression 0.711 0.262 7.370 0.007 
Mild to Moderate depression -0.181 0.316 -0.330 0.568 
Other mental comorbidities 0.116 0.232 0.250 0.618 
diabetes 0.269 0.366 0.540 0.463 
hyperlipedemia -0.269 0.410 -0.430 0.511 
hypertension 0.324 0.284 1.300 0.254 
Charlson Comorbidity Index -0.174 0.105 -2.740 0.098 
Pre-index period psychiatric medication use  
( days of supply) 
Mood stabilizers 0.000 0.001 0.150 0.695 
Antipsychotics -0.003 0.003 -1.240 0.265 
Antidepressants 0.001 0.001 0.580 0.448 
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Table 47: Negative binomial model for the impact of index antipsychotic therapy of 
number of mental health-related physician visit among bipolar disorder patients 
 Beta S.E t-statistic Significance 
(p) 
Benzodiazepines 0.001 0.001 0.620 0.432 
Pre-index healthcare utilization and cost 
Number of psychotherapy 
visits 0.000 0.030 0.000 0.990 
Number of medication 
management visits -0.096 0.037 -6.660 0.010 
Number of pre-index mental-
health related ER visits 0.109 0.200 0.300 0.585 
Pre-index mental-health 
related physician visits 0.330 0.075 19.530 <.0001 
Number of pre-index mental-
health related hospitalizations 0.046 0.100 0.210 0.643 
Year of index prescription (ref: 1999) 
• 2000 0.331 0.273 1.470 0.225 
• 2001 0.224 0.329 0.460 0.496 
Index prescription (ref: quetiapine) 
Risperidone 0.564 0.357 2.490 0.115 
Olanzapine 0.226 0.270 0.700 0.402 
Typicals -0.067 0.290 -0.050 0.818 
  
Model fit statistics: 
 
-2 Log Likelihood = 1059.08, χ2 = 129.05, p = 0.0001 





Table 48: Psychiatric medication use comparison (Quetiapine versus other 
antipsychotics) among schizophrenia patients 
 
 
O Significant difference between quetiapine and olanzapine cohorts at p<0.05 
R Significant difference between quetiapine and risperidone cohorts at p<0.05 





N = 346 
Risperidone 
N = 201 
Quetiapine 
N = 149 
Typical 
N = 303 
































164  Q 
(54.1%) 
Anxiolytics/Hypnotics/Sedatives N (%) 





20  Q 
(6.6%) 







Antiparkinsons N (%) 















Table 48: Psychiatric medication use comparison (Quetiapine versus other 




O Significant difference between quetiapine and olanzapine cohorts at p<0.05 
R Significant difference between quetiapine and risperidone cohorts at p<0.05 
T Significant difference between quetiapine and typicals cohorts at p<0.05
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 Though significantly greater proportions of patients in the quetiapine cohort 
(61.7%) were using antidepressants compared to the olanzapine cohort (45.9%), 
risperidone cohort (41.3%) and typicals cohort (30.7%) in the pre-index period, 
proportions of patients on antidepressants were almost similar among the atypical cohort 
in the post-index index.  The quetiapine cohort did have greater proportions of patients 
(75.8%) on antidepressants in the post-index period than typical antipsychotics (54.1%).  
 Though there was no significant difference in proportions of patients on 
antiparkinsons  drugs in the pre-index period between quetiapine and other 
antipsychotics, there were significantly greater proportion of patients on antiparkinson 
drugs among typical antipsychotic cohort (21.8%) compared to quetiapine cohort (8.0%) 
in the post-index period.   
 Proportions of patients with benzodiazepine use were greater in quetiapine cohort 
as compared to other antipsychotics in both pre-index and post-index periods.  There 
were no significant differences in the proportion of patients using anxiolytics/ hypnotics/ 
sedatives in the pre-index and post-index periods.  As the sample size of patients using 
clozapine was very small, statistical tests could not be carried out.     
Bipolar Disorder 
 
 Results of univariate analysis of mental-health-related pharmacy utilization are 
presented in table 49.  Results of Mantel Hansel tests show that there was no significant 
difference in the proportion of patients on mood stabilizers in the pre-index and post-
index period between quetiapine and other antipsychotics.  There were significantly a 
greater proportion of patients on antidepressants in the quetiapine cohort as compared to 
the other antipsychotics in the pre-index period.  There were significantly a greater 
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proportion of patients on antidepressants in the quetiapine cohort (81.1%) than in typical 
antipsychotic cohort (51.7%) in the post-index period.  There were significantly greater 
proportions of patients on anxiolytics/ hypnotics/ sedatives in the quetiapine cohort 
during the pre-index period as compared to the other cohorsts.  However, the proportions 
of patients on anxiolytics/ hypnotics/ sedatives were greater in the risperidone cohort 
(24.7%) than quetiapine cohort (20.7%) in the post-index period.  The proportions of 
patients on anxiolytics/ hypnotics/ sedatives were greater in the quetiapine cohort than in 
the typical antipsychotic cohort (18.0%).    
 There were significantly greater proportions of patients on antiparkinsons drugs in 
the typical antipsychotic cohort (19.0%) than in the quetiapine cohort (5.6%).  There 
were a significantly greater proportion of patients (48.1%) on benzodiazepines in the 
quetiapine cohort as compared to the other antipsychotics in the pre-index period.  The 
post-index comparisons show significantly greater proportions of patients on 
benzodiazepines in the quetiapine cohort (48.1%) compared to olanzapine (43.1%) and 
typical antipsychotic cohorts (44.3%).  
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Table 49: Psychiatric medication use comparison (Quetiapine versus other 
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Table 49: Psychiatric medication use comparison (Quetiapine versus other 
antipsychotics) among bipolar disorder patients (contd.)  
 
 Olanzapine N = 283 
Risperidone 
N = 201 
Quetiapine 
N = 106 
Typical 























































O Significant difference between quetiapine and olanzapine cohorts at p<0.05 
R Significant difference between quetiapine and risperidone cohorts at p<0.05 
T Significant difference between quetiapine and typicals cohorts at p<0.05
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Results for research objective 14 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine with 
risperidone, olanzapine, and typical antipsychotics on patient’s adherence to the index 
medications in the post-index period. 
Schizophrenia  
 Results of univariate analysis presented in table 50 show that there was a 
significant difference in the average medication possession ratio between quetiapine 
(0.78 + 0.25) and typical antipsychotic cohort (0.55 + 0.32).  Results of the multivariate 
analysis presented in table showed that patients initiated on typical antipsychotics were 
about 22% less adherent than patients initiated on quetiapine (Table 51).  
Bipolar Disorder 
 Results of univariate analysis presented in table 52 show that there was a 
significant difference in the average medication possession ratio between quetiapine 
(0.71 + 0.25) and typical antipsychotic cohort (0.46 + 0.34).  Results of the multivariate 
analysis presented in table showed that patients initiated on typical antipsychotics were 
about 24.4% less adherent than patients initiated on quetiapine (Table 53).  
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Table 50: Univariate comparison of medication possession ratio (mpr) among 
schizophrenia patients 
 
O Significant difference between quetiapine and olanzapine cohorts at p<0.05 
R Significant difference between quetiapine and risperidone cohorts at p<0.05 
T Significant difference between quetiapine and typicals cohorts at p<0.05 
 
 Olanzapine N = 346 
Risperidone 
N = 201 
Quetiapine 
N = 149 
Typical 
N = 303 
 
Medication Possession Ratio  
(MPR) 









Table 51: Ordinary Least Squares (OLS) regression model for adherence to the 
index antipsychotic therapy among schizophrenia patients 
 
 Beta S.E t-statistic Significance 
(p) 
Demographic characteristics 
Age (in years) 0.001 0.001 1.250 0.212 
Males (ref: females) 0.000 0.000 -0.300 0.762 
Whites (ref: non-whites) 0.001 0.030 0.030 0.978 
Metro (ref: non-metro) -0.043 0.023 -1.870 0.062 
Prescribing physician type  
Psychiatric prescriber  0.000 0.000 0.230 0.818 
Schizophrenia subtype (ref: only schizophrenia) 
Schizoaffective disorder -0.042 0.024 -1.730 0.084 
Both schizoaffective disorder 
and schizophrenia -0.046 0.025 -1.810 0.070 
Pre-index co-morbidities 
Alcohol and substance abuse -0.036 0.023 -1.580 0.114 
Bipolar disorder -0.008 0.030 -0.270 0.784 
Major depression 0.057 0.025 2.260 0.024 
Mild to Moderate depression -0.002 0.030 -0.080 0.938 
Other mental comorbidities 0.002 0.022 0.090 0.931 
diabetes -0.021 0.033 -0.620 0.537 
hyperlipedemia 0.064 0.037 1.720 0.085 
hypertension -0.070 0.027 -2.620 0.009 
Charlson Comorbidity Index -0.009 0.008 -1.160 0.246 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers 0.000 0.000 2.060 0.039 
Antipsychotics 0.000 0.000 0.800 0.424 
Antidepressants 0.000 0.000 1.780 0.075 
Benzodiazepines 0.000 0.000 0.270 0.790 
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Table 51: Ordinary Least Squares (OLS) regression model for adherence to the 
index antipsychotic therapy among schizophrenia patients 
 
 Beta S.E t-statistic Significance 
(p) 
Pre-index healthcare utilization and cost 
Number of psychotherapy 
visits 0.001 0.002 
 
0.270 0.788 
Number of medication 
management visits -0.011 0.003 -3.560 0.000 
Number of pre-index mental-
health related ER visits -0.022 0.019 -1.130 0.261 
Pre-index mental-health 
related physician visits -0.005 0.007 -0.690 0.492 
Number of pre-index mental-
health related hospitalizations 0.027 0.010 2.870 0.004 
Year of index prescription (ref: 1999) 
• 2000 0.020 0.025 0.810 0.419 
• 2001 0.043 0.029 1.490 0.138 
Index prescription (ref: quetiapine) 
Risperidone -0.026 0.032 -0.800 0.421 
Olanzapine -0.011 0.028 -0.370 0.711 
Typicals -0.220 0.031 -7.190 <.0001 
 
Model fit statistics: 
 




Table 52: Univariate comparison of medication possession ratio (mpr) among 
bipolar disorder patients 
 
 Olanzapine N = 313 
Risperidone 
N = 231 
Quetiapine 
N = 106 
Typical 
N = 205 








0.71  Q   
(+0.25) 
0.46  T 
(+0.34) 
 
O Significant difference between quetiapine and olanzapine cohorts at p<0.05 
R Significant difference between quetiapine and risperidone cohorts at p<0.05 
T Significant difference between quetiapine and typicals cohorts at p<0.05 
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Table 53: Ordinary Least Squares (OLS) regression model for adherence to the 
index antipsychotic therapy among bipolar disorder patients 
 
        Beta     S.E       t-statistic      Significance 
(p) 
Demographic characteristics 
Age (in years) 0.001 0.001 1.420 0.157
18 years or above (ref: less 
than 18 years) 0.038 0.026 1.460 0.145
Males (ref: females) 0.000 0.000 -1.090 0.277
Whites (ref: non-whites) 0.012 0.035 0.340 0.731
Metro (ref: non-metro) -0.055 0.027 -2.060 0.040
Prescribing physician type 
Psychiatric prescriber  0.000 0.000 -0.340 0.735
Bipolar Disorder subtype (ref:  Bipolar disorder I) 
Bipolar disorder II -0.043 0.028 -1.520 0.130
Mixed -0.040 0.028 -1.440 0.150
Pre-index co-morbidities 
Alcohol and substance abuse -0.055 0.026 -2.160 0.031
Bipolar disorder 0.001 0.033 0.040 0.967
Major depression 0.042 0.027 1.510 0.131
Mild to Moderate depression 0.009 0.033 0.290 0.774
Other mental comorbidities 0.011 0.024 0.470 0.635
diabetes -0.026 0.037 -0.700 0.485
hyperlipedemia 0.085 0.041 2.060 0.040
hypertension -0.073 0.029 -2.510 0.012
Charlson Comorbidity Index -0.013 0.008 -1.580 0.114
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers 0.000 0.000 2.300 0.022
Antipsychotics 0.000 0.000 0.620 0.534
Antidepressants 0.000 0.000 2.310 0.021
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Table 53: Ordinary Least Squares (OLS) regression model for adherence to the 
index antipsychotic therapy among bipolar disorder patients 
 
        Beta     S.E       t-statistic      Significance 
(p) 
Benzodiazepines 0.000 0.000 -0.100 0.924 
Pre-index healthcare utilization and cost 
Number of psychotherapy 
visits 0.001 0.003 
 
0.240 0.814 
Number of medication 
management visits -0.013 0.003 -3.800 0.000 
Number of pre-index mental-
health related ER visits -0.019 0.020 -0.940 0.347 
Pre-index mental-health 
related physician visits -0.007 0.007 -0.890 0.372 
Number of pre-index mental-
health related hospitalizations 0.023 0.010 2.250 0.025 
Year of index prescription (ref: 1999) 
• 2000 0.021 0.027 0.790 0.430 
• 2001 0.052 0.031 1.650 0.099 
Index prescription (ref: quetiapine) 
Risperidone -0.038 0.035 -1.060 0.290 
Olanzapine -0.030 0.033 -0.920 0.359 
Typicals -0.244 0.036 -6.760 <.0001 
 
Model fit statistics: 
 
Adjusted R-square =    15.13%, F = 5.47, p < 0.0001 
(contd.) 
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Results for research objective 15 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine with 
risperidone, olanzapine, and typical antipsychotics on subsequent index antipsychotic 
therapy modification  
Schizophrenia  
 Table 54 presents information on modification of index antipsychotic therapy.  
The average time to modification of therapy for the quetiapine cohort was 228.5 days as 
compared to 208.2 days for the olanzapine cohort, 201.8 days for the risperidone cohort 
and 192.8 days for the typical antipsychotic cohort.  About 36.91% of patients in the 
quetiapine cohort, 50.58% in the olanzapine cohort, 47.76% in the risperidone cohort and 
74.26% in the typical antipsychotic cohort modified the index antipsychotic therapy 
within the 12-month follow-up period.   
 Figure 6 presents the Kaplan Meier survival curves for time to modification of 
therapy for all four study cohorts.  The survival curves were significantly different as 
indicated by log rank statistics of 43.86 (p < 0.00).  Cox proportional hazard model 
presented in table 55 revealed that patients initiated on risperidone were 1.5 times more 
likely and patients initiated on typical antipsychotics were about 2.5 times more likely to 
modify therapy i.e discontinue or switch or augment with another antipsychotic 
(polytherapy) as compared to patients initiated on quetiapine (p <.0001).  
Bipolar Disorder  
 
 Table 56 presents information on modification of index antipsychotic therapy.  
The average time to modification of therapy for the quetiapine cohort was 219.7 days 
compared to 200.9 days for the olanzapine cohort, 194.8 days for the risperidone cohort 
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and 179.2 days for the typical antipsychotic cohort.  About 38.7% of patients in the 
quetiapine cohort, 55.5% in the olanzapine cohort, 39.8% in the risperidone cohort and 
64.4% in the typical antipsychotic cohort modified the index antipsychotic therapy within 
the 12-month follow-up period.   
 The Kaplan Meier survival curves presented in figure 7 revealed that hazards 
were different for the typical antipsychotic cohort within 250 days of initiating patients 
on index antipsychotics and after 250 days of initiation on index antipsychotics.  
Therefore, an extended Cox proportional hazards model was used to estimate impact of 
index antipsychotic use on time to modification of therapy.  There was no significant 
difference in the hazard of discontinuation or switch or polytherapy between quetiapine 
and other antipsychotics in the initial 250 days of therapy.  However, patients initiated on 
typical antipsychotics were about 6.3 times more likely to modify therapy i.e discontinue 
or switch or augment with another antipsychotic (polytherapy) compared to patients 
initiated on quetiapine in later 250 days of antipsychotic therapy (p <.0001).  The 
extended Cox proportional hazard model has been presented in table 57.  
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Table 54: Therapy modification among schizophrenia patients  
 
 Olanzapine N = 346 
Risperidone 
N = 201 
Quetiapine 
N = 149 
Typical 
N = 303 
Time to index therapy modification in days  
Mean (+std ) 







Patients having therapy modification  
N (%)  








Figure 6: Kaplan-Meier Survival Curves for the time to modification of index 
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 Overall Comparisons 
 
  Chi-Square df Sig. 
Log Rank (Mantel-Cox) 43.867 3 .000




Table 55: Cox Proportional hazard model for the impact of index antipsychotic 
therapy on time to discontinuation/ switch or polytherapy among schizophrenia 
patients 




95% CI for Hazard 
Ratio 





Age (in years) -0.010 0.005 0.065 0.990 0.980 1.001 
Males (ref: 
females) -0.101 0.117 0.389 0.904 0.719 1.137 
Whites (ref: non-
whites) -0.062 0.196 0.751 0.940 0.639 1.381 
Metro (ref: non-
metro) 0.043 0.136 0.749 1.044 0.800 1.363 
Prescribing physician type 
Psychiatric 
prescriber  0.117 0.140 0.403 1.124 0.855 1.478 
Schizoaffective 




schizophrenia -0.107 0.155 0.490 0.899 0.663 1.217 
Pre-index co-morbidities 
Alcohol and 
substance abuse 0.201 0.133 0.131 1.223 0.942 1.587 
Bipolar disorder 0.082 0.180 0.648 1.086 0.763 1.544 
Major depression 0.062 0.151 0.678 1.064 0.793 1.430 
Mild to Moderate 
depression 0.030 0.164 0.853 1.031 0.748 1.421 
Other mental 
comorbidities 0.045 0.135 0.740 1.046 0.803 1.363 
Diabetes -0.141 0.194 0.468 0.869 0.595 1.270 
Hyperlipedemia 0.077 0.220 0.728 1.080 0.701 1.663 
Hypertension 0.193 0.156 0.214 1.213 0.894 1.646 
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Table 55: Cox Proportional hazard model for the impact of index antipsychotic 
therapy on time to discontinuation/ switch or polytherapy among schizophrenia 
patients 




95% CI for Hazard 
Ratio 





Comorbidity Index 0.091 0.047 0.052 1.095 0.999 1.201 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers 0.000 0.000 0.407 1.000 0.999 1.001 
Antipsychotics -0.002 0.002 0.353 0.998 0.995 1.002 
Antidepressants 0.000 0.000 0.166 1.000 1.000 1.001 
Benzodiazepines 0.000 0.001 0.546 1.000 0.999 1.001 
Pre-index healthcare utilization and cost 
Number of 
psychotherapy 
visits 0.000 0.013 0.990 1.000 0.976 1.025 
Number of 
medication 
management visits -0.030 0.020 0.124 0.970 0.933 1.008 
Number of pre-
index mental-
health related ER 
visits -0.020 0.097 0.835 0.980 0.811 1.184 
Pre-index mental-
health related 




hospitalizations -0.019 0.056 0.727 0.981 0.879 1.094 
Year of index prescription (ref: 1999) 
• 2000 0.269 0.140 0.055 1.309 0.994 1.723 
• 2001 0.189 0.170 0.265 1.208 0.867 1.684 
Index prescription (ref: quetiapine) 
Risperidone 0.411 0.204 0.045 1.508 1.010 2.251 
(contd.) 
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Table 55: Cox Proportional hazard model for the impact of index antipsychotic 
therapy on time to discontinuation/ switch or polytherapy among schizophrenia 
patients 




95% CI for Hazard 
Ratio 




Olanzapine 0.248 0.182 0.173 1.281 0.897 1.830 
Typicals 0.913 0.189 <.0001 2.491 1.721 3.605 
 
Model fit statistics: 
 
-2 Log Likelihood = 3911.63, chi-square =  56.10, p < 0.002 
(contd.) 
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Table 56: Therapy modification among bipolar disorder patients  
 
 Olanzapine N = 283 
Risperidone 
N = 231 
Quetiapine 
N = 106 
Typical 
N = 205 
Time to index therapy modification in days  
Mean (+std ) 







Patients having therapy modification  
N (%)  









Figure 7: Kaplan-Meier Survival Curves for time to modification of index 
antipsychotic prescription in bipolar disorder patients  
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 Overall Comparisons 
 
  Chi-Square df Sig. 
Log Rank (Mantel-Cox) 27.155 3 .000




Table 57: Extended Cox Proportional hazard model for the impact of index 
antipsychotic therapy on time to discontinuation/ switch or polytherapy among 
bipolar disorder patients 




95% CI for Hazard 
Ratio 





Age (in years) -0.009 0.006 0.122 0.991 0.979 1.000 
18 years or above 
(ref: less than 18 
years) -0.258 0.161 0.109 0.773 0.563 1.059 
Males (ref: 
females) -0.172 0.131 0.187 0.842 0.651 1.087 
Whites (ref: non-
whites) 0.215 0.236 0.362 1.240 0.780 1.970 
Metro (ref: non-
metro) 0.005 0.159 0.973 1.005 0.737 1.372 
Prescribing physician type 
Psychiatric 
prescriber  0.131 0.161 0.415 1.140 0.832 1.562 
Bipolar Disorder subtype (ref: Bipolar disorder I) 
Bipolar disorder I 0.090 0.168 0.590 1.094 0.788 1.520 
Mixed  -0.126 0.175 0.471 0.882 0.626 1.242 
Pre-index co-morbidities 
Alcohol and 
substance abuse 0.338 0.155 0.029 1.402 1.035 1.901 
Bipolar disorder 0.126 0.206 0.540 1.134 0.758 1.699 
Major depression 0.259 0.168 0.124 1.295 0.932 1.800 
Mild to Moderate 
depression 0.045 0.189 0.813 1.046 0.723 1.513 
Other mental 
comorbidities -0.045 0.156 0.774 0.956 0.705 1.298 
Diabetes 0.062 0.216 0.775 1.064 0.697 1.623 
Hyperlipedemia -0.078 0.251 0.755 0.925 0.565 1.512 
Hypertension 0.254 0.168 0.132 1.289 0.927 1.792 
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Table 57: Extended Cox Proportional hazard model for the impact of index 
antipsychotic therapy on time to discontinuation/ switch or polytherapy among 
bipolar disorder patients 




95% CI for Hazard 
Ratio 







-0.041 0.055 0.462 0.960 0.861 1.070 
Pre-index period psychiatric medication use (days of supply) 
Mood stabilizers -0.001 0.001 0.068 0.999 0.998 1.000 
Antipsychotics 0.001 0.002 0.479 1.001 0.998 1.005 
Antidepressants 0.000 0.000 0.389 1.000 1.000 1.001 
Benzodiazepines -0.001 0.001 0.388 0.999 0.998 1.001 
Pre-index healthcare utilization and cost 
Number of 
psychotherapy 
visits -0.008 0.014 0.585 0.992 0.964 1.021 
Number of 
medication 
management visits -0.018 0.022 0.408 0.982 0.942 1.025 
Number of pre-
index mental-
health related ER 
visits -0.093 0.103 0.369 0.911 0.745 1.116 
Pre-index mental-
health related 




hospitalizations -0.010 0.060 0.873 0.990 0.881 1.114 
Year of index prescription (ref: 1999) 
• 2000 0.204 0.157 0.193 1.226 0.902 1.666 
• 2001 0.268 0.189 0.156 1.307 0.903 1.893 
Index prescription (ref: quetiapine) 
Risperidone 0.347 0.231 0.133 1.415 0.900 2.223 
(contd.) 
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Table 57: Extended Cox Proportional hazard model for the impact of index 
antipsychotic therapy on time to discontinuation/ switch or polytherapy among 
bipolar disorder patients 




95% CI for Hazard 
Ratio 




Olanzapine 0.232 0.210 0.270 1.261 0.835 1.903 
Typicals 
 (less than 250 
days) 0.238 0.274 0.386 1.268 0.741 2.171 
Typicals 
 (equal or more 
than 250 days) 1.847 0.255 <.0001 6.338 3.844 10.452 
 
Model fit statistics: 
 
-2 Log Likehood = 3072.98, χ2 =   101.17, p < 0.0001 
(contd.) 
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PHASE 2 - Discussion  
 The aim of phase II is to compare quetiapine with risperidone, olanzapine, and 
typical antipsychotics on multiple healthcare outcomes such as healthcare costs, inpatient, 
outpatient, ER and pharmacy utilization, adherence and treatment modification.  Intent-
to-treat methodology was used for the economic comparisons. Intent to treat 
methodology includes the costs of patient dropouts due to adverse effects or treatment 
failure into economic evaluations.  Without the intent-to-treat perspective, it will be 
difficult to include the cost impact of the additional expenses incurred by the patients 
who do not respond to treatment or fail treatment while comparing different treatment 
options.  Policy makers find studies with intent-to-treat methodology and studies 
reporting costs of all patients instead only those patients who repond to initial treatment 
more useful while making healthcare decisions (Croghan, Johnstone, Buesching, & 
Kessler, 1999).      
Total and mental healthcare costs for schizophrenia and bipolar disorder patients 
The study demonstrated that there were no difference in the total and mental 
health-related costs between schizophrenia patients initiated on quetiapine and other 
antipsychotics.  These findings were reported after controlling for various confounders 
such as patient demographics, co-morbidities, pre-index medication use, healthcare 
utilization and costs.  To our knowledge, this is the first study reporting total and mental 
healthcare cost comparisons of quetiapine with other antipsychotics for schizophrenia 
patients.   
Till date, pharmacoeconomic evaluations of antipsychotics have compared the 
impact of risperidone, olanzapine and typical antipsychotics on healthcare costs and 
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utilizations.   Most of these studies have also not found any significant difference in total 
and mental healthcare costs between the different antipsychotic treatments.   The lack of 
difference is mainly due to variable effect of the antipsychotic use on healthcare 
component costs such as inpatient costs, outpatient costs, and pharmacy costs.  Usually 
the high pharmacy costs associated with atypical antipsychotics were offset by lesser 
inpatient and outpatient costs.  For example, Edgell and colleagues reported that 
olanzapine had higher pharmacy costs and lower inpatient costs compared to risperidone 
resulting in no significant difference in total healthcare costs (Edgell et al., 2000).  
Gibson and colleagues also report no significant difference in total healthcare costs 
between olanzapine, risperidone and typical antipsychotics (Gibson et al., 2004). 
However, after excluding the cost of index prescription, they found that the total costs 
associated with olanzapine were significantly lower than risperidone.   Few other studies 
have reported varying results.  A study by Zhao and colleagues comparing risperidone 
and olanzapine use among uncontrolled schizophrenia population from a employer-based 
insurance population reported lower total costs for olanzapine than risperidone (Zhao, 
2004).  On the other hand, a study by Rascati and colleagues comparing olanzapine and 
risperidone in a Texas Medicaid population reported lower costs for risperidone as 
compared to olanzapine (Rascati et al., 2003).   
The PRIZE (the Partial Responders International schizophrenia Evaluation) study 
conducted in a UK population as compared quetiapine treatment to haloperidol in terms 
of clinical endpoints (Emsley, Raniwalla, Bailey, & Jones, 2000).  A markov model 
based on this study results estimated similar total costs with quetiapine (₤38,106) 
compared to haloperidol (₤38,350) (Tilden et al., 2002).  This study reported that higher 
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acquisition costs of quetiapine were offset by higher inpatient and outpatient costs of 
haloperidol.  In present study, the impact of the index antipsychotic on each component 
of healthcare costs were evaluated to examine cost offsets among these healthcare 
components.  
Total healthcare costs evaluation for bipolar disorder patients found no significant 
differences between quetiapine and other index antipsychotics.  However, evaluation of 
mental healthcare costs for bipolar disorder patients revealed that patients initiated on 
quetiapine incur lower mental healthcare costs compared to patients initiated on typical 
antipsychotics.  There were no significant differences in mental healthcare costs between 
quetiapine and other atypical antipsychotics.    
There is only one other study that compared the impact of antipsychotics on 
healthcare costs and utilization in bipolar disorder patients.  This study reported that 
patients on quetiapine incurred $76 lesser mental-health related charges per patient per 
month compared to olanzapine.  There was no significant difference in costs between 
risperidone and quetiapine (Gianfrancesco et al., 2005).  This study did not include 
comparison with typical antipsychotics.  The difference in results between our study and 
the study by Gianfrancesco may be due to differences in patient population and study 
methodology.  The study by Gianfrancesso was conducted in a private health plan 
population using treatment episode methodology.  Comparisons between the 
antipsychotics in the study by Gianfrancesso were based on costs incurred between the 
initiation of therapy and discontinuation with the therapy.  Therefore, it did not consider 
costs associated with treatment discontinuation or adverse effects in the analysis.  With 
the use of treatment episode methodology, it is possible that a person who has not 
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stabilized on earlier antipsychotic therapy may get initiated on another antipsychotic in 
the next episode and incur higher costs.  Therefore, treatment episodes with newer 
antipsychotics may have higher costs due to inclusion of more severe patients.   
Mental health-related inpatient utilization and cost 
 Our study found no significant difference in inpatient costs between quetiapine 
and other atypical antipsychotics.  However, mental health-related inpatient costs among 
patients initiated on typical antipsychotics were higher than those of patients initiated on 
quetiapine.  The Markov model by Tilden and colleagues had also estimated lower 
inpatient costs with quetiapine (₤22,798) as compared to haloperidol (₤24,716) (Tilden et 
al., 2002).  Two other studies comparing costs between the atypical antipsychotics 
(olanzapine and risperidone) have also reported similar inpatient costs between the 
atypical antipsychotics.(Byerly et al., 2003; Jerrell, 2002).   
 Analysis of inpatient utilization revealed that there were no significant differences 
in the proportion of schizophrenia patient who were hospitalized and number of inpatient 
visits between quetiapine and typical antipsychotic cohorts.  A study by Jerrell and 
colleagues also reported no significant difference in time to hospitalization and number of 
hospitalizations in patients initiated on risperidone, olanzapine and typical antipsychotics 
(Jerrell, 2002).   
 Our study did not find any significant difference in mental health-related inpatient 
utilization and costs between quetiapine and other antipsychotics in bipolar disorder 
patients.  These results are consistent with the findings of the study by Gianfrancesso 
reporting no significant differences in inpatient costs (Gianfrancesco et al., 2005).  It is 
likely that among bipolar disorder patients antipsychotics are being used as an adjunct to 
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other medications like mood stabilizers and antidepressants to manage patients. 
Therefore, there may not be a significant impact of antipsychotic on inpatient utilization 
by itself.   
Mental health-related ER and outpatient utilization and cost 
 Our study categorized the outpatient costs into ER and outpatient costs.  We 
found that there was no significant difference between quetiapine and other 
antipsychotics in terms of ER costs and ER utilization for both schizophrenia and bipolar 
disorder patients.   Study of outpatient utilization is complex for mental health patients as 
outpatient utilization can be psychotherapy, psychotherapy tests, routine physician visits 
or emergency room visits.  Utilization of outpatient services can also depend upon access 
to mental health clinics or hospitals which may be lacking in many places especially rural 
areas.  Many patients lacking access to appropriate healthcare service may use ER for 
routine care services (Lehman & Steinwachs, 1998).    
 Studies that categorize healthcare utilization usually separate them into inpatient 
and outpatient services.  ER utilization and costs are usually aggregated with those of 
other outpatient services (Byerly et al., 2003; Jerrell, 2002).  This may be due to lower 
utilization rates for ER services compared to other services.   
 In our study, comparison of mental health-related physician visits, psychotherapy 
and medication management visits revealed there were significant differences between 
quetiapine and other antipsychotics among both schizophrenia and bipolar disorder 
patients.  Multivariate analysis was conducted for the outpatient costs and physician 
visits.  Though there were no significant differences between the cohorts in terms of 
number of mental health-related physician visits, the outpatient costs were slightly higher 
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for patients initiated on typical antipsychotics as compared to patients initiated on 
quetiapine.  The utilization of psychotherapy sessions and medication management visits 
are probably reflected in the analysis of outpatient costs.    
 There were no significant differences in outpatient costs between quetiapine and 
other atypical antipsychotics in schizophrenia and bipolar disorder patients.  However, 
the outpatient costs of typical antipsychotic were slightly higher than quetiapine.  Markov 
modeling by Tinden and colleagues estimated higher outpatient costs for typicals 
(₤9,698) as compared to quetiapine (₤9,036) in the schizophrenia population.  This may 
be due to better treatment response and lesser side-effects associated with quetiapine 
(Tilden et al., 2002).  Comparison of outpatient costs among schizophrenia patients by 
Jerrell and colleagues also found no difference between the atypical antipsychotics -
risperidone and olanzapine (Jerrell, 2002).  However, interpreting the impact of 
antipsychotic on outpatient costs can be complicated.  Schizophrenia and bipolar disorder 
patients require regular care not only in the acute phases of disease but also in the 
maintenance phase.  Many patients with schizophrenia and bipolar disorder are also 
treated for substance abuse in outpatient settings.  Therefore, utilization of non-
emergency services may also be an indicator of appropriate treatment and patient 
management that may improve patient outcomes in future (American Psychiatric 
Association, 1997; Lehman et al., 2004a; Lehman et al., 2004c).   
Mental health-related pharmacy utilization and cost 
 Our study found that the pharmacy costs for patients initiated on olanzapine were 
significantly higher than quetiapine in both the schizophrenia and bipolar disorder 
populations.  This may be result of higher acquisition costs of olanzapine, greater use of 
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concomitant medications in the olanzapine cohort, or better adherence or persistence with 
olanzapine therapy.   Further analysis of number of days of therapy with the index 
antipsychotic revealed no significant difference between days of therapy with olanzapine 
and quetiapine in the post-index period.  Therefore, a higher pharmacy cost in the 
olanzapine cohort compared to quetiapine is not due to better adherence or persistence 
with olanzapine therapy.  Uses of concomitant medications were similar for psychiatric 
drugs between olanzapine and quetiapine cohort.  Even after controlling for use of 
concomitant medications as well as other confounding factors such as patient 
demographics and co-morbidities, the difference in pharmacy costs between quetiapine 
and olanzapine was still significant suggesting a very high acquisition cost for 
olanzapine.  As expected, the pharmacy costs of quetiapine were significantly higher than 
typical antipsychotics mainly due to higher acquisition costs for quetiapine.    
 Though the drug acquisition cost for each healthcare system may differ, the 
Average Wholesale Price (AWP) per month is higher for olanzapine (approx: $599) 
compared to risperidone (approx: $385), quetiapine (approx: $351) and typical 
antipsychotics (approx: $40) according to the Red Book.  This is reflected in the results 
of all studies comparing pharmacy costs of antipsychotics.  Most studies have compared 
inpatient pharmacy costs between antipsychotics.  Kasper and colleagues reported 
significantly higher average total inpatient drug costs for olanzapine ($297.5) as 
compared to risperidone ($159.9) based on retrospective chart reviews of hospitalized 
schizophrenia patients (Kasper et al., 2001).  Analysis of daily drug costs from an 
inpatient data by Kelly and colleagues found patients initiated on risperidone incurred 
lower drug costs ($6.42) compared to schizophrenia patients initiated on olanzapine 
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($12.29) (Kelly et al., 2001).  Analysis of VA data revealed that there are no significant 
differences in inpatient and outpatient costs among schizophrenia patients initiated on 
risperidone or olanzapine, and therefore it is more economic to prescribe risperidone due 
to its lower drug acquisition costs (Byerly et al., 2003).  Similarly, Gibson and colleagues 
report that after subtracting the cost of index antipsychotic from total costs, post-index 
cost of olanzapine treated schizophrenia patient cohort was lower than risperidone treated 
schizophrenia cohort.  None of these analyses have included quetiapine in their cost 
comparisons.   
 The only study reporting cost comparisons among schizophrenia patients for 
quetiapine examined total pharmacy costs in an acute care inpatient medical setting. 
Based on retrospective chart reviews of patients initiated on olanzapine, risperidone or 
quetiapine, the study reported that the average daily pharmacy cost was $4.35  less for  
risperidone and $1.41 less for quetiapine as compared to olanzapine (Mladsi et al., 2004).  
This study has certain limitations.  The results of this study apply only to those patients 
who respond to the treatment as the study sample included only those patients who were 
discharged within 30 days of hospitalizations.  In addition, the study did not control for 
use of concomitant medications during the inpatient stay.  However, the results of all the 
studies suggest that patients initiated on olanzapine do incur higher pharmacy costs.  
 The only study reporting pharmacy costs for bipolar disorder patients on 
antipsychotics was the study by Gianfrancesso using the treatment episode mythology.  
Despite the difference in methodology from our study, this study reports results similar to 
ours that the per-patient per-month pharmacy costs of olanzapine group was 49% more 
than that of quetiapine group (Gianfrancesco et al., 2005).   
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 Our study found that use of concomitant medications was highly prevalent among 
schizophrenia and bipolar disorder patients in both pre-index as well as post-index 
period.  Few studies have reporting detailed utilization of concomitant medication use in 
these patient populations.  A study by Al-Zakhwani and colleagues reported greater use 
of mood stabilizers among patient on atypical antipsychotic (44.5%) as compared to 
patient on typical antipsychotics (31.88%).  The use of antidepressants was also more 
prevalent among atypical users (81.0%) compared to typical users (51.8%) (Al Zakwani 
et al., 2003).  Menzin and colleagues reported lower likelihood of receiving anxiolytics 
(OR=0.44) and anticholinergics (OR=0.15) among patients on atypical antipsychotics 
compared to patients on typical antipsychotics (Menzin et al., 2003).  Greater use of 
anticholinergic drugs for typical antipsychotics is indicative of need for treatment of extra 
pyramidal symptoms among patients initiated on typical antipsychotics.   
 Pre-index and post-index prevalence of mood stabilizer use was similar among all 
study antipsychotic drugs for bipolar disorder patients initiated on antipsychotics.  Pre 
and post index prevalence of benzodiazepine use was very high among bipolar disorder 
patients initiated on quetiapine.  However, there was a very slight change in the 
proportion of patients on benzodiazepine in the post-index period from the pre-index 
period.  Proportions of patients on anxiolytics/hypnotics/sedatives and antidepressants 
were very high across all study cohorts.  However, proportion of patients on 
antiparkinson and anticholinergics were not very high across study antipsychotic cohorts 
among bipolar disorder patients as compared to schizophrenia patients.  The study by 
Gainfrancesso did not find any significant differences in concomitant medication use 
between risperidone, olanzapine and quetiapine in bipolar disorder patients.  
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Index antipsychotic adherence and therapy modification  
 Though there was no significant difference in adherence measured in terms of 
medication possession ratio between quetiapine and atypical antipsychotics, there were 
significant differences in adherence between quetiapine and typical antipsychotics for 
both schizophrenia and bipolar disorder.  Published studies have shown lower adherence 
for typical antipsychotics due to side-effects such as extrapyramidal symptoms and 
tardive dyskinesia (Crismon ML et al., 1997; APA, 1997; Carpenter, Jr. et al., 1994).  A 
study by Al-Zakhwani and colleagues compared persistence with index therapy and 
medication possession ratio between typicals and atypical antipsychotics in a patient 
population with psychosis (Al Zakwani et al., 2003).  They reported that average days of 
supply of atypical antipsychotic in a year were 136 days compared to 80 days with 
typical antipsychotics.  The medication possession ratio reported for atypical 
antipsychotics was 0.53 compared to 0.24 for typical antipsychotics.  Though the lower 
adherence for typical antipsychotics as compared to atypical antipsychotics is consistent 
with our study results, the ratio of adherence in their study population was considerably 
lower than that found in our study (about 0.7 for atypicals and 0.5 for typicals).  This may 
be because their study sample was not restricted to schizophrenia or bipolar disorder 
population.  It is possible that patients in their study may be receiving antipsychotics for 
short term duration for disease conditions that are not indicated for antipsychotic use.   
 Another study by Menzin and colleagues conducted in the California Medicaid 
schizophrenia population compared persistence with therapy, switching and 
discontinuation between atypical and typical antipsychotics (Menzin et al., 2003).  They 
found that patients initiated on atypical antipsychotics (61%) had greater days of index 
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medication supply in 1-year post-index period compared to typicals (58%).  They also 
reported higher rates of discontinuation among patients initiated on typicals (58%) as 
compared to patients initiated on atypicals (33%).  Though their analysis did not include 
quetiapine, their results with respect to comparison of atypical with typical are consistent 
with our study.  Dolder and colleagues compared adherence between atypical 
antipsychotics (including risperidone, olanzapine, or quetiapine) to typical antipsychotics 
in a California VA population with psychosis.   They reported poorer adherence rates 
with typical antipsychotics (50.1%) compared to atypical antipsychotics (54.9%) (Dolder 
et al., 2002).    
 To our knowledge, there are no studies comparing quetiapine with other atypical 
antipsychotics and typical antipsychotics in terms of persistence with therapy, adherence, 
or therapy modifications such as interrupted, switching and polytherapy.  In addition to 
comparisons of quetiapine with other antipsychotics in terms of persistence with therapy 
and adherence, this study conducted a detailed analysis examining time to modification 
of index antipsychotic.  Modification of index antipsychotic can take place due to 
discontinuation of index antipsychotic use, switching to another antipsychotic or 
augmenting with another antipsychotic (later polytherapy).  This study found that the 
patients initiated on typical antipsychotic had higher the risk of therapy modification as 
compared to patients initiated on quetiapine among schizophrenia patients.  Among 
bipolar disorder patients, the risk of therapy modification with typical antipsychotics 
increased 6-fold in the latter part of post-index period.  Though specific reasons for 
therapy modifications such as physicians’ judgment or patient preference cannot be 
ascertained from a retrospective database analysis, therapy modification can have 
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implications on costs and utilization  (Centorrino et al., 2004; McCombs et al., 2000; 




 This chapter presents conclusions drawn from the study, lists limitations and 
implications of the study and provides recommendations for future research.  
Phase 1 
 The primary goal of the phase I was to describe and evaluate antipsychotic 
utilization patterns among schizophrenia and bipolar disorder patients.  
Conclusions from research objective 1 
To determine the annual prevalence rate of schizophrenia and bipolar disorder in West 
Virginia Medicaid from 1998 to 2002 
 This was an exploratory question examining the overall prevalence rate of 
schizophrenia and bipolar disorder among WV Medicaid enrollees from 1998 and 2002.  
The annual prevalence rates of schizophrenia in the WV Medicaid population from 1998 
to 2002 ranged from 0.9% to 1.5%.  These rates were similar to the national estimate of 
1.1% prevalence.  The annual prevalence rate for bipolar disorder in the WV Medicaid 
population from 1998 to 2002 ranged from 0.6% to 1.7%.  These rates were lower than 
the national estimate of 1.3 to 1.6% for the year 1998 but similar to the national estimates 
between the years 1999 and 2000.  The annual prevalence rate of bipolar disorder among 
population between 20 and 64 years of age between the year 2000 and 2002 ranged from 
3.2% to 3.5% which is similar to the national estimate of 3.7% among adult US 
population.   
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Conclusions from research objective 2 
To determine the medical conditions for which antipsychotics are being prescribed in the 
West Virginia Medicaid population as well as describe patterns of distribution of certain 
demographic factors such as age, gender, and ethnicity in patients using antipsychotics.  
 This was an exploratory analysis to determine the mental health conditions as well 
as describe patterns of distribution of certain demographic factors such as age, gender, 
and ethnicity in patients who were initiated on antipsychotics in the West Virginia 
Medicaid population.  We conclude that there were patients who were initiated on 
antipsychotics for conditions that are not yet FDA indicated for antipsychotic use such as   
non-schizophrenic psychosis, attention deficit disorder, major depression, mild to 
moderate depression, and anxiety.  As WV Medicaid population consists of large 
percentage of Caucasian women, the variation in distribution according to gender and 
race among patients initiated on antipsychotics followed the general demographic 
characteristics of WV Medicaid beneficiaries.  Therefore, it cannot be concluded from 
our study that the initiation of antipsychotics varies by gender or race.  
Conclusions from research objective 3 
For schizophrenia and bipolar disorder patients, determine different types of utilization 
pattern of antipsychotics.  
 The null hypotheses for this research question was there are no differences in the 
utilization patterns of antipsychotics among patients.  This hypothesis was investigated 
among schizophrenia and bipolar disorder patients.  For both schizophrenia and bipolar 
disorder patients, there were significant number of patients using antipsychotic 
polytherapy, switching from index antipsychotic, having interrupted/ non-adherent 
296 
therapy with index antipsychotic and having continuous/ adherent therapy with index 
antipsychotic.  Lower proportion of less than 18 years old bipolar disorder patients 
received continuous/ adherent index antipsychotic therapy compared to bipolar disorder 
patients who are 18 years or older.  As these utilization patterns were defined on the basis 
of refill claims, they only indicate that the patient has refilled the medication.  They do 
not indicate whether the patient has taken the medication.  However, these definitions 
based on refill claims can be accepted to capture the utilization patterns of antipsychotics 
as 1) several studies have validated the positive correlation between refill claims and 
patient diaries and drug blood serum levels and 2) As Medicaid offers complete 
prescription drug coverage, Medicaid patients may not refill prescriptions outside the 
system.  Therefore, we reject our null hypothesis and conclude from this study that 
significantly different antipsychotic utilization patterns exist among schizophrenia and 
bipolar disorder patients.    
Conclusions from research objective 4 
For schizophrenia and bipolar disorder patients, determine the gaps between the refills 
of antipsychotics.  
The null hypotheses for this research question was there are no gaps in the 
antipsychotic therapy among schizophrenia and bipolar disorder patients.  Large 
proportion of schizophrenia and bipolar disorder patients had gaps of greater than 15 days 
between the refills of antipsychotics.  Among bipolar disorder patients, there were 
differences in duration of gaps and proportions of patients with large gaps between 
patients who are 18 years or older and patients who are less than 18 years.  As Medicaid 
offers comprehensive coverage for prescriptions, patients in Medicaid are not very likely 
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to fill their prescriptions outside the system.  Therefore, we can reject our hypothesis and 
conclude that there are gaps in the antipsychotic therapy among schizophrenia and 
bipolar disorder patients 
Conclusions from research objective 5 
For schizophrenia and bipolar disorder patients, determine predictors of different 
utilization patterns of antipsychotics    
 The null hypothesis for this research question was there is no association between 
utilization patterns of antipsychotics and patient demographics, prescribing physician 
type, mental health diagnosis, other medical diagnosis, type of antipsychotic, year of 
index antipsychotic, pre-index concomitant medication use, pre-index alcohol and 
substance abuse and pre-index healthcare utilization among schizophrenia and bipolar 
disorder patients.  Based on our results the null hypothesis was rejected.  We concluded 
that factors such as schizophrenia subtypes, alcohol and substance abuse, major 
depression, prior use of mood stabilizers and antidepressants in the pre-index period and 
use of typical antipsychotic as index antipsychotic were significant predictors of different 
patterns of utilization of antipsychotics among schizophrenia patients.  We also 
concluded that among bipolar disorder patients, factors such as less than 18 years of age, 
psychiatric prescriber, alcohol and substance abuse, major depression, anxiety, prior use 
of mood stabilizers, and use of typical antipsychotic as index antipsychotic were 
significant predictors of different patterns of utilization of antipsychotics.  
Conclusions from research objective 6 
For schizophrenia and bipolar disorder patients, determine the relationship between 
utilization pattern of antipsychotics and total health-related healthcare costs.  
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The null hypothesis was there is no association between utilization patterns of 
antipsychotics and total health healthcare utilization and costs for schizophrenia and 
bipolar disorder patients.  This null hypothesis was rejected based on our results.  We 
concluded that compared to continuous/adherent antipsychotic therapy with index 
antipsychotic, patterns of antipsychotic utilization such as polytherapy, and interrupted/ 
non-adherent therapy were significantly associated with higher total healthcare costs for 
schizophrenia patients.  We also concluded that switching from index antipsychotic was 
not significantly associated with total healthcare costs compared to continuous/adherent 
antipsychotic therapy with index antipsychotic for schizophrenia patients.  Among 
bipolar disorder patients, it was concluded that patterns of antipsychotic utilization such 
as polytherapy, switching from index antipsychotic and interrupted/ non-adherent therapy 
were significantly associated with higher total healthcare costs compared to 
continuous/adherent antipsychotic therapy with index antipsychotic.  
Conclusions from research objective 7 
For schizophrenia and bipolar disorder patients, determine the relationship between 
utilization pattern of antipsychotics and mental health care utilization and costs.  
The null hypothesis was there is no association between utilization patterns of 
antipsychotics and mental health healthcare utilization and costs for schizophrenia and 
bipolar disorder patients.  Based on the results, we concluded that the patterns of 
antipsychotic utilization such as polytherapy, and interrupted/ non-adherent therapy were 
significantly associated with higher mental healthcare costs as compared to 
continuous/adherent antipsychotic therapy with index antipsychotic, for both 
schizophrenia and bipolar disorder patients.  We also concluded that switching from 
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index antipsychotic was not significantly associated with mental healthcare costs 
compared to continuous/adherent antipsychotic therapy with index antipsychotic among 
both schizophrenia and bipolar disorder patients.  
Phase 2 
 The aim of phase II is to compare quetiapine with risperidone, olanzapine, and 
typical antipsychotics on multiple healthcare outcomes such as healthcare costs, inpatient, 
outpatient, ER and pharmacy utilization, adherence and treatment modification.   
Conclusions from research objective 8 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine 
with risperidone, olanzapine, and typical antipsychotics on total and mental healthcare 
costs  
The null hypothesis was that there is no difference in the impact of quetiapine 
compared with risperidone, olanzapine, and typical antipsychotics on total and mental 
healthcare costs for schizophrenia and bipolar disorder patients.  After controlling for 
various confounding such as patient demographics, prescribing physician type, mental 
health diagnosis, other medical diagnosis, type of antipsychotic, year of index 
antipsychotic, pre-index concomitant medication use, pre-index alcohol and substance 
abuse and pre-index healthcare utilization, there were no significant differences in total 
and mental healthcare costs among patients initiated on quetiapine compared to patients 
initiated on risperidone, olanzapine, or typical antipsychotics for schizophrenia patients 
(ref: table).  Therefore, the null hypothesis was accepted as true for schizophrenia 
patients.  However, there were significant differences in total and mental healthcare costs 
among patients initiated on quetiapine compared to patients initiated on typical 
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antipsychotics for bipolar disorder patients.  Therefore, the null hypothesis was rejected 
and it was concluded that bipolar disorder patients initiated on typical antipsychotics 
incur higher mental and total healthcare costs.  
Conclusions from research objective 9 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine 
with risperidone, olanzapine, and typical antipsychotics on components of mental 
healthcare costs (costs associated with mental health-related inpatient, emergency room, 
outpatient and pharmacy services)  
The null hypothesis was that there is no difference in the impact of quetiapine 
compared with risperidone, olanzapine, and typical antipsychotics on components of 
mental healthcare costs (costs associated with mental health-related inpatient, emergency 
room, outpatient and pharmacy services) for schizophrenia and bipolar disorder patients.  
The null hypothesis was rejected for this research objective.  Based on the results, we 
concluded that schizophrenia patients initiated on typical antipsychotics incurred slightly 
higher inpatient and outpatient costs but lower pharmacy costs compared to patients 
initiated on quetiapine.  We also concluded that schizophrenia patients initiated on 
olanzapine incurred higher pharmacy costs compared to patients initiated on quetiapine.  
We also conclude that bipolar disorder patients initiated on typical antipsychotics incur 
slightly higher outpatient costs and lower pharmacy costs than patients who are initiated 
on quetiapine.  Bipolar disorder patients initiated on olanzapine incur higher pharmacy 
costs than patients initiated on quetiapine.  
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Conclusions from research objective 10 
For schizophrenia and bipolar patients, to compare the impact of quetiapine with 
risperidone, olanzapine, and typical antipsychotics on mental health-related healthcare 
hospitalizations.  
The null hypothesis was that there is no difference in the impact of quetiapine 
compared with risperidone, olanzapine, and typical antipsychotics on mental health-
related healthcare hospitalizations for schizophrenia and bipolar disorder patients.  Based 
on the results, we conclude that there were no significant difference in the number of 
mental health-related hospitalizations, proportion of patients hospitalized and time to first 
hospitalization among patients initiated on quetiapine and patients initiated on 
risperidone, olanzapine, or typical antipsychotics for both bipolar disorder and 
schizophrenia.  However, the length of stay in hospital among schizophrenia patients 
initiated on typical antipsychotics was longer compared to patients initiated on 
quetiapine.  Relevant information on hospitalization such as patient condition at the time 
of hospitalization and hospital discharge information were not controlled for in the 
analysis as they are not available in the administrative database.  Therefore, we cannot 
conclude that there were no differences in inpatient utilization between the quetiapine and 
other antipsychotic cohorts.  The null hypothesis was inconclusive for this objective.  
Conclusions from research objective 11 
For schizophrenia patients and bipolar disorder patients, to compare the impact of 
quetiapine with risperidone, olanzapine, and typical antipsychotics on mental healthcare-
related emergency room visits. 
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The null hypothesis was that there is no difference in the impact of quetiapine 
compared with risperidone, olanzapine, and typical antipsychotics on mental healthcare-
related emergency room visits for schizophrenia and bipolar disorder patients.  The null 
hypothesis was accepted and we concluded that there were no significant differences in 
the number of mental health-related ER visits and proportion of patients having ER visit 
among patients initiated on quetiapine and patients initiated on risperidone, olanzapine, 
or typical antipsychotics for both bipolar disorder and schizophrenia.  
Conclusions from research objective 12 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine 
with risperidone, olanzapine, and typical antipsychotics on mental healthcare-related 
outpatient visits.  
The null hypothesis was that there is no difference in the impact of quetiapine 
compared with risperidone, olanzapine, and typical antipsychotics on mental health-
related outpatient visits for schizophrenia and bipolar disorder patients.  Based on 
univariate analyis, outpatient visits such as psychotherapy, physician office visits and 
medication management visits were significantly greater among patients initiated on 
quetiapine compared to patients initiated on risperidone, olanzapine, and typical 
antipsychotics for schizophrenia and bipolar disorder patients.  However, after controlling 
for various confounding such as patient demographics, prescribing physician type, mental 
health diagnosis, other medical diagnosis, type of antipsychotic, year of index 
antipsychotic, pre-index concomitant medication use, pre-index alcohol and substance 
abuse and pre-index healthcare utilization, we conclude that there was no significant 
303 
difference in physician office visits among patients initiated on quetiapine and patients 
initiated on risperidone, olanzapine, or typical antipsychotics.  
Conclusions from research objective 13 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine 
with risperidone, olanzapine, and typical antipsychotics on psychiatric medication 
utilization.  
The null hypothesis was that there is no difference in the impact of quetiapine 
compared with risperidone, olanzapine, and typical antipsychotics on psychiatric 
medication utilization for schizophrenia and bipolar disorder patients.  This null 
hypothesis was rejected as we found significant differences in the proportion of patients 
using different psychiatric drugs among patients initiated on quetiapine and patients 
initiated on risperidone, olanzapine, and typical antipsychotics.  Among schizophrenia 
and bipolar disorder patients, lesser proportion of patients initiated on quetiapine used 
antiparkinsons drugs compared to patients initiated on typical antipsychotics.  Also, 
larger proportion of patients initiated on quetiapine used benzodiazepine and 
antidepressants compared to patients initiated on typicals.  Among bipolar disorder 
patients, greater proportion of patients initiated on risperidone used anxiolytics/ 
hypnotics/ sedatives compared to patients initiated on quetiapine.  However, greater 
proportion of patients initiated on quetiapine used anxiolytics/ hypnotics/ sedatives 
compared to patients initiated on typicals antipsychotics.   
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Conclusions from research objective 14 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine 
with risperidone, olanzapine, and typical antipsychotics on patient’s adherence to the 
index medications in the post-index period. 
The null hypothesis was that there is no difference in the impact of quetiapine 
compared with risperidone, olanzapine, and typical antipsychotics on patient’s adherence 
to index medication for schizophrenia and bipolar disorder patients.  Based on the results, 
we reject null hypothesis and conclude that the patients initiated on quetiapine showed 
similar adherence to index antipsychotics compared to patients initiated on olanzapine 
and risperidone but better adherence to index antipsychotics compared to patients 
initiated on typical antipsychotics for both schizophrenia and bipolar disorder patients.    
Conclusions from research objective 15 
For schizophrenia and bipolar disorder patients, to compare the impact of quetiapine 
with risperidone, olanzapine, and typical antipsychotics on subsequent index 
antipsychotic therapy modification  
The null hypothesis was that there is no difference in the impact of quetiapine 
compared with risperidone, olanzapine, and typical antipsychotics on subsequent 
modification of index antipsychotic therapy by discontinuing, switching or augmenting 
by additional antipsychotics for schizophrenia and bipolar disorder patients.  The null 
hypothesis was rejected and we concluded that there is significant difference in the 
impact of quetiapine as compared to risperidone, olanzapine and typical antipsychotics on 
subsequent modification of index antipsychotics.  Patients initiated on typical 
antipsychotics and risperidone had higher hazard to modify the index antipsychotic 
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therapy compared to patients initiated on quetiapine among schizophrenia patients.  There 
are no significant differences in the hazard of index antipsychotic therapy modification 
among patients initiated on quetiapine compared to patients initiated on risperidone or 
olanzapine among bipolar patients.  Bipolar patients initiated on typical antipsychotics 
had higher hazard to modify index antipsychotic therapy compared to patients initiated on 
quetiapine therapy.  
Limitations 
Pattern of antipsychotic use were identified based on events such as polytherapy, 
switching or discontinuation from index antipsychotic that occurred first after initiation 
of patient on index antipsychotic.  However, it is possible that patients may show 
multiple patterns of antipsychotic utilization in course of treatment.  A patient who has 
switched to another antipsychotic may have later discontinued antipsychotic treatment all 
together or switched back to index antipsychotic.  As various combinations of such 
patterns may exist among patients, it is difficult to define, categorize and evaluate them.  
In addition, factors such as duration of polytherapy will also impact the costs associated 
with it.  However, as we found significant increase in costs associated with at least one 
event of polytherapy, it is likely that the cost will increase further with longer duration of 
polytherapy.  Though our study describes the pattern of antipsychotic use, it is not 
possible to explore all the reasons for such patterns of utilization from the information 
available in administrative claims data.   Various factors such as physician’s clinical 
judgment and past experience, marketing influence of pharmaceutical companies, and 
patient preferences can also impact these patterns.   
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We have used refill records of antipsychotics to measure adherence with the 
therapy.  This indicates that claim for that drug was paid to the provider and not that the 
medication was taken correctly by the patient.  Information such as dates of service, 
amounts dispensed, and days of supply were used to calculate adherence.  This is not a 
direct but a proxy measure of adherence.  However, studies have shown significant 
correlations between adherence measured from refill information and other methods such 
as self-report, pill count, medication diary, and serum drug levels(Choo et al., 1999; 
Deyo, Inui, & Sullivan, 1981).  In addition, claims records are useful in calculating gaps 
in therapy.  As Medicaid offers comprehensive coverage for prescriptions, patients in 
Medicaid are not very likely to fill their prescriptions outside the system.  Therefore, long 
gaps between the refills found among the patients in our study demonstrates significant 
non-adherence to antipsychotic therapy in our population.   
As schizophrenia and bipolar disorder are chronic illnesses, studying long term 
impact of drug use is important for making policy decisions.  Our study follow-up period 
was restricted to one-year due to loss of continuously eligible patients and a change in 
WV Medicaid prior authorization policy for antipsychotics in the year 2003. The latter 
would have biased our study results.  If the impact on hospitalization and ER cost is due 
to non-adherence or therapy discontinuation, the impact is likely to significantly increase 
in longer follow-ups.   
The use of intent-to-treat methodology attributes all costs incurred in the follow-
up period to the index drug.  It may be argued that it is inappropriate to assign costs 
incurred by the patient while on another drug to the index drug.  However, intent-to-treat 
methodology allows us to account for costs associated with patients who do not respond 
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to treatment or fail treatment while comparing different treatment options.  This approach 
is more useful to healthcare policy makers while making formulary decisions (Croghan et 
al., 1999).    
Patients initiated on any of the typical antipsychotics during the index period were 
pooled together to form single cohort of typical antipsychotics.  All healthcare utilization 
and costs incurred by these patients were aggregated and attributed to the typical 
antipsychotic cohort, irrespective of the type of typical antipsychotic.   
Generalizability of the study is limited to populations that are similar to WV 
Medicaid.  Factors such age, sex, race, socioeconomic status, geography, co-pays, 
formularies, and provider access should be taken into account before generalizing the 
results to a different population.  Practice patterns and costs may also vary by time and 
introduction of new drugs.   
The study is vulnerable to the limitations of using administrative claims data for 
research purpose (Motheral et al., 1997).  Inaccurate identification of cases can seriously 
affect the validity of study.  However, care was taken in our study to identify patients 
with schizophrenia and bipolar disorder based on validated algorithms for identifying this 
population from an administrative database (Lurie P et al., 1992; Simon et al., 1999).  It 
is also possible that differences in costs and utilization may be due to unobserved patient 
differences such as disease severity.  However,  a study by Sernyak has validated the use 
of sociodemographic variables, prior utilization and cost variables obtained from 
administrative data as risk adjusters to predict future utilization and costs (Sernyak et al., 
2003).  We have statistically controlled for various confounding factors including patient 
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demographics, prescribing physician type, mental health diagnosis, other medical 
diagnosis, type of antipsychotic, year of index antipsychotic, pre-index concomitant 
medication use, pre-index alcohol and substance abuse and pre-index healthcare 
utilization.   
Research Implications 
Implications for payers 
Considering the rising prescription drug expenditures and adverse effects of 
inappropriate therapy, it is important to take steps to improve prescribing and use of 
prescription drugs.   This is particularly imperative in the case of use of expensive 
antipsychotics in schizophrenia and bipolar disorder population.  This patient population 
is known to be non-adherent to medications and suffer from alcohol and substance use 
disorder that further aggravates the problem.  Our study found very high level of non-
adherence to antipsychotic medication.  The healthcare costs of non-adherent patients 
were higher compared to adherent patients.  If payers are paying for expensive drugs, 
they need to be used appropriately to maximize the benefits gained from them.  Our study 
results should encourage payers to develop policies to improve medication adherence in 
schizophrenia and bipolar disorder patients.  Prescribing behaviors such as polytherapy 
and off-label use of antipsychotics should be investigated.  
Implications for providers 
The study findings should make the physicians aware of the extent of non-
adherence to antipsychotic therapy among schizophrenia and bipolar disorder patients.  
The issue of non-adherence should be given attention during patient evaluation and 
making pharmacotherapy choice.  Our study results also show significant off-label use of 
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antipsychotics for mental health conditions.  Patients using antipsychotics for off-label 
indications should be monitored closely by physicians and pharmacists for adverse 
effects.    
Direction for Future Research 
 Studies with longer follow-up period are needed to capture the impact of 
antipsychotic non-adherence and treatment modification on healthcare costs and 
utilization.  Future economic evaluations should include new atypical drugs such as 
Ziprasidone (Pfizer 2001) and Aripiprazole (Bristol Myers Squibb 2002) that could not 
be evaluated during the study period of this research.  As schizophrenia and bipolar 
disorder are associated with loss of productivity, disability and caregiver burden, the 
impact of pharmacotherapy on productivity and societal costs should be evaluated.  
Studies assessing impact of antipsychotic pharmacotherapy of quality-of-life are also 
needed.  
 Our study findings reveal that a large proportion of schizophrenia and bipolar 
disorder patients on antipsychotics were concomitantly utilizing various psychiatric drugs 
such as mood stabilizers and antidepressants.  Clinical trials investigating efficacy and 
safety of such drug combinations are necessary to assist in developing treatment 
guidelines for disease conditions.  Future studies can also examine the role of 
antipsychotic monotherapy versus antipsychotic combination therapy with mood 
stabilizer among bipolar disorder patients.  Though we found prevalence of off-label 
antipsychotic use among various disease conditions such as major depression, attention-
deficit disorder, autism, and others, clinical evidence supporting such use is lacking. 
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Randomized clinical trials are needed to evaluate if antipsychotics offer any therapeutic 
advantage among patients with these disease conditions.  
 Reasons for switching antipsychotic and using antipsychotic polytherapy can be 
explored using a physician survey.  Survey of physicians can also provide more 
information regarding outcomes associated with antipsychotic polypharmacy and off-
label antipsychotic use.  There is a need for developing and evaluating behavioral 
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